Third O
, O
consistent I-GENE
with I-GENE
these I-GENE
data I-GENE
, O
N O
- O
acetylcysteine O
reduced O
the O
stimulatory I-GENE
effect I-GENE
of O
HGF O
on I-GENE
stress I-GENE
kinase I-GENE
activities I-GENE
, O
while I-GENE
p42 I-GENE
/ I-GENE
44 I-GENE
mitogen I-GENE
activated I-GENE
kinase I-GENE
( I-GENE
MAPK I-GENE
) I-GENE
was I-GENE
unmodified I-GENE
, O
suggesting I-GENE
an I-GENE
involvement I-GENE
of O
c I-GENE
- I-GENE
Jun O
- I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK O
) O
and O
p38 O
MAPK O
in O
HIF O
- O
1 O
activation O
. O

The I-GENE
Sox I-GENE
gene I-GENE
family I-GENE
( I-GENE
Sry I-GENE
like I-GENE
HMG O
box I-GENE
gene I-GENE
) I-GENE
is I-GENE
characterised I-GENE
by I-GENE
a O
conserved O
DNA O
sequence O
encoding O
a O
domain O
of O
approximately O
80 O
amino O
acids O
which I-GENE
is I-GENE
responsible I-GENE
for O
sequence O
specific O
DNA O
binding O
. O

Respiratory O
parameters I-GENE
suggested I-GENE
that I-GENE
M6G I-GENE
produced I-GENE
less I-GENE
respiratory I-GENE
depression I-GENE
than I-GENE
morphine I-GENE
. O

This I-GENE
slow I-GENE
progression I-GENE
through I-GENE
the O
early I-GENE
G1 I-GENE
- I-GENE
phase O
resulted I-GENE
in O
decreased I-GENE
phosphorylation O
of O
the O
RB I-GENE
protein I-GENE
and O
subsequent I-GENE
delay I-GENE
into I-GENE
the O
S I-GENE
phase O
transition I-GENE
. O

Responses O
of O
TLD O
Mg2SiO4 O
: O
Tb O
and O
radiophotoluminescent O
glass I-GENE
to O
heavy I-GENE
charged I-GENE
particles I-GENE
and O
space I-GENE
radiation I-GENE
. O

In O
the O
meantime O
, O
one I-GENE
has I-GENE
succeeded I-GENE
to O
establish I-GENE
the O
deammonification I-GENE
processes I-GENE
in O
a O
continuous I-GENE
flow I-GENE
moving I-GENE
- I-GENE
bed O
pilot O
plant O
. O

An I-GENE
18 I-GENE
- I-GENE
kb I-GENE
genomic I-GENE
clone I-GENE
including I-GENE
sequences O
encoding O
for O
the O
two I-GENE
GHS I-GENE
- I-GENE
R I-GENE
variants I-GENE
was I-GENE
isolated I-GENE
. O

In I-GENE
the O
further I-GENE
development I-GENE
of O
bladder I-GENE
neck I-GENE
suspension I-GENE
according I-GENE
to O
Stamey O
- O
Pereyra O
, O
the O
use I-GENE
of O
miniature I-GENE
bone I-GENE
anchors I-GENE
received I-GENE
considerable I-GENE
support I-GENE
. O

CHAP O
and O
the O
Department O
of O
Veterans O
Affairs O
. O

Finally I-GENE
, O
a O
chromogenic O
method I-GENE
was I-GENE
used I-GENE
, O
based I-GENE
on I-GENE
thrombin O
inhibition I-GENE
and O
the O
substrate O
S I-GENE
- I-GENE
2238 I-GENE
. O

As I-GENE
an I-GENE
oral I-GENE
, O
nontoxic I-GENE
compound I-GENE
with I-GENE
a O
mechanism I-GENE
of O
action I-GENE
distinct I-GENE
from O
that O
of O
ABL O
tyrosine I-GENE
kinase I-GENE
inhibition I-GENE
, O
FTI I-GENE
SCH66336 I-GENE
shows I-GENE
promise O
for O
the O
treatment I-GENE
of O
BCR I-GENE
/ O
ABL O
- O
induced O
leukemia O
. O

Recruitment O
of O
an I-GENE
RNA I-GENE
polymerase I-GENE
II I-GENE
complex I-GENE
is I-GENE
mediated O
by I-GENE
the O
constitutive O
activation O
domain O
in O
CREB O
, O
independently I-GENE
of O
CREB O
phosphorylation O
. O

Our I-GENE
results I-GENE
are I-GENE
reassuring I-GENE
and O
we I-GENE
therefore I-GENE
advise I-GENE
that I-GENE
in O
patients I-GENE
undergoing I-GENE
free I-GENE
jejunum I-GENE
flap I-GENE
reconstruction I-GENE
of O
the O
hypopharyngo O
- I-GENE
esophageal I-GENE
tract I-GENE
voice I-GENE
restoration I-GENE
should I-GENE
be I-GENE
attempted I-GENE
by I-GENE
placing I-GENE
a O
voice I-GENE
prosthesis I-GENE
through I-GENE
a O
secondary I-GENE
tracheo I-GENE
- I-GENE
esophageal I-GENE
puncture I-GENE
and O
providing I-GENE
intensive I-GENE
speech I-GENE
training I-GENE
. O

Regarding O
gestational I-GENE
risk I-GENE
, O
3 I-GENE
, O
243 I-GENE
drugs I-GENE
used I-GENE
( I-GENE
34 I-GENE
%) I-GENE
belonged I-GENE
to O
category I-GENE
A I-GENE
risk I-GENE
, O
1 O
, O
923 O
( O
22 O
. O
6 I-GENE
%) I-GENE
to O
category I-GENE
B I-GENE
, O
3 O
, O
798 O
( O
39 O
. O
7 O
%) I-GENE
to O
category I-GENE
C I-GENE
, O
289 I-GENE
( O
3 O
. O
0 O
%) I-GENE
to O
category I-GENE
D I-GENE
, O
and O
55 O
( O
0 O
. O
6 I-GENE
%) I-GENE
to O
category I-GENE
X I-GENE
. O

The I-GENE
human I-GENE
ABCG1 I-GENE
gene I-GENE
encodes I-GENE
a O
member O
of O
the O
ATP I-GENE
- I-GENE
binding I-GENE
cassette I-GENE
( I-GENE
ABC I-GENE
) I-GENE
superfamily I-GENE
of O
transporter I-GENE
proteins I-GENE
and O
is I-GENE
highly I-GENE
induced O
when I-GENE
macrophages I-GENE
are I-GENE
incubated I-GENE
with I-GENE
oxysterols I-GENE
. O

At I-GENE
the O
end I-GENE
of O
each I-GENE
day I-GENE
of O
migration I-GENE
the O
pulmonary I-GENE
hemolymph I-GENE
PO2 I-GENE
decreased I-GENE
by I-GENE
1 I-GENE
- I-GENE
2 I-GENE
. O
5 O
kPa O
, O
but I-GENE
the O
hemocyanin I-GENE
remained I-GENE
saturated I-GENE
with I-GENE
O2 O
and O
the O
venous I-GENE
reserve I-GENE
was I-GENE
largely I-GENE
unchanged I-GENE
( I-GENE
O2 I-GENE
> I-GENE
0 O
. O
4 I-GENE
mmol I-GENE
x O
l O
(- O
1 O
)). O

We I-GENE
have I-GENE
investigated I-GENE
the O
role I-GENE
of O
NGF O
in O
regulating O
gene I-GENE
transcription I-GENE
in O
PC12 I-GENE
and O
INS I-GENE
- I-GENE
1 I-GENE
cells I-GENE
, O
in O
order I-GENE
to O
define I-GENE
if I-GENE
there I-GENE
are I-GENE
NGF I-GENE
- I-GENE
regulated I-GENE
genes I-GENE
per I-GENE
se I-GENE
. O

Thus I-GENE
, O
through I-GENE
a O
change I-GENE
in O
conformation I-GENE
upon I-GENE
repair O
of O
the O
6RG I-GENE
lesion I-GENE
, O
MGMT O
switches O
from O
a O
DNA O
repair O
factor O
to O
a O
transcription O
regulator O
( O
R O
- O
MGMT O
), O
enabling O
the O
cell O
to O
sense I-GENE
as O
well O
as O
respond I-GENE
to O
mutagens O
. O

TaqMan O
analysis I-GENE
of O
gene I-GENE
expression O
following I-GENE
chronic I-GENE
FA I-GENE
treatment I-GENE
showed I-GENE
neither I-GENE
a O
decrease I-GENE
in O
the O
amount I-GENE
of O
leptin O
receptor I-GENE
( I-GENE
Ob I-GENE
- I-GENE
R I-GENE
) I-GENE
mRNA I-GENE
, O
nor I-GENE
an I-GENE
increase I-GENE
in O
the O
negative O
regulators O
of O
STAT O
signalling I-GENE
, O
SOCS3 I-GENE
( I-GENE
suppressors I-GENE
of O
cytokine I-GENE
signalling I-GENE
) O
or O
cytokine O
inducible O
sequence O
( O
CIS O
). O

Nine O
animals I-GENE
served O
as O
control O
animals I-GENE
, O
whereas I-GENE
20 I-GENE
animals I-GENE
received I-GENE
a O
focal O
arachnoid O
scar O
at O
C1 I-GENE
- I-GENE
C2 I-GENE
, O
which I-GENE
was I-GENE
produced I-GENE
by I-GENE
placement I-GENE
of O
a O
kaolin O
- O
soaked O
fibrin O
sponge O
on I-GENE
the O
posterior I-GENE
surface O
of O
the O
spinal O
cord I-GENE
. O

A I-GENE
comparison I-GENE
of O
the O
duplicated I-GENE
Vkappa I-GENE
genes I-GENE
suggests I-GENE
positive I-GENE
selection I-GENE
on I-GENE
the O
complementarity O
- O
determining O
regions O
of O
the O
duplicated I-GENE
genes I-GENE
by I-GENE
point I-GENE
mutations I-GENE
. O

They I-GENE
have I-GENE
not I-GENE
been I-GENE
previously I-GENE
reported I-GENE
as O
a O
reaction I-GENE
to O
i O
. O
v O
. O
contrast I-GENE
material I-GENE
. O

The I-GENE
presence I-GENE
of O
AS I-GENE
- I-GENE
oligo I-GENE
had I-GENE
no O
further I-GENE
effect I-GENE
on I-GENE
the O
FSH O
- O
mediated O
activation O
of O
the O
EB O
*- O
mTf O
- O
CAT O
construct O
but O
reduced O
cAMP O
- O
mediated O
activation O
. O

The O
homologous O
active O
- O
site O
framework O
of O
these I-GENE
enzymes I-GENE
with I-GENE
distinct I-GENE
structures I-GENE
suggests I-GENE
convergent I-GENE
evolution I-GENE
of O
a O
common I-GENE
catalytic I-GENE
mechanism I-GENE
. O

Additional O
education I-GENE
and O
research I-GENE
is I-GENE
needed I-GENE
to O
provide I-GENE
further I-GENE
direction I-GENE
for O
intervention I-GENE
and O
incorporation I-GENE
into I-GENE
practice I-GENE
. O

Many I-GENE
of O
the O
important I-GENE
genes I-GENE
associated I-GENE
with I-GENE
G1 I-GENE
regulation O
have I-GENE
been I-GENE
shown I-GENE
to O
play I-GENE
a O
key I-GENE
role I-GENE
in O
proliferation O
, O
differentiation I-GENE
and O
oncogenic I-GENE
transformation I-GENE
and O
programmed I-GENE
cell I-GENE
death I-GENE
( I-GENE
apoptosis I-GENE
). O

Drug I-GENE
interactions I-GENE
have I-GENE
been I-GENE
found I-GENE
with I-GENE
drugs I-GENE
that I-GENE
compete I-GENE
for O
the O
same I-GENE
CYP450 I-GENE
isoenzymes I-GENE
as O
statins O
. O

Regulation I-GENE
of O
laminin I-GENE
beta2 I-GENE
chain I-GENE
gene I-GENE
expression O
in O
human O
cancer O
cell O
lines I-GENE
. O

Mutation I-GENE
of O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
site I-GENE
in O
the O
Mdr1b I-GENE
promoter I-GENE
prevents I-GENE
its I-GENE
induction I-GENE
by I-GENE
TNF O
- I-GENE
alpha I-GENE
. O

Effect I-GENE
of O
heat I-GENE
treatments I-GENE
on I-GENE
the O
meltability O
of O
cheeses O
. O

In I-GENE
vitro I-GENE
binding I-GENE
studies I-GENE
demonstrate I-GENE
that I-GENE
eIF I-GENE
- I-GENE
5A I-GENE
is I-GENE
required I-GENE
for O
efficient I-GENE
interaction I-GENE
of O
Rev I-GENE
- I-GENE
NES I-GENE
with I-GENE
CRM1 I-GENE
/ I-GENE
exportin1 I-GENE
and O
that I-GENE
eIF I-GENE
- I-GENE
5A I-GENE
interacts I-GENE
with I-GENE
the O
nucleoporins I-GENE
CAN I-GENE
/ I-GENE
nup214 I-GENE
, O
nup153 I-GENE
, O
nup98 I-GENE
, O
and O
nup62 O
. O

Forced O
expression O
of O
BZAP45 I-GENE
strongly I-GENE
stimulates I-GENE
H4 I-GENE
promoter I-GENE
( I-GENE
nt I-GENE
- I-GENE
215 I-GENE
to O
- I-GENE
1 I-GENE
)/ I-GENE
CAT O
reporter I-GENE
gene I-GENE
activity I-GENE
. O

Copyright I-GENE
2001 I-GENE
Academic I-GENE
Press I-GENE
. O

The I-GENE
diagnosis I-GENE
of O
HCV I-GENE
arthritis I-GENE
in O
patients I-GENE
with I-GENE
positive I-GENE
rheumatoid I-GENE
factor I-GENE
and O
chronic I-GENE
inflammatory I-GENE
polyarthritis I-GENE
may I-GENE
be I-GENE
difficult I-GENE
. O

The I-GENE
UBA I-GENE
domains I-GENE
of O
RAD23 I-GENE
and O
DDI1 I-GENE
are I-GENE
required I-GENE
for O
these I-GENE
interactions I-GENE
. O

E47 I-GENE
protein I-GENE
levels I-GENE
remain I-GENE
high I-GENE
until I-GENE
the O
double I-GENE
positive I-GENE
developmental I-GENE
stage O
, O
at O
which I-GENE
point I-GENE
they I-GENE
drop I-GENE
to O
relatively I-GENE
moderate I-GENE
levels I-GENE
, O
and O
are I-GENE
further I-GENE
downregulated I-GENE
upon I-GENE
transition I-GENE
to O
the O
single O
positive I-GENE
stage O
. O

By I-GENE
Caveman I-GENE
. O

These I-GENE
findings I-GENE
suggest I-GENE
that I-GENE
the O
adapter I-GENE
Gab1 I-GENE
may I-GENE
redirect I-GENE
c I-GENE
- I-GENE
Met I-GENE
signaling O
through I-GENE
PI3K I-GENE
away O
from O
a O
c I-GENE
- I-GENE
Akt O
/ I-GENE
Pak1 I-GENE
cell I-GENE
survival I-GENE
pathway O
. O

Another I-GENE
mutant I-GENE
, O
T255A I-GENE
, O
lost I-GENE
the O
ability I-GENE
to O
bind I-GENE
E4orf6 I-GENE
, O
but I-GENE
unexpectedly I-GENE
, O
viral I-GENE
late I-GENE
- I-GENE
gene I-GENE
expression O
was I-GENE
not I-GENE
affected I-GENE
. O

However I-GENE
, O
the O
N63S O
mutation O
in O
the O
wild I-GENE
- I-GENE
type I-GENE
VP5 I-GENE
background I-GENE
increased I-GENE
the O
interaction O
, O
as O
judged I-GENE
by I-GENE
the O
beta I-GENE
- I-GENE
galactosidase O
activity I-GENE
, O
by I-GENE
a O
factor I-GENE
of O
9 I-GENE
relative I-GENE
to O
when I-GENE
the O
PR7 I-GENE
mutation I-GENE
was I-GENE
present I-GENE
. O

Here I-GENE
we I-GENE
report I-GENE
the O
isolation I-GENE
and O
characterization I-GENE
of O
the O
forkhead O
homologue O
in O
rhabdomyosarcoma O
( O
FKHR O
), O
a O
recently I-GENE
described I-GENE
member O
of O
the O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
3 I-GENE
/ I-GENE
forkhead I-GENE
homeotic O
gene I-GENE
family I-GENE
, O
as O
a O
nuclear I-GENE
hormone I-GENE
receptor I-GENE
( I-GENE
NR I-GENE
) I-GENE
intermediary I-GENE
protein I-GENE
. O

Unlike I-GENE
other I-GENE
progenitor I-GENE
cells I-GENE
of O
the O
brain O
, O
SVZa O
progenitor I-GENE
cells I-GENE
have I-GENE
the O
capacity I-GENE
to O
divide I-GENE
even I-GENE
though I-GENE
they I-GENE
express I-GENE
a O
neuronal O
phenotype O
. O

We I-GENE
previously I-GENE
reported I-GENE
that I-GENE
Tax I-GENE
induced O
cell O
cycle O
progression I-GENE
from O
G0 I-GENE
/ O
G1 O
phase O
to O
S O
and O
G2 O
/ O
M I-GENE
phases I-GENE
in O
human I-GENE
T I-GENE
- I-GENE
cell I-GENE
line I-GENE
Kit I-GENE
225 I-GENE
cells I-GENE
. O

Phosphotyrosyl O
peptides O
block O
Stat3 O
- O
mediated O
DNA O
binding I-GENE
activity I-GENE
, O
gene I-GENE
regulation O
, O
and O
cell O
transformation I-GENE
. O

In I-GENE
Exp I-GENE
. O

Human I-GENE
brain I-GENE
cDNA I-GENE
library I-GENE
screening I-GENE
and O
5 I-GENE
' I-GENE
rapid I-GENE
amplification I-GENE
of O
cDNA I-GENE
ends I-GENE
yielded I-GENE
full I-GENE
- I-GENE
length I-GENE
DENTT I-GENE
cDNA I-GENE
containing I-GENE
an I-GENE
1899 I-GENE
- I-GENE
bp O
open O
reading O
frame O
encoding O
a O
predicted I-GENE
633 I-GENE
- I-GENE
amino I-GENE
- I-GENE
acid I-GENE
protein I-GENE
with I-GENE
four I-GENE
potential O
nuclear I-GENE
localization I-GENE
signals I-GENE
( O
NLSs O
) O
and O
two O
coiled O
- O
coil O
regions O
. O

NaeI O
, O
a O
novel I-GENE
DNA I-GENE
endonuclease I-GENE
, O
shows I-GENE
topoisomerase O
and O
recombinase O
activities I-GENE
when I-GENE
a O
Lys O
residue O
is I-GENE
substituted I-GENE
for O
Leu O
43 O
. O

We I-GENE
used I-GENE
a O
rev I-GENE
- I-GENE
and O
RRE I-GENE
- I-GENE
defective I-GENE
HIV I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) O
molecular O
clone O
in O
complementation O
experiments I-GENE
to O
establish I-GENE
a O
method I-GENE
for O
the O
rapid I-GENE
isolation I-GENE
of O
posttranscriptional I-GENE
regulatory I-GENE
elements O
from O
the O
mammalian I-GENE
genome I-GENE
by I-GENE
selecting I-GENE
for O
rescue I-GENE
of O
virus O
replication O
. O

OBJECTIVES I-GENE
: O
The I-GENE
objective I-GENE
of O
this I-GENE
review I-GENE
was I-GENE
to O
compare I-GENE
the O
effectiveness I-GENE
, O
safety I-GENE
and O
acceptability O
of O
the O
diaphragm I-GENE
with I-GENE
and O
without I-GENE
spermicide I-GENE
. O

DESIGN I-GENE
: O
Retrospective I-GENE
study I-GENE
. O

Considering O
that O
the O
reactor O
is I-GENE
thoroughly I-GENE
mixed I-GENE
during O
each I-GENE
discharge I-GENE
and O
that I-GENE
LD50 I-GENE
= I-GENE
0 O
. O
9 O
values I-GENE
are I-GENE
nearly I-GENE
independent I-GENE
of O
E I-GENE
. O
coli I-GENE
concentrations I-GENE
in O
the O
range I-GENE
of O
2 O
x O
10 O
( O
3 O
) O
< I-GENE
or O
= I-GENE
E I-GENE
coli I-GENE
/ I-GENE
cfu I-GENE
mL I-GENE
(- I-GENE
1 I-GENE
) I-GENE
< I-GENE
or O
= I-GENE
3 I-GENE
x O
10 O
( O
6 O
), O
we O
ascribe O
the O
nonexponential O
Pn O
decay O
of O
single O
- O
strain O
E O
. O
coli I-GENE
colonies I-GENE
to O
a O
shielding O
phenomenon I-GENE
where I-GENE
inactive I-GENE
cells I-GENE
protect I-GENE
the O
successively I-GENE
smaller I-GENE
numbers I-GENE
of O
viable I-GENE
cells I-GENE
in O
the O
EHD O
. O

These I-GENE
genes I-GENE
encode I-GENE
a O
tryptophanyl I-GENE
tRNA I-GENE
, O
the O
protein O
translocase O
component O
SecE O
, O
the O
antiterminator O
protein I-GENE
NusG I-GENE
, O
and O
the O
ribosomal I-GENE
proteins I-GENE
L11 I-GENE
and O
L1 I-GENE
in O
addition I-GENE
to O
PkwR I-GENE
, O
a O
putative I-GENE
regulatory I-GENE
protein I-GENE
of O
the O
LacI I-GENE
- I-GENE
GalR I-GENE
family I-GENE
. O

Body O
fat I-GENE
distribution I-GENE
was I-GENE
determined I-GENE
by I-GENE
abdominal I-GENE
computed I-GENE
tomography I-GENE
. O

The I-GENE
telomerase O
RNA I-GENE
- I-GENE
protein I-GENE
complex I-GENE
responsible I-GENE
for O
maintenance O
of O
telomeric I-GENE
DNA O
at O
chromosome O
ends I-GENE
, O
is I-GENE
usually I-GENE
inactive I-GENE
in O
most I-GENE
primary O
somatic I-GENE
human I-GENE
cells I-GENE
, O
but I-GENE
is I-GENE
specifically I-GENE
activated I-GENE
with I-GENE
in O
vitro I-GENE
immortalization O
and O
during O
tumorigenesis I-GENE
. O

This I-GENE
is I-GENE
a O
challenging I-GENE
task I-GENE
insofar I-GENE
as O
direct I-GENE
measures I-GENE
of O
ISF I-GENE
glucose I-GENE
are I-GENE
not I-GENE
readily I-GENE
available I-GENE
. O

SELECTION I-GENE
CRITERIA I-GENE
: O
All I-GENE
randomised I-GENE
controlled O
trials I-GENE
comparing I-GENE
IUSs I-GENE
with I-GENE
other I-GENE
forms I-GENE
of O
reversible I-GENE
contraceptives I-GENE
and O
reporting I-GENE
on I-GENE
pre I-GENE
- I-GENE
determined I-GENE
outcomes I-GENE
in O
women I-GENE
of O
reproductive I-GENE
years I-GENE
. O

There I-GENE
was I-GENE
a O
statistically I-GENE
significant I-GENE
correlation I-GENE
between I-GENE
simultaneous I-GENE
weekly I-GENE
average I-GENE
pollen I-GENE
levels I-GENE
in O
Philadelphia O
and O
in O
Cherry O
Hill O
( O
Acer O
, O
r O
( O
p O
) O
= I-GENE
0 O
. O
987 O
, O
Quercus O
, O
r O
( O
p O
) O
= I-GENE
0 O
. O
645 O
, O
Betula O
, O
r O
( O
p O
) O
= I-GENE
0 O
. O
896 O
, O
Pinus O
, O
r O
( O
p O
) O
= I-GENE
0 O
. O
732 O
, O
Cupressaceae O
, O
r O
( O
p O
) O
= I-GENE
0 O
. O
695 O
, O
Poaceae O
, O
r O
( O
p O
) O
= I-GENE
0 O
. O
950 O
, O
Ambrosia O
, O
r O
( O
p O
) O
= I-GENE
0 O
. O
903 O
, O
and O
Rumex O
, O
r O
( O
p O
) O
= I-GENE
0 O
. O
572 I-GENE
, O
P I-GENE
< I-GENE
0 O
. O
001 I-GENE
). O

Through O
two I-GENE
novel I-GENE
mechanisms I-GENE
, O
Arf I-GENE
inhibits I-GENE
the O
oncoprotein I-GENE
Hdm2 I-GENE
, O
a O
negative O
regulator O
of O
p53 O
. O

2 O
: O
The I-GENE
dynamic I-GENE
moduli O
of O
microcrystalline O
cellulose O
. O

Such I-GENE
knowledge I-GENE
could I-GENE
advance I-GENE
diagnosis I-GENE
and O
treatment I-GENE
of O
the O
patient I-GENE
and O
counseling O
of O
the O
affected I-GENE
family I-GENE
. O

Here I-GENE
we I-GENE
show I-GENE
that I-GENE
independent I-GENE
of O
uncertainties O
in O
the O
models I-GENE
, O
terrestrial I-GENE
planets I-GENE
with I-GENE
dense I-GENE
atmosphere I-GENE
like I-GENE
Venus I-GENE
can I-GENE
evolve I-GENE
into I-GENE
one I-GENE
of O
only I-GENE
four I-GENE
possible I-GENE
rotation I-GENE
states I-GENE
. O

Our I-GENE
results I-GENE
suggest I-GENE
that I-GENE
WASP I-GENE
activates I-GENE
transcription I-GENE
following I-GENE
TCR O
stimulation O
in O
a O
manner I-GENE
that I-GENE
is I-GENE
independent I-GENE
of O
its I-GENE
role I-GENE
in O
Arp2 I-GENE
/ I-GENE
3 I-GENE
- I-GENE
directed I-GENE
actin O
polymerization O
. O

In I-GENE
contrast I-GENE
, O
the O
ubiquitous I-GENE
expression O
of O
p19 I-GENE
( I-GENE
INK4d I-GENE
) I-GENE
has I-GENE
not I-GENE
been I-GENE
previously I-GENE
described I-GENE
in O
human I-GENE
or O
murine I-GENE
B I-GENE
- I-GENE
lineage I-GENE
cells I-GENE
. O

This I-GENE
animal I-GENE
model I-GENE
of O
dystonia I-GENE
appears I-GENE
to O
be I-GENE
a O
model I-GENE
of O
NAD I-GENE
in O
man I-GENE
from O
the O
viewpoint O
of O
treatment I-GENE
- I-GENE
response I-GENE
. O

These I-GENE
results I-GENE
indicate I-GENE
that I-GENE
evaluation I-GENE
of O
exposure I-GENE
to O
S I-GENE
. O
neurona I-GENE
by I-GENE
WB I-GENE
analysis I-GENE
of O
serum I-GENE
may I-GENE
be I-GENE
misleading I-GENE
in O
young I-GENE
horses I-GENE
. O

The I-GENE
Delta6CCI I-GENE
virus I-GENE
was I-GENE
extremely I-GENE
attenuated I-GENE
in O
replication I-GENE
capacity I-GENE
yet I-GENE
retained I-GENE
infectiousness I-GENE
for O
CEMx174 I-GENE
and O
MT4 I-GENE
cells I-GENE
. O

OBJECTIVE I-GENE
: O
To I-GENE
determine I-GENE
the O
association I-GENE
of O
depressive I-GENE
symptoms I-GENE
with I-GENE
HIV I-GENE
- I-GENE
related I-GENE
mortality I-GENE
and O
decline I-GENE
in O
CD4 I-GENE
lymphocyte I-GENE
counts I-GENE
among I-GENE
women I-GENE
with I-GENE
HIV I-GENE
. O

Phase I-GENE
II I-GENE
study I-GENE
of O
paclitaxel O
and O
oral I-GENE
etoposide I-GENE
in O
patients I-GENE
with I-GENE
locally I-GENE
advanced I-GENE
or O
metastatic I-GENE
non I-GENE
- I-GENE
small I-GENE
cell O
lung O
cancer O
. O

Analyses O
revealed I-GENE
that I-GENE
scale I-GENE
matters I-GENE
above I-GENE
and O
beyond I-GENE
the O
effect I-GENE
of O
quadrat I-GENE
area I-GENE
. O

Rind O
et I-GENE
al I-GENE
.' I-GENE
s I-GENE
study I-GENE
' I-GENE
s I-GENE
main I-GENE
conclusions I-GENE
were I-GENE
not I-GENE
supported I-GENE
by I-GENE
the O
original I-GENE
data I-GENE
. O

Not O
Available O

Lactate O
accumulation I-GENE
peak I-GENE
was I-GENE
unaffected I-GENE
by I-GENE
supplementation I-GENE
( O
HMB O
, O
8 O
. O
1 I-GENE
+/- I-GENE
1 I-GENE
. O
1 I-GENE
mM I-GENE
; O
LEU O
, O
6 O
. O
2 I-GENE
+/- I-GENE
0 O
. O
8 O
mM I-GENE
; O
CON O
, O
7 O
. O
5 O
+/- I-GENE
1 I-GENE
. O
3 I-GENE
mM I-GENE
). O

However I-GENE
, O
the O
abi1 I-GENE
- I-GENE
1 I-GENE
gene I-GENE
product I-GENE
has I-GENE
no O
effect I-GENE
on I-GENE
the O
ABA I-GENE
suppression I-GENE
of O
a O
GA I-GENE
- I-GENE
responsive I-GENE
alpha I-GENE
- I-GENE
amylase O
gene I-GENE
. O

Polyclonal O
antibodies I-GENE
against I-GENE
the O
N I-GENE
- I-GENE
terminal I-GENE
part I-GENE
( O
amino O
acids O
12 O
- O
363 O
) O
and O
the O
C I-GENE
- I-GENE
terminal I-GENE
part I-GENE
( O
amino O
acids O
330 I-GENE
- I-GENE
730 I-GENE
) O
of O
rainbow O
trout O
HIF O
- O
1alpha O
protein O
recognized O
rainbow O
trout O
and O
chinook O
salmon O
HIF O
- O
1alpha O
protein O
in O
Western I-GENE
blot I-GENE
analysis I-GENE
. O

Southern I-GENE
blot I-GENE
analysis I-GENE
of O
genomic O
DNA O
from O
somatic I-GENE
cell I-GENE
hybrids I-GENE
showed I-GENE
that I-GENE
endothelial I-GENE
- I-GENE
TACC I-GENE
- I-GENE
related I-GENE
cDNA I-GENE
maps I-GENE
to O
chromosome O
10 O
. O

PABP I-GENE
is I-GENE
a O
modular I-GENE
protein I-GENE
, O
with I-GENE
four I-GENE
N I-GENE
- I-GENE
terminal I-GENE
RNA I-GENE
- I-GENE
binding I-GENE
domains I-GENE
and O
an I-GENE
extensive I-GENE
C I-GENE
terminus I-GENE
. O

9 O
. O
7 O
( O
95 O
% O
CI O
: O
9 O
. O
6 O
- O
9 O
. O
7 O
) O
micromol O
/ O
L I-GENE
among I-GENE
women I-GENE
( I-GENE
P I-GENE
= I-GENE
0 O
. O
003 O
). O

The I-GENE
mean I-GENE
waiting I-GENE
time I-GENE
to O
receive I-GENE
the O
pancreas I-GENE
transplant I-GENE
was I-GENE
244 I-GENE
days I-GENE
for O
SPK I-GENE
and O
167 I-GENE
days I-GENE
for O
PAK I-GENE
recipients I-GENE
( I-GENE
P I-GENE
= I-GENE
0 O
. O
001 I-GENE
). O

Zarix O
expected I-GENE
patient I-GENE
enrollment I-GENE
in O
Canadian I-GENE
clinical I-GENE
sites I-GENE
to O
begin I-GENE
in O
Spring I-GENE
2001 I-GENE
[ I-GENE
397955 I-GENE
], I-GENE
[ I-GENE
405928 I-GENE
]. I-GENE

The I-GENE
isoform I-GENE
, O
designated I-GENE
HDAC9a I-GENE
, O
is I-GENE
132 I-GENE
aa I-GENE
shorter I-GENE
at O
the O
C I-GENE
terminus I-GENE
than I-GENE
HDAC9 I-GENE
. O

Long O
- I-GENE
range I-GENE
comparison I-GENE
of O
human I-GENE
and O
mouse I-GENE
SCL I-GENE
loci I-GENE
: O
localized I-GENE
regions I-GENE
of O
sensitivity I-GENE
to O
restriction I-GENE
endonucleases I-GENE
correspond I-GENE
precisely I-GENE
with I-GENE
peaks I-GENE
of O
conserved O
noncoding I-GENE
sequences I-GENE
. O

In I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
, O
eIF6 I-GENE
is I-GENE
encoded I-GENE
by I-GENE
a O
single I-GENE
- I-GENE
copy I-GENE
essential I-GENE
gene I-GENE
. O

Three I-GENE
patients I-GENE
received I-GENE
additional I-GENE
cycles I-GENE
of O
5 I-GENE
- I-GENE
fluorouracil I-GENE
+/- I-GENE
leucovorin I-GENE
as O
maintenance I-GENE
chemotherapy I-GENE
. O
RESULTS I-GENE
: O
Thirty I-GENE
males I-GENE
and O
21 I-GENE
females I-GENE
with I-GENE
a O
median I-GENE
age I-GENE
of O
55 I-GENE
years I-GENE
( I-GENE
range I-GENE
31 O
-- O
73 O
years I-GENE
) I-GENE
were I-GENE
treated I-GENE
. O

RESULTS I-GENE
: O
Within I-GENE
7 I-GENE
days I-GENE
, O
all I-GENE
groups I-GENE
re I-GENE
- I-GENE
acquired I-GENE
responding I-GENE
for O
heroin I-GENE
under I-GENE
CRF I-GENE
at O
rates I-GENE
similar I-GENE
to O
their I-GENE
pre I-GENE
- I-GENE
lesion I-GENE
performance I-GENE
. O

The I-GENE
application I-GENE
of O
the O
biotechnology O
at O
the O
plants O
for O
treatment I-GENE
of O
the O
surface O
storm O
waters O
from O
the O
industrial O
zone I-GENE
Telychka O
of O
the O
city O
of O
Kyiv O
has I-GENE
allowed I-GENE
the O
content I-GENE
of O
petroleum O
in O
water I-GENE
dropped O
to O
the O
Dnieper O
to O
be I-GENE
constantly I-GENE
reduced O
50 I-GENE
- I-GENE
100 O
times I-GENE
. O

Using I-GENE
immunochemical I-GENE
co O
- I-GENE
precipitation I-GENE
methods I-GENE
, O
we I-GENE
also I-GENE
found I-GENE
that I-GENE
the O
two I-GENE
proteins I-GENE
are I-GENE
bound O
in O
vivo I-GENE
. O

Utility O
of O
OAE O
screener O
( O
GSI O
70 O
) O
for O
the O
evaluation I-GENE
of O
distortion I-GENE
product I-GENE
otoacoustic I-GENE
emissions I-GENE
] I-GENE
The I-GENE
purpose I-GENE
of O
this I-GENE
study I-GENE
was I-GENE
to O
investigate I-GENE
the O
ability I-GENE
of O
the O
OAE I-GENE
screener I-GENE
GSI I-GENE
70 I-GENE
to O
evaluate I-GENE
of O
cochlea I-GENE
function I-GENE
in O
neonates I-GENE
, O
infants I-GENE
and O
adults I-GENE
. O

Our I-GENE
results I-GENE
demonstrated I-GENE
that I-GENE
50 I-GENE
% I-GENE
of O
the O
hepatic O
artery I-GENE
- I-GENE
alone I-GENE
ALT I-GENE
graft I-GENE
showed I-GENE
almost I-GENE
normal I-GENE
structure O
histologically I-GENE
at O
1 I-GENE
month I-GENE
after I-GENE
grafting I-GENE
, O
with I-GENE
bile I-GENE
secretion O
preserved O
. O

Mean I-GENE
Hg I-GENE
concentrations I-GENE
in O
the O
livers O
of O
mice I-GENE
at O
some I-GENE
sites I-GENE
in O
Isle I-GENE
Royale I-GENE
are I-GENE
not I-GENE
significantly I-GENE
lower I-GENE
( I-GENE
P I-GENE
= I-GENE
0 O
. O
62 O
) O
than I-GENE
Hg I-GENE
concentrations I-GENE
considered I-GENE
by I-GENE
some I-GENE
government I-GENE
agencies I-GENE
to O
be I-GENE
unhealthy I-GENE
for O
human I-GENE
consumption I-GENE
. O

We I-GENE
show I-GENE
here I-GENE
that I-GENE
the O
in O
vitro I-GENE
transcription I-GENE
extract I-GENE
contains I-GENE
a O
binding I-GENE
activity I-GENE
that I-GENE
is I-GENE
specific O
for O
the O
initiator O
element O
and O
thus I-GENE
may I-GENE
participate I-GENE
in O
recruiting I-GENE
RNA I-GENE
polymerase I-GENE
II I-GENE
to O
the O
SL I-GENE
RNA I-GENE
gene I-GENE
promoter I-GENE
. O

The I-GENE
desirability I-GENE
function I-GENE
is I-GENE
based I-GENE
on I-GENE
the O
search I-GENE
for O
a O
global I-GENE
optimum I-GENE
[ I-GENE
D I-GENE
= I-GENE
f I-GENE
( I-GENE
Y1 I-GENE
, O
Y2 I-GENE
, O
..., I-GENE
Yn I-GENE
)] I-GENE
by I-GENE
the O
transformation I-GENE
of O
the O
measured I-GENE
property O
to O
a O
dimensionless O
scale I-GENE
for O
each I-GENE
criterion I-GENE
. O

Naltrexone O
hydrochloride O
is O
a O
synthetic O
opioid I-GENE
receptor I-GENE
antagonist I-GENE
recently I-GENE
used I-GENE
in O
efforts O
to O
provide I-GENE
rapid I-GENE
opioid I-GENE
detoxification I-GENE
. O

We I-GENE
mapped I-GENE
the O
DGCR6 I-GENE
gene I-GENE
to O
chromosome O
22q11 I-GENE
within I-GENE
a O
low I-GENE
copy I-GENE
repeat I-GENE
, O
termed I-GENE
sc11 I-GENE
. O
1a I-GENE
, O
and O
identified I-GENE
a O
second I-GENE
copy I-GENE
of O
the O
gene I-GENE
, O
DGCR6L I-GENE
, O
within I-GENE
the O
duplicate I-GENE
locus I-GENE
, O
termed I-GENE
sc11 I-GENE
. O
1b I-GENE
. O

Proliferative O
vasculopathy O
and O
cutaneous I-GENE
hemorrhages I-GENE
in O
porcine I-GENE
neonates I-GENE
infected O
with I-GENE
the O
porcine I-GENE
reproductive I-GENE
and O
respiratory I-GENE
syndrome O
virus O
. O

The I-GENE
child I-GENE
left O
behind I-GENE
. O

Using I-GENE
the O
two I-GENE
- I-GENE
hybrid O
system O
, O
we I-GENE
show I-GENE
that I-GENE
nonprenylated I-GENE
Rac1 O
interacts I-GENE
very I-GENE
weakly I-GENE
with I-GENE
Rho O
- I-GENE
GDI I-GENE
, O
pointing O
to O
the O
predominant I-GENE
role I-GENE
of O
protein I-GENE
- I-GENE
isoprene O
interaction O
in O
complex I-GENE
formation I-GENE
. O

In I-GENE
contrast I-GENE
, O
neither I-GENE
I I-GENE
. O
argentina I-GENE
nor I-GENE
I I-GENE
. O
theezans I-GENE
exerted I-GENE
any I-GENE
effect I-GENE
on I-GENE
BF I-GENE
or O
intestinal O
propulsion O
. O

The I-GENE
region I-GENE
containing I-GENE
both I-GENE
serines I-GENE
is I-GENE
homologous O
to O
the O
N O
- O
terminal O
destruction O
box O
of O
IkappaBalpha O
, O
- O
beta O
, O
and O
- I-GENE
epsilon I-GENE
. O

No I-GENE
dominant I-GENE
clinical I-GENE
factor I-GENE
of O
risk I-GENE
was I-GENE
found I-GENE
, O
but I-GENE
multiple I-GENE
regression I-GENE
analysis I-GENE
identified I-GENE
age I-GENE
, O
body I-GENE
surface I-GENE
area I-GENE
, O
valve I-GENE
size I-GENE
, O
shop I-GENE
order I-GENE
fracture I-GENE
rate I-GENE
, O
and O
manufacturing O
period I-GENE
as O
risk I-GENE
factors I-GENE
for O
OSF I-GENE
. O

A I-GENE
novel I-GENE
growth I-GENE
- I-GENE
related I-GENE
nuclear I-GENE
protein I-GENE
binds I-GENE
and O
inhibits I-GENE
rat I-GENE
aldolase I-GENE
B I-GENE
gene I-GENE
promoter I-GENE
. O

Northern I-GENE
blot I-GENE
analysis I-GENE
revealed I-GENE
that I-GENE
mlt I-GENE
1 I-GENE
is I-GENE
normally I-GENE
expressed O
in O
brain O
, O
spleen O
, O
stom O
ach O
, O
and O
liver O
. O

NO O
metabolites I-GENE
were I-GENE
determined I-GENE
by I-GENE
the O
measurement I-GENE
of O
nitrate O
/ O
nitrite O
( O
NOx O
, O
micromol O
/ O
mmol I-GENE
creatinine O
) O
and O
cyclic I-GENE
guanosine I-GENE
monophosphate I-GENE
( I-GENE
cGMP I-GENE
, O
nmol I-GENE
/ I-GENE
mmol I-GENE
creatinine O
) O
in O
plasma O
and O
urine I-GENE
. O

As I-GENE
a O
complement I-GENE
to O
genome I-GENE
- I-GENE
wide I-GENE
mapping I-GENE
and O
sequencing I-GENE
efforts I-GENE
, O
it I-GENE
is I-GENE
often I-GENE
important I-GENE
to O
generate I-GENE
detailed I-GENE
maps I-GENE
and O
sequence I-GENE
data I-GENE
for O
specific O
regions O
of O
interest I-GENE
. O

The I-GENE
observed I-GENE
phenotypes I-GENE
may I-GENE
be I-GENE
explained I-GENE
by I-GENE
( O
i O
) O
a O
selective I-GENE
disruption I-GENE
of O
very I-GENE
- I-GENE
low I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
secretion I-GENE
due I-GENE
to O
decreased I-GENE
expression O
of O
genes O
encoding O
apolipoprotein O
B O
and O
microsomal O
triglyceride O
transfer O
protein O
, O
( O
ii I-GENE
) I-GENE
an I-GENE
increase I-GENE
in O
hepatic I-GENE
cholesterol I-GENE
uptake I-GENE
due I-GENE
to O
increased I-GENE
expression O
of O
the O
major O
high O
- I-GENE
density I-GENE
lipoprotein I-GENE
receptor I-GENE
, O
scavenger I-GENE
receptor I-GENE
BI I-GENE
, O
and O
( O
iii I-GENE
) I-GENE
a O
decrease I-GENE
in O
bile I-GENE
acid I-GENE
uptake I-GENE
to O
the O
liver O
due I-GENE
to O
down I-GENE
- I-GENE
regulation O
of O
the O
major O
basolateral O
bile I-GENE
acid I-GENE
transporters I-GENE
sodium I-GENE
taurocholate I-GENE
cotransporter I-GENE
protein I-GENE
and O
organic I-GENE
anion I-GENE
transporter I-GENE
protein I-GENE
1 I-GENE
. O

Effects I-GENE
of O
aerosol I-GENE
- I-GENE
vapor I-GENE
JP I-GENE
- I-GENE
8 I-GENE
jet I-GENE
fuel I-GENE
on I-GENE
the O
functional O
observational O
battery I-GENE
, O
and O
learning I-GENE
and O
memory I-GENE
in O
the O
rat O
. O

In I-GENE
mouse I-GENE
, O
Mmip1 I-GENE
( I-GENE
Mad I-GENE
member I-GENE
interacting I-GENE
protein I-GENE
1 I-GENE
) I-GENE
and O
Smc3 I-GENE
share I-GENE
99 I-GENE
% I-GENE
sequence I-GENE
identity I-GENE
and O
are I-GENE
products O
of O
the O
same I-GENE
gene I-GENE
. O

To I-GENE
identify I-GENE
the O
important I-GENE
cis I-GENE
- I-GENE
DNA I-GENE
regulatory I-GENE
element I-GENE
( I-GENE
s I-GENE
) I-GENE
involved I-GENE
in O
the O
tissue O
-, O
region O
-, O
and O
cell O
- O
specific O
expression O
of O
the O
mE I-GENE
- I-GENE
RABP I-GENE
gene I-GENE
, O
the O
5 O
- O
kb O
DNA O
fragment I-GENE
was I-GENE
sequenced I-GENE
. O

Regional O
blood O
blow O
was I-GENE
measured I-GENE
by I-GENE
means I-GENE
of O
microspheres I-GENE
in O
predefined O
regions O
of O
the O
C6 O
, O
T11 O
, O
and O
L6 O
vertebrae O
. O

Breast O
cancer O
risk I-GENE
assessment I-GENE
: O
Who O
holds O
the O
magic O
crystal O
ball O
? O

The I-GENE
frameshift I-GENE
initiated I-GENE
by I-GENE
ADEx2 I-GENE
is I-GENE
believed I-GENE
to O
alter I-GENE
the O
regular I-GENE
coding I-GENE
sequence I-GENE
, O
acting I-GENE
as O
a O
loss O
- O
of O
- I-GENE
function I-GENE
ASIP I-GENE
mutation I-GENE
. O

CONCLUSIONS I-GENE
: O
Adding O
MMF O
, O
a O
potent I-GENE
topical O
corticosteroid O
, O
to O
an I-GENE
emollient I-GENE
cream I-GENE
is I-GENE
statistically I-GENE
significantly I-GENE
more I-GENE
effective I-GENE
than I-GENE
emollient I-GENE
cream I-GENE
alone I-GENE
in O
reducing I-GENE
acute I-GENE
radiation I-GENE
dermatitis I-GENE
. O

Copyright I-GENE
2001 I-GENE
Academic I-GENE
Press I-GENE
. O

CONCLUSIONS I-GENE
: O
Although I-GENE
the O
levels I-GENE
of O
oxLDL I-GENE
antibodies I-GENE
might I-GENE
be I-GENE
modified I-GENE
in O
early I-GENE
hypertension I-GENE
, O
once I-GENE
advanced I-GENE
coronary I-GENE
artery I-GENE
disease O
has I-GENE
developed I-GENE
the O
presence I-GENE
of O
hypertension I-GENE
does I-GENE
not I-GENE
affect I-GENE
anti I-GENE
- I-GENE
oxLDL I-GENE
levels I-GENE
. O

As I-GENE
an I-GENE
application I-GENE
of O
reverse I-GENE
genetics I-GENE
, O
we I-GENE
introduced I-GENE
one I-GENE
nucleotide I-GENE
change I-GENE
( O
UCU O
to O
ACU O
) O
to O
immediate O
downstream O
of O
the O
RNA O
- O
editing O
site O
of O
the O
V O
gene O
in O
the O
full I-GENE
- I-GENE
length I-GENE
hPIV2 I-GENE
cDNA I-GENE
and O
were I-GENE
able I-GENE
to O
obtain I-GENE
infectious I-GENE
viruses I-GENE
[ I-GENE
rPIV2V I-GENE
(-)] O
from O
the O
cDNA O
. O

At I-GENE
both I-GENE
companies I-GENE
sites I-GENE
Salmonella I-GENE
enteritidis I-GENE
and O
Salmonella I-GENE
typhimurium I-GENE
Tr104 I-GENE
were I-GENE
also I-GENE
isolated I-GENE
occasionally I-GENE
from O
various I-GENE
locations I-GENE
. O

Most I-GENE
yeast I-GENE
peroxisomal I-GENE
matrix I-GENE
proteins I-GENE
contain I-GENE
a O
type I-GENE
1C I-GENE
- I-GENE
terminal I-GENE
peroxisomal I-GENE
targeting I-GENE
signal I-GENE
( I-GENE
PTS1 I-GENE
) I-GENE
consisting I-GENE
of O
the O
tripeptide O
SKL O
or O
a O
conservative I-GENE
variant I-GENE
thereof I-GENE
. O

Tumor I-GENE
- I-GENE
like I-GENE
accumulation I-GENE
on I-GENE
Tl I-GENE
- I-GENE
201 I-GENE
SPECT I-GENE
in O
subacute I-GENE
hemorrhagic I-GENE
cerebral I-GENE
infarction I-GENE
. O

WRN I-GENE
helicase I-GENE
resolves I-GENE
alternate I-GENE
DNA I-GENE
structures O
including I-GENE
tetraplex O
and O
triplex O
DNA O
, O
and O
Holliday O
junctions I-GENE
. O

The I-GENE
increase I-GENE
in O
number I-GENE
of O
terminal O
hairs O
, O
which I-GENE
are I-GENE
defined I-GENE
as O
hairs I-GENE
more I-GENE
than I-GENE
60 I-GENE
microm I-GENE
in O
diameter I-GENE
, O
in O
the O
designated I-GENE
area I-GENE
( O
0 O
. O
5 O
cm I-GENE
square I-GENE
= I-GENE
0 O
. O
25 O
cm2 I-GENE
area I-GENE
) O
of O
the O
procyanidin O
B I-GENE
- I-GENE
2 I-GENE
group I-GENE
subjects I-GENE
after I-GENE
the O
6 I-GENE
- I-GENE
month I-GENE
trial I-GENE
was I-GENE
significantly I-GENE
greater I-GENE
than I-GENE
that I-GENE
of O
the O
placebo I-GENE
control O
group I-GENE
subjects I-GENE
( I-GENE
procyanidin I-GENE
B I-GENE
- I-GENE
2 I-GENE
, O
1 I-GENE
. O
99 I-GENE
+/- I-GENE
2 I-GENE
. O
58 I-GENE
( I-GENE
mean I-GENE
+/- I-GENE
SD I-GENE
)/ O
0 O
. O
25 O
cm2 I-GENE
; O
placebo I-GENE
, O
- O
0 O
. O
82 I-GENE
+/- I-GENE
3 I-GENE
. O
40 I-GENE
( I-GENE
mean I-GENE
+/- I-GENE
SD I-GENE
)/ O
0 O
. O
25 O
cm2 I-GENE
; O
P I-GENE
< I-GENE
0 O
. O
02 I-GENE
, O
two I-GENE
- I-GENE
sample I-GENE
t I-GENE
test I-GENE
). O

SKP1 I-GENE
- I-GENE
SnRK I-GENE
protein I-GENE
kinase I-GENE
interactions I-GENE
mediate I-GENE
proteasomal I-GENE
binding I-GENE
of O
a O
plant O
SCF O
ubiquitin O
ligase O
. O

Based I-GENE
on I-GENE
the O
hypothesis I-GENE
that I-GENE
evolutionarily I-GENE
conserved O
regions I-GENE
are I-GENE
functionally I-GENE
important I-GENE
and O
likely I-GENE
to O
interact I-GENE
with I-GENE
coactivators I-GENE
, O
we I-GENE
compared I-GENE
the O
amino O
acid O
sequence O
of O
C O
/ O
EBPalpha O
from O
different I-GENE
species I-GENE
( O
frog O
to O
human O
) O
and O
identified I-GENE
four I-GENE
highly I-GENE
conserved O
regions O
( O
CR1 I-GENE
- I-GENE
CR4 I-GENE
) I-GENE
within I-GENE
the O
transactivation O
domain O
. O

Colorectal O
cancer O
was I-GENE
shown I-GENE
to O
disproportionately O
overburden O
Ashkenazi O
Jews O
, O
who I-GENE
may I-GENE
also I-GENE
be I-GENE
at O
increased I-GENE
risk I-GENE
for O
ovarian I-GENE
, O
pancreatic I-GENE
and O
stomach I-GENE
cancer O
, O
and O
non O
- I-GENE
Hodgkin I-GENE
' I-GENE
s I-GENE
lymphoma I-GENE
. O

Percentages O
of O
recovery I-GENE
for O
overload I-GENE
and O
dilution I-GENE
tests I-GENE
were I-GENE
between I-GENE
87 I-GENE
and O
120 I-GENE
%. I-GENE

This I-GENE
shows I-GENE
that I-GENE
in O
situations I-GENE
of O
separated I-GENE
breaks I-GENE
, O
NHEJ I-GENE
deficiency I-GENE
leads I-GENE
to O
genomic O
rearrangements O
, O
in O
agreement I-GENE
with I-GENE
chromosomal I-GENE
studies I-GENE
. O

Copyright I-GENE
2001 I-GENE
S I-GENE
. O

After I-GENE
nerve I-GENE
injury I-GENE
, O
the O
nociceptive O
responses I-GENE
through I-GENE
type I-GENE
I I-GENE
neurons I-GENE
, O
which I-GENE
are I-GENE
polymodal I-GENE
C I-GENE
- I-GENE
fibers I-GENE
and O
drive I-GENE
NK1 I-GENE
- I-GENE
receptor I-GENE
mechanisms I-GENE
in O
spinal I-GENE
pain I-GENE
transmission I-GENE
, O
were I-GENE
completely I-GENE
lost I-GENE
, O
but I-GENE
without I-GENE
changes I-GENE
in O
type I-GENE
II I-GENE
ones I-GENE
, O
which I-GENE
are I-GENE
polymodal I-GENE
C I-GENE
- I-GENE
fibers I-GENE
and O
drive I-GENE
NMDA I-GENE
receptor I-GENE
- I-GENE
mechanisms I-GENE
, O
while I-GENE
type I-GENE
III I-GENE
ones I-GENE
, O
which I-GENE
are I-GENE
capsaicin I-GENE
- I-GENE
insensitive I-GENE
( I-GENE
possibly I-GENE
A I-GENE
- I-GENE
fibers I-GENE
) I-GENE
and O
drive I-GENE
NMDA I-GENE
- I-GENE
receptor I-GENE
mechanisms I-GENE
, O
were I-GENE
markedly I-GENE
enhanced O
. O

SV1 I-GENE
has I-GENE
a O
33 I-GENE
- I-GENE
amino I-GENE
acid I-GENE
insert I-GENE
in O
the O
S1 I-GENE
transmembrane I-GENE
domain I-GENE
that I-GENE
does I-GENE
not I-GENE
alter I-GENE
S1 I-GENE
overall I-GENE
hydrophobicity I-GENE
, O
but I-GENE
makes I-GENE
the O
S0 I-GENE
- I-GENE
S1 I-GENE
linker I-GENE
longer I-GENE
. O

A I-GENE
variety I-GENE
of O
receptor I-GENE
- I-GENE
mediated O
signaling O
pathways I-GENE
are I-GENE
controlled O
by I-GENE
both I-GENE
positive I-GENE
and O
negative O
extracellular O
regulators O
. O

A O
20 O
- O
base O
pair O
oligonucleotide O
containing O
this I-GENE
nonamer I-GENE
confers I-GENE
up O
- I-GENE
regulation O
by I-GENE
hypoxia I-GENE
and O
inhibition I-GENE
by I-GENE
unsaturated I-GENE
fatty I-GENE
acids O
when I-GENE
placed I-GENE
upstream O
of O
a O
heterologous I-GENE
promoter I-GENE
in O
a O
lacZ O
reporter O
construct O
. O

Our I-GENE
results I-GENE
indicate I-GENE
that I-GENE
D I-GENE
( O
4 O
) O
and O
D O
( O
2L I-GENE
) I-GENE
receptors I-GENE
activate I-GENE
the O
ERK O
kinase I-GENE
cascade I-GENE
by I-GENE
first O
mobilizing O
signaling O
by I-GENE
the O
PDGF I-GENE
receptor I-GENE
, O
followed I-GENE
by I-GENE
the O
subsequent I-GENE
activation O
of O
ERK1 O
/ O
2 I-GENE
by I-GENE
pathways I-GENE
associated I-GENE
with I-GENE
this I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
. O

Raes O
, O
P O
. O

Finally I-GENE
, O
we I-GENE
compared I-GENE
the O
differential I-GENE
screening I-GENE
techniques I-GENE
in O
terms I-GENE
of O
sensitivity I-GENE
, O
efficiency I-GENE
and O
occurrence I-GENE
of O
false I-GENE
positives I-GENE
. O

C O
/ O
EBPbeta O
LIP I-GENE
overexpressing I-GENE
HC11 I-GENE
cells I-GENE
did I-GENE
not I-GENE
express I-GENE
beta I-GENE
- I-GENE
casein O
mRNA I-GENE
( I-GENE
mammary I-GENE
epithelial I-GENE
cell I-GENE
differentiation I-GENE
marker I-GENE
) O
in O
response O
to O
lactogenic O
hormones O
. O

NF I-GENE
- I-GENE
kappaB I-GENE
is I-GENE
involved I-GENE
in O
the O
regulation O
of O
CD154 O
( O
CD40 O
ligand O
) O
expression O
in O
primary O
human I-GENE
T I-GENE
cells I-GENE
. O

Subacute O
diencephalic O
angioencephalopathy O
( O
SDAE O
) O
is I-GENE
a O
rare I-GENE
and O
fatal I-GENE
disease O
of O
unknown I-GENE
etiology I-GENE
that I-GENE
involves I-GENE
the O
thalami O
bilaterally O
. O

NGF O
elicits O
a O
more I-GENE
delayed I-GENE
and O
sustained I-GENE
ERK O
phosphorylation O
than I-GENE
EGF I-GENE
, O
consistent I-GENE
with I-GENE
previous I-GENE
reports I-GENE
. O

TBARS I-GENE
levels I-GENE
, O
oxygen I-GENE
- I-GENE
radical I-GENE
absorbing I-GENE
capacity I-GENE
assay I-GENE
and O
AFR I-GENE
release I-GENE
assessed I-GENE
by I-GENE
electron I-GENE
paramagnetic I-GENE
resonance I-GENE
( I-GENE
EPR I-GENE
) I-GENE
were I-GENE
used I-GENE
to O
explore I-GENE
the O
existence I-GENE
of O
oxidative I-GENE
stress I-GENE
in O
diabetes I-GENE
. O

Pulmonary O
vein O
varix O
in O
association I-GENE
with I-GENE
bilateral I-GENE
pulmonary I-GENE
vein I-GENE
stenosis I-GENE
. O

Derivation O
and O
initial I-GENE
characterization I-GENE
of O
a O
mouse I-GENE
mammary I-GENE
tumor I-GENE
cell I-GENE
line I-GENE
carrying I-GENE
the O
polyomavirus I-GENE
middle I-GENE
T I-GENE
antigen I-GENE
: O
utility O
in O
the O
development I-GENE
of O
novel I-GENE
cancer O
therapeutics O
. O

The I-GENE
images I-GENE
showed I-GENE
rapid I-GENE
, O
predominantly I-GENE
urinary I-GENE
excretion I-GENE
of O
99mTc I-GENE
ciprofloxacin O
, O
with O
low O
to O
absent I-GENE
brain O
, O
lung O
and O
bone O
marrow I-GENE
uptake I-GENE
and O
low O
liver O
uptake I-GENE
and O
excretion I-GENE
. O

Thus I-GENE
, O
the O
anti I-GENE
- I-GENE
interferon I-GENE
functions I-GENE
of O
vIRF I-GENE
- I-GENE
2 I-GENE
may I-GENE
contribute I-GENE
to O
the O
establishment I-GENE
of O
a O
chronic I-GENE
or O
latent I-GENE
infection I-GENE
. O

Topological O
and O
mutational I-GENE
analysis I-GENE
of O
Saccharomyces I-GENE
cerevisiae I-GENE
Ste14p I-GENE
, O
founding O
member O
of O
the O
isoprenylcysteine O
carboxyl O
methyltransferase I-GENE
family I-GENE
. O

Two I-GENE
remotely I-GENE
situated I-GENE
exons I-GENE
within I-GENE
the O
complement I-GENE
C3 I-GENE
gene I-GENE
locus I-GENE
encode I-GENE
an I-GENE
alternate I-GENE
5 I-GENE
' I-GENE
end I-GENE
and O
proximal I-GENE
ORF I-GENE
under I-GENE
the O
control O
of O
a O
bidirectional O
promoter O
. O

Although I-GENE
there I-GENE
was I-GENE
a O
high I-GENE
correlation I-GENE
between I-GENE
sap I-GENE
flux I-GENE
densities I-GENE
registered I-GENE
by I-GENE
the O
old I-GENE
and O
new I-GENE
sensors I-GENE
, O
significant I-GENE
differences I-GENE
in O
sap I-GENE
flux I-GENE
densities I-GENE
between I-GENE
the O
duplicated I-GENE
sensors I-GENE
were I-GENE
detected I-GENE
. O

Their I-GENE
numbers I-GENE
have I-GENE
regularly I-GENE
increased I-GENE
since I-GENE
the O
mid I-GENE
- I-GENE
1970s I-GENE
. O

The I-GENE
hcKrox I-GENE
gene I-GENE
family I-GENE
regulates I-GENE
multiple I-GENE
extracellular I-GENE
matrix I-GENE
genes I-GENE
. O

NB I-GENE
- I-GENE
506 I-GENE
completely I-GENE
inhibits I-GENE
the O
capacity I-GENE
of O
topoisomerase O
I O
to O
phosphorylate I-GENE
, O
in O
vitro I-GENE
, O
the O
human O
splicing O
factor O
2 O
/ O
alternative O
splicing O
factor I-GENE
( I-GENE
SF2 I-GENE
/ I-GENE
ASF I-GENE
). O

Recent I-GENE
studies I-GENE
using I-GENE
isolated I-GENE
rat I-GENE
adipocytes I-GENE
and O
chemically I-GENE
synthesized I-GENE
PIG I-GENE
compounds I-GENE
point I-GENE
to O
IRS1 I-GENE
/ I-GENE
3 I-GENE
tyrosine I-GENE
phosphorylation O
by I-GENE
p59Lyn I-GENE
kinase I-GENE
as O
the O
site O
of O
cross I-GENE
- I-GENE
talk O
, O
the O
negative O
regulation O
of O
which I-GENE
by I-GENE
interaction I-GENE
with I-GENE
caveolin I-GENE
is I-GENE
apparently I-GENE
abrogated I-GENE
by I-GENE
PIG I-GENE
. O

To I-GENE
investigate I-GENE
the O
effects I-GENE
of O
exogenous O
hyaluronic O
acid O
, O
the O
development I-GENE
of O
port I-GENE
- I-GENE
site I-GENE
metastasis I-GENE
was I-GENE
examined I-GENE
using I-GENE
mouse I-GENE
adenocarcinoma I-GENE
cell I-GENE
- I-GENE
line I-GENE
colon I-GENE
26 O
cells I-GENE
. O

METHODS I-GENE
: O
Thyroid I-GENE
status I-GENE
was I-GENE
measured I-GENE
at O
baseline I-GENE
( I-GENE
1990 I-GENE
- I-GENE
93 I-GENE
), O
through I-GENE
assessment I-GENE
of O
serum I-GENE
antibodies I-GENE
to O
thyroid O
peroxidase O
( O
TPO O
- O
Abs O
, O
positive I-GENE
: O
> I-GENE
10 I-GENE
IU I-GENE
/ I-GENE
ml I-GENE
), O
serum I-GENE
TSH I-GENE
levels I-GENE
, O
and O
when I-GENE
TSH I-GENE
was I-GENE
abnormal I-GENE
(< I-GENE
0 O
. O
4 O
or O
> I-GENE
4 I-GENE
. O
0 O
mU O
/ O
l O
), O
serum I-GENE
thyroxin I-GENE
levels I-GENE
( I-GENE
T4 I-GENE
). O

Mechanical O
ventilation I-GENE
in O
control I-GENE
lungs I-GENE
produced I-GENE
a O
47 I-GENE
% I-GENE
decrease I-GENE
in O
chord I-GENE
compliance I-GENE
, O
an I-GENE
increase I-GENE
in O
lung O
lavage O
levels I-GENE
of O
tumor I-GENE
necrosis I-GENE
factor I-GENE
( I-GENE
TNF O
)- I-GENE
alpha I-GENE
( I-GENE
722 I-GENE
+/- I-GENE
306 I-GENE
pg I-GENE
/ I-GENE
ml I-GENE
), O
interleukin O
( O
IL I-GENE
)- I-GENE
1beta O
( I-GENE
902 I-GENE
+/- I-GENE
322 I-GENE
pg I-GENE
/ I-GENE
ml I-GENE
), O
and O
macrophage I-GENE
inflammatory I-GENE
protein I-GENE
- I-GENE
2 I-GENE
( I-GENE
MIP I-GENE
- I-GENE
2 I-GENE
) I-GENE
( I-GENE
363 I-GENE
+/- I-GENE
104 I-GENE
pg I-GENE
/ I-GENE
ml I-GENE
) I-GENE
as O
compared I-GENE
with I-GENE
low I-GENE
levels I-GENE
of O
cytokines I-GENE
detected I-GENE
in O
preventilation I-GENE
data I-GENE
, O
and O
no O
change I-GENE
in O
percentage I-GENE
of O
surfactant I-GENE
large I-GENE
aggregates I-GENE
( I-GENE
LA I-GENE
). O

Autoregulation O
enables I-GENE
different I-GENE
pathways I-GENE
to O
control I-GENE
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
beta I-GENE
( I-GENE
C I-GENE
/ I-GENE
EBP O
beta I-GENE
) I-GENE
transcription I-GENE
. O

In I-GENE
the O
past I-GENE
decade I-GENE
, O
there I-GENE
have I-GENE
been I-GENE
enormous O
advances O
in O
the O
use I-GENE
of O
Bayesian O
methodology O
for O
analysis I-GENE
of O
epidemiologic I-GENE
data I-GENE
, O
and O
there I-GENE
are I-GENE
now I-GENE
many I-GENE
practical I-GENE
advantages I-GENE
to O
the O
Bayesian O
approach I-GENE
. O

In I-GENE
strains I-GENE
lacking O
tup11 I-GENE
and O
tup12 I-GENE
, O
the O
atf1 I-GENE
- I-GENE
pcr1 I-GENE
transcriptional I-GENE
activator I-GENE
continues I-GENE
to O
play I-GENE
a O
central I-GENE
role I-GENE
in O
fbp1 I-GENE
- I-GENE
lacZ O
expression O
; O
however I-GENE
, O
spc1 I-GENE
MAPK I-GENE
phosphorylation O
of O
atf1 I-GENE
is I-GENE
no O
longer I-GENE
essential I-GENE
for O
its I-GENE
activation O
. O

Single O
amino O
acid O
substitutions I-GENE
at O
the O
acyl O
- O
CoA O
- O
binding O
domain O
interrupt O
14 O
[ O
C O
] O
palmitoyl O
- O
CoA O
binding O
of O
ACBP2 I-GENE
, O
an I-GENE
Arabidopsis I-GENE
acyl I-GENE
- I-GENE
CoA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
with I-GENE
ankyrin I-GENE
repeats I-GENE
. O

RESULTS I-GENE
: O
Sixty I-GENE
per I-GENE
cent I-GENE
of O
African I-GENE
Americans I-GENE
exposed I-GENE
in O
26 O
community I-GENE
outbreaks I-GENE
were I-GENE
TST I-GENE
positive I-GENE
compared I-GENE
to O
only I-GENE
40 I-GENE
% I-GENE
of O
whites I-GENE
following I-GENE
comparable I-GENE
exposures I-GENE
. O

For I-GENE
immunological I-GENE
methods I-GENE
, O
identification I-GENE
of O
such I-GENE
antigens I-GENE
with I-GENE
intermolecular I-GENE
variability I-GENE
, O
e O
. O
g I-GENE
., I-GENE
the O
structural O
aescin O
analogs O
, O
is I-GENE
of O
unknown I-GENE
validity I-GENE
. O

It I-GENE
was I-GENE
found I-GENE
that I-GENE
intrathecal I-GENE
administration I-GENE
( O
i O
. O
t I-GENE
.) I-GENE
of O
D2 I-GENE
receptor I-GENE
agonist I-GENE
LY171555 I-GENE
or O
D1 I-GENE
/ I-GENE
D2 I-GENE
receptor I-GENE
agonist I-GENE
apomorphine I-GENE
increased I-GENE
pain I-GENE
threshold I-GENE
and O
had I-GENE
a O
potentiating I-GENE
effect I-GENE
on I-GENE
AA I-GENE
. O

Interactions O
between I-GENE
the O
checkpoint I-GENE
abrogator I-GENE
UCN I-GENE
- I-GENE
01 I-GENE
and O
several I-GENE
pharmacological I-GENE
inhibitors O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( I-GENE
MAPK I-GENE
) I-GENE
kinase I-GENE
( I-GENE
MEK O
)/ I-GENE
MAPK I-GENE
pathway O
have I-GENE
been I-GENE
examined I-GENE
in O
a O
variety I-GENE
of O
human I-GENE
leukemia I-GENE
cell I-GENE
lines I-GENE
. O

Analysis I-GENE
of O
regulatory O
regions O
in O
the O
promoter O
of O
the O
ctr4 I-GENE
(+) I-GENE
copper I-GENE
transporter I-GENE
gene I-GENE
in O
fission I-GENE
yeast I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
reveals I-GENE
the O
identity I-GENE
of O
a O
conserved O
copper O
- O
signaling O
element O
( O
CuSE I-GENE
), O
which I-GENE
is I-GENE
recognized I-GENE
by I-GENE
the O
transcription I-GENE
factor I-GENE
Cuf1 I-GENE
. O

However I-GENE
, O
during O
our I-GENE
work I-GENE
with I-GENE
a O
replication I-GENE
- I-GENE
deficient O
virus I-GENE
expressing I-GENE
the O
ASF I-GENE
/ I-GENE
SF2 I-GENE
splicing I-GENE
factor I-GENE
from O
a O
progesterone I-GENE
antagonist I-GENE
- I-GENE
inducible I-GENE
gene I-GENE
cassette I-GENE
, O
we I-GENE
discovered I-GENE
that I-GENE
ASF I-GENE
/ I-GENE
SF2 I-GENE
was I-GENE
expressed O
at O
a O
significant I-GENE
level I-GENE
in O
the O
293 I-GENE
producer I-GENE
cell I-GENE
line I-GENE
, O
even I-GENE
in O
the O
absence I-GENE
of O
inducer O
. O

This I-GENE
study I-GENE
suggests I-GENE
that I-GENE
PSP I-GENE
is I-GENE
more I-GENE
common I-GENE
than I-GENE
previously I-GENE
considered I-GENE
, O
is I-GENE
commonly I-GENE
misdiagnosed I-GENE
and O
that I-GENE
the O
majority I-GENE
of O
cases I-GENE
are I-GENE
not I-GENE
initially I-GENE
referred I-GENE
to O
neurologists O
. O

Between O
1967 I-GENE
and O
1994 I-GENE
, O
495 I-GENE
patients I-GENE
underwent I-GENE
surgery I-GENE
for O
primary O
PTC O
at O
the O
Department O
of O
Surgery O
, O
Helsinki O
University I-GENE
Central I-GENE
Hospital I-GENE
. O

The I-GENE
described I-GENE
results I-GENE
show I-GENE
that I-GENE
DTD I-GENE
is I-GENE
fast I-GENE
, O
simple I-GENE
, O
and O
easy O
to O
automate O
; O
requires I-GENE
only I-GENE
a O
small I-GENE
amount I-GENE
of O
sample I-GENE
( I-GENE
approximately O
50 I-GENE
mg I-GENE
); I-GENE
and O
affords I-GENE
quantitative I-GENE
information I-GENE
about I-GENE
the O
main I-GENE
groups I-GENE
of O
compounds I-GENE
present I-GENE
in O
cheeses O
. O

Srb10 I-GENE
is I-GENE
a O
physiological I-GENE
regulator I-GENE
of O
Gcn4 I-GENE
stability I-GENE
because I-GENE
both I-GENE
phosphorylation O
and O
turnover I-GENE
of O
Gcn4 I-GENE
are I-GENE
diminished I-GENE
in O
srb10 I-GENE
mutants I-GENE
. O

The I-GENE
promoter I-GENE
activity I-GENE
of O
the O
proximal O
region O
was I-GENE
found I-GENE
to O
be I-GENE
restricted I-GENE
to O
a O
subset I-GENE
of O
prestalk I-GENE
cells I-GENE
. O

Two I-GENE
nuclear I-GENE
medicine I-GENE
physicians I-GENE
blinded O
to O
the O
surgical I-GENE
findings I-GENE
interpreted I-GENE
all I-GENE
available I-GENE
images I-GENE
and O
various I-GENE
Tc I-GENE
- I-GENE
99m I-GENE
MIBI I-GENE
image I-GENE
combinations I-GENE
at O
15 O
minutes I-GENE
alone I-GENE
; O
15 O
minutes I-GENE
and O
2 I-GENE
hours I-GENE
, O
15 O
minutes I-GENE
and O
4 I-GENE
hours I-GENE
; O
and O
15 O
minutes I-GENE
and O
2 I-GENE
and O
4 I-GENE
hours I-GENE
each I-GENE
with I-GENE
and O
without I-GENE
correlative I-GENE
pertechnetate I-GENE
thyroid I-GENE
imaging I-GENE
. O

We I-GENE
demonstrated I-GENE
that I-GENE
, O
under I-GENE
serum I-GENE
- I-GENE
starved I-GENE
conditions I-GENE
, O
KMS I-GENE
- I-GENE
11 I-GENE
and O
OPM I-GENE
- I-GENE
2 I-GENE
cells I-GENE
express I-GENE
appreciable I-GENE
levels I-GENE
of O
phosphorylated O
FGFR3 I-GENE
mutants I-GENE
indicating I-GENE
a O
constitutive O
activation O
of O
the O
Y373C I-GENE
and O
K650E I-GENE
receptors I-GENE
; O
the O
addition I-GENE
of O
the O
aFGF I-GENE
ligand I-GENE
further I-GENE
increased I-GENE
the O
level I-GENE
of O
receptor I-GENE
phosphorylation O
. O

Identical O
effects I-GENE
were I-GENE
obtained I-GENE
when I-GENE
inhibitors O
and O
dominant O
negative O
mutants I-GENE
were I-GENE
tested I-GENE
on I-GENE
the O
- I-GENE
29 I-GENE
to O
+ I-GENE
139 I-GENE
bp O
region O
of O
the O
cyclin I-GENE
D1 I-GENE
promoter I-GENE
. O

In I-GENE
this I-GENE
paper I-GENE
the O
tyrosine O
dephosphorylating O
enzymes O
, O
the O
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatases I-GENE
( I-GENE
PTPs I-GENE
), O
are I-GENE
studied I-GENE
which I-GENE
can I-GENE
be I-GENE
grouped I-GENE
into I-GENE
two I-GENE
subfamilies O
, O
the O
soluble O
PTPs O
and O
the O
receptor O
PTPs O
( O
RPTPs O
). O

Coexposure O
to O
FP I-GENE
also I-GENE
resulted I-GENE
in O
a O
more I-GENE
pronounced I-GENE
and O
sustained I-GENE
activation O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
/ I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
protein I-GENE
kinase I-GENE
cascade I-GENE
after I-GENE
PMA I-GENE
treatment I-GENE
, O
although I-GENE
disruption I-GENE
of O
this I-GENE
pathway O
by I-GENE
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
1 I-GENE
inhibitor I-GENE
U0126 I-GENE
did I-GENE
not I-GENE
prevent I-GENE
potentiation I-GENE
of O
apoptosis I-GENE
. O

The I-GENE
LA I-GENE
50s I-GENE
derived I-GENE
from O
this I-GENE
combined I-GENE
data I-GENE
when I-GENE
compared I-GENE
with I-GENE
our I-GENE
earlier I-GENE
series I-GENE
from O
1965 I-GENE
to O
1970 I-GENE
also I-GENE
did I-GENE
not I-GENE
show I-GENE
a O
significant I-GENE
change I-GENE
in O
mortality I-GENE
. O

Most I-GENE
patients I-GENE
harboring I-GENE
metronidazole I-GENE
- I-GENE
and O
clarithromycin I-GENE
- I-GENE
resistant I-GENE
strains I-GENE
were I-GENE
eradicated I-GENE
at O
an I-GENE
equal I-GENE
rate I-GENE
by I-GENE
each I-GENE
of O
the O
three I-GENE
regimens I-GENE
. O

Responses O
of O
single O
- I-GENE
unit I-GENE
carotid I-GENE
body I-GENE
chemoreceptors I-GENE
in O
adult I-GENE
rats I-GENE
. O

Thus I-GENE
, O
MKK7 I-GENE
is I-GENE
an I-GENE
essential I-GENE
and O
specific O
regulator O
of O
stress O
- O
induced O
SAPK O
/ O
JNK O
activation O
in O
mast O
cells I-GENE
and O
MKK7 I-GENE
negatively I-GENE
regulates I-GENE
growth I-GENE
factor I-GENE
and O
antigen I-GENE
receptor I-GENE
- I-GENE
driven O
proliferation O
in O
hematopoietic I-GENE
cells I-GENE
. O

The I-GENE
N I-GENE
- I-GENE
terminal I-GENE
portion I-GENE
of O
Notch O
( O
IC I-GENE
) I-GENE
inhibited I-GENE
p50 I-GENE
DNA I-GENE
binding I-GENE
and O
interacted I-GENE
specifically I-GENE
with I-GENE
p50 I-GENE
subunit I-GENE
, O
not I-GENE
p65 I-GENE
of O
NF I-GENE
- I-GENE
kappaB I-GENE
. O

To I-GENE
account I-GENE
for O
this I-GENE
observation I-GENE
, O
other I-GENE
possible I-GENE
causes I-GENE
include I-GENE
increased I-GENE
CSF I-GENE
pulsation I-GENE
in O
children I-GENE
creating I-GENE
motion I-GENE
artifact I-GENE
, O
changes I-GENE
in O
arterial I-GENE
oxygen I-GENE
concentration I-GENE
intrinsic O
to O
propofol O
or O
related O
to O
the O
supplemental O
oxygen I-GENE
normally I-GENE
administered I-GENE
, O
or O
changes I-GENE
in O
CSF I-GENE
protein I-GENE
levels I-GENE
related I-GENE
to O
propofol I-GENE
binding I-GENE
to O
proteins I-GENE
for O
uptake I-GENE
into I-GENE
CSF I-GENE
. O

Molecular I-GENE
cloning I-GENE
and O
characterization I-GENE
of O
OsPSK I-GENE
, O
a O
gene O
encoding O
a O
precursor O
for O
phytosulfokine O
- I-GENE
alpha I-GENE
, O
required I-GENE
for O
rice O
cell O
proliferation O
. O

The I-GENE
present I-GENE
study I-GENE
was I-GENE
initiated I-GENE
to O
explore I-GENE
the O
potential O
of O
a O
hybrid O
biological I-GENE
reactor I-GENE
, O
combining I-GENE
trickling I-GENE
filter I-GENE
( I-GENE
TF I-GENE
) I-GENE
and O
activated I-GENE
sludge I-GENE
process I-GENE
( O
ASP O
), O
to O
treat I-GENE
wastewater O
containing O
trichloroethylene O
( O
TCE O
) O
at O
ambient O
temperature O
at O
different I-GENE
hydraulic I-GENE
retention I-GENE
time I-GENE
( I-GENE
HRT I-GENE
). O

If I-GENE
you I-GENE
think I-GENE
education I-GENE
is I-GENE
expensive O
-- O
try O
ignorance O
-- O
Bok O
' O
s O
Law O
. O

The I-GENE
COD I-GENE
and O
color I-GENE
removals I-GENE
were I-GENE
both I-GENE
more I-GENE
than I-GENE
90 O
% I-GENE
when I-GENE
FeCl3 I-GENE
was I-GENE
used I-GENE
as O
the O
coagulation O
( O
dosages O
of O
two I-GENE
- I-GENE
step I-GENE
coagulation I-GENE
were I-GENE
0 O
. O
031 O
and O
0 O
. O
012 I-GENE
mol I-GENE
/ I-GENE
L I-GENE
respectively I-GENE
) I-GENE
after I-GENE
a O
ferrous I-GENE
hydrogen I-GENE
peroxide I-GENE
oxidation I-GENE
pretreatment I-GENE
at O
a O
H2O2 I-GENE
dosage I-GENE
of O
0 O
. O
06 I-GENE
mol I-GENE
/ I-GENE
L I-GENE
. O

An I-GENE
element I-GENE
within I-GENE
the O
5 O
' O
untranslated O
region O
of O
human I-GENE
Hsp70 I-GENE
mRNA I-GENE
which I-GENE
acts I-GENE
as O
a O
general O
enhancer O
of O
mRNA O
translation O
. O

The I-GENE
selective I-GENE
alteration I-GENE
of O
the O
genome I-GENE
using I-GENE
Cre O
recombinase O
to O
target O
the O
rearrangement I-GENE
of O
genes I-GENE
flanked I-GENE
by I-GENE
LOX I-GENE
recognition I-GENE
sequences I-GENE
has I-GENE
required I-GENE
the O
use I-GENE
of O
two I-GENE
separate I-GENE
genetic I-GENE
constructs O
in O
trans O
, O
one O
containing O
cre O
and O
the O
other I-GENE
containing I-GENE
the O
gene I-GENE
of O
interest I-GENE
flanked I-GENE
by I-GENE
LOX I-GENE
sites I-GENE
. O

It I-GENE
has I-GENE
been I-GENE
suggested I-GENE
that I-GENE
members I-GENE
of O
this I-GENE
protein I-GENE
family I-GENE
exhibit I-GENE
both I-GENE
prolyl O
isomerase O
and O
chaperone O
activity I-GENE
. O

Newcastle O
disease O
antibody I-GENE
titre I-GENE
is I-GENE
dependent I-GENE
on I-GENE
serum I-GENE
calcium O
concentration I-GENE
. O

In I-GENE
three I-GENE
cases I-GENE
( I-GENE
21 I-GENE
. O
4 I-GENE
%), I-GENE
the O
MR I-GENE
imaging I-GENE
was I-GENE
interpreted I-GENE
as O
negative O
, O
but I-GENE
microscopic I-GENE
tumor I-GENE
was I-GENE
shown I-GENE
around I-GENE
seroma I-GENE
on I-GENE
reexcision I-GENE
. O

2 O
were O
nonviable O
, O
and O
the O
mutant I-GENE
Vp1s I-GENE
unexpectedly I-GENE
failed I-GENE
to O
localize I-GENE
to O
the O
nucleus I-GENE
though I-GENE
Vp2 I-GENE
and O
Vp3 I-GENE
did I-GENE
, O
suggesting I-GENE
that I-GENE
the O
mutated O
NLS1 O
acted O
as O
a O
dominant O
signal O
for O
the O
cytoplasmic O
localization O
of O
Vp1 O
. O

Compared O
with I-GENE
normal I-GENE
control O
subjects I-GENE
, O
all I-GENE
74 I-GENE
TOF I-GENE
patients I-GENE
had I-GENE
decreased I-GENE
systolic I-GENE
and O
diastolic I-GENE
myocardial O
velocities O
and O
a O
longer I-GENE
isovolumic I-GENE
relaxation I-GENE
time I-GENE
. O

The I-GENE
corresponding I-GENE
orifice O
voltages O
for O
the O
three I-GENE
instruments I-GENE
were I-GENE
20 I-GENE
/ I-GENE
50 I-GENE
/ I-GENE
80 O
V I-GENE
( I-GENE
API I-GENE
365 I-GENE
), O
30 O
/ O
90 O
/ O
130 O
V O
( O
API I-GENE
2000 I-GENE
) O
and O
40 O
/ O
80 O
/ O
120 I-GENE
V I-GENE
( I-GENE
API I-GENE
3000 I-GENE
). O

We I-GENE
compared I-GENE
previously I-GENE
the O
methylation I-GENE
status I-GENE
between I-GENE
normal I-GENE
liver I-GENE
and O
liver I-GENE
tumors I-GENE
in O
SV40 I-GENE
T I-GENE
/ I-GENE
t I-GENE
antigen I-GENE
transgenic I-GENE
mice I-GENE
( I-GENE
MT I-GENE
- I-GENE
D2 I-GENE
mice I-GENE
) I-GENE
using I-GENE
Restriction I-GENE
Landmark I-GENE
Genomic I-GENE
Scanning O
for O
Methylation O
( O
RLGS O
- O
M O
) O
and O
identified I-GENE
several I-GENE
loci I-GENE
/ I-GENE
spots I-GENE
that I-GENE
appeared I-GENE
to O
be I-GENE
methylated I-GENE
frequently I-GENE
in O
liver I-GENE
tumors I-GENE
. O

We I-GENE
have I-GENE
cloned O
a O
novel I-GENE
mouse I-GENE
protein I-GENE
, O
TAF I-GENE
( I-GENE
II I-GENE
) O
140 O
, O
containing O
an O
HFD O
and O
a O
plant O
homeodomain I-GENE
( I-GENE
PHD I-GENE
) I-GENE
finger I-GENE
, O
which I-GENE
we I-GENE
demonstrated I-GENE
by I-GENE
immunoprecipitation I-GENE
to O
be I-GENE
a O
mammalian O
TFIID O
component O
. O

3D I-GENE
image I-GENE
- I-GENE
processing O
permits I-GENE
to O
analyse I-GENE
ultrasound I-GENE
data I-GENE
interactively I-GENE
in O
three I-GENE
orthogonal I-GENE
planes I-GENE
( I-GENE
section I-GENE
mode I-GENE
) O
or O
in O
realistic O
3D O
views O
( O
rendering O
mode I-GENE
). O

A O
proposal O
of O
50 I-GENE
performance I-GENE
indicators I-GENE
divided I-GENE
into I-GENE
five I-GENE
different I-GENE
groups I-GENE
is I-GENE
presented I-GENE
here I-GENE
, O
namely I-GENE
structural I-GENE
indicators I-GENE
, O
operational I-GENE
indicators I-GENE
, O
water I-GENE
and O
service I-GENE
quality I-GENE
indicators I-GENE
, O
personnel I-GENE
indicators I-GENE
and O
economic I-GENE
indicators I-GENE
. O

These I-GENE
analyses I-GENE
re I-GENE
- I-GENE
open I-GENE
the O
question I-GENE
whether I-GENE
all I-GENE
the O
CesA I-GENE
genes I-GENE
encode I-GENE
cellulose I-GENE
synthases I-GENE
or O
whether I-GENE
some I-GENE
of O
the O
sub I-GENE
- I-GENE
class I-GENE
members I-GENE
may I-GENE
encode I-GENE
other I-GENE
non I-GENE
- I-GENE
cellulosic I-GENE
( I-GENE
1 I-GENE
--> I-GENE
4 I-GENE
) I-GENE
beta I-GENE
- I-GENE
glycan O
synthases O
in O
plants O
. O

The I-GENE
relationship I-GENE
of O
the O
factor O
V O
Leiden O
mutation O
or O
the O
deletion O
- I-GENE
deletion I-GENE
polymorphism I-GENE
of O
the O
angiotensin O
converting I-GENE
enzyme I-GENE
to O
postoperative I-GENE
thromboembolic I-GENE
events I-GENE
following I-GENE
total O
joint I-GENE
arthroplasty I-GENE
. O

In I-GENE
contrast I-GENE
, O
exogenous I-GENE
PTHrP1 I-GENE
- I-GENE
34 I-GENE
and O
1 I-GENE
- I-GENE
86 I-GENE
peptides I-GENE
did I-GENE
not I-GENE
significantly I-GENE
affect I-GENE
IL I-GENE
- I-GENE
8 I-GENE
production I-GENE
; O
moreover O
, O
PTHrP I-GENE
- I-GENE
neutralizing I-GENE
antibodies I-GENE
did I-GENE
not I-GENE
inhibit I-GENE
the O
production I-GENE
of O
IL I-GENE
- I-GENE
8 I-GENE
by I-GENE
transfected I-GENE
PTHrP I-GENE
. O

Furthermore I-GENE
, O
this I-GENE
kinase I-GENE
- I-GENE
deficient O
mutant I-GENE
inhibited I-GENE
2 I-GENE
- I-GENE
MeSADP I-GENE
- I-GENE
induced O
caspase O
- O
3 O
stimulation O
and O
the O
associated O
decrease I-GENE
in O
cell I-GENE
number I-GENE
. O

Against O
gram I-GENE
- I-GENE
positive I-GENE
organisms I-GENE
, O
E I-GENE
- I-GENE
4767 I-GENE
and O
E I-GENE
- I-GENE
5065 I-GENE
were I-GENE
, O
in O
general O
, O
eight I-GENE
- I-GENE
and O
fourfold I-GENE
more I-GENE
active I-GENE
than I-GENE
tosufloxacin I-GENE
, O
which I-GENE
is I-GENE
the O
most I-GENE
potent I-GENE
of O
the O
reference I-GENE
compounds I-GENE
. O

The I-GENE
results I-GENE
presented I-GENE
here I-GENE
show I-GENE
that I-GENE
AR1 I-GENE
of O
the O
promoter I-GENE
- I-GENE
proximal I-GENE
CAP I-GENE
subunit I-GENE
was I-GENE
required I-GENE
for O
papBA I-GENE
transcription I-GENE
even I-GENE
in O
the O
absence I-GENE
of O
the O
histone O
- I-GENE
like I-GENE
protein I-GENE
H I-GENE
- I-GENE
NS I-GENE
. O

CONCLUSIONS I-GENE
: O
Under I-GENE
current I-GENE
immunization I-GENE
practices O
, O
the O
authors I-GENE
estimate I-GENE
that I-GENE
nearly I-GENE
13 O
, O
000 O
Asian O
and O
Pacific O
Islander O
children I-GENE
living I-GENE
in O
the O
United I-GENE
States I-GENE
today I-GENE
will I-GENE
become I-GENE
infected O
with O
HBV O
in O
the O
future I-GENE
, O
resulting I-GENE
in O
more I-GENE
than I-GENE
600 I-GENE
liver I-GENE
carcinoma I-GENE
deaths I-GENE
. O

METHODS I-GENE
: O
A I-GENE
structured I-GENE
interview I-GENE
was I-GENE
undertaken I-GENE
at O
the O
time I-GENE
of O
initial I-GENE
consultation O
and O
at O
subsequent I-GENE
1 I-GENE
- I-GENE
year I-GENE
intervals I-GENE
regarding I-GENE
type I-GENE
of O
BHS I-GENE
, O
frequency I-GENE
of O
spells O
, O
associated O
phenomenon I-GENE
, O
sequelae O
, O
family I-GENE
history I-GENE
, O
and O
age I-GENE
at O
termination O
of O
spells O
. O

Cell I-GENE
. O

Rapid O
evolution I-GENE
of O
the O
DNA O
- O
binding O
site O
in O
LAGLIDADG O
homing O
endonucleases O
. O

These I-GENE
mutations I-GENE
, O
when I-GENE
placed I-GENE
in O
a O
wild I-GENE
- I-GENE
type I-GENE
fliF I-GENE
background I-GENE
, O
had I-GENE
no O
mutant O
phenotype O
. O

Inhibition I-GENE
of O
JNK1 O
and O
ERK O
kinase I-GENE
activities I-GENE
either I-GENE
by I-GENE
expression O
of O
the O
dominant O
negative O
mutant O
JNK1 O
or O
by I-GENE
treatment I-GENE
with I-GENE
a O
selective I-GENE
chemical I-GENE
inhibitor I-GENE
of O
ERK O
( O
PD098059 I-GENE
) I-GENE
substantially I-GENE
abrogates O
the O
UV O
induction I-GENE
of O
the O
GADD45 I-GENE
promoter I-GENE
. O

At I-GENE
termination O
( O
gd O
20 O
), O
confirmed I-GENE
- I-GENE
pregnant I-GENE
females I-GENE
( I-GENE
21 I-GENE
to O
25 I-GENE
per I-GENE
group I-GENE
) I-GENE
were I-GENE
evaluated I-GENE
for O
clinical I-GENE
status I-GENE
and O
gestational I-GENE
outcome I-GENE
; O
live I-GENE
fetuses I-GENE
were I-GENE
examined I-GENE
for O
external I-GENE
, O
visceral I-GENE
, O
and O
skeletal I-GENE
malformations I-GENE
. O

In I-GENE
mammals I-GENE
, O
the O
transcriptional O
repressors O
in O
the O
Wnt O
pathway O
are I-GENE
not I-GENE
well O
defined I-GENE
. O

Intravenous I-GENE
L I-GENE
- I-GENE
carnitine I-GENE
treatment I-GENE
increased I-GENE
plasma I-GENE
carnitine I-GENE
concentrations I-GENE
, O
improved I-GENE
patient I-GENE
- I-GENE
assessed I-GENE
fatigue O
, O
and O
may I-GENE
prevent I-GENE
the O
decline I-GENE
in O
peak I-GENE
exercise I-GENE
capacity I-GENE
in O
hemodialysis I-GENE
patients I-GENE
. O

The O
Van O
der O
Hoeve O
' O
s O
syndrome O
lesions I-GENE
as O
poorly I-GENE
mineralized O
, O
with O
low O
calcium O
salt I-GENE
and O
apparent I-GENE
increase I-GENE
of O
phosphates O
. O

A I-GENE
computerized I-GENE
method I-GENE
of O
determining O
the O
focal I-GENE
point I-GENE
of O
electrical I-GENE
activity I-GENE
in O
the O
pallidum O
of O
parkinsonian O
patients I-GENE
was I-GENE
developed I-GENE
using I-GENE
on I-GENE
- I-GENE
line I-GENE
quantitative I-GENE
physiological I-GENE
data I-GENE
analysis I-GENE
. O

The I-GENE
first O
hypothesis I-GENE
was I-GENE
supported I-GENE
in O
the O
sense I-GENE
that I-GENE
stimulus I-GENE
differences I-GENE
might I-GENE
affect I-GENE
behaviour I-GENE
even I-GENE
without I-GENE
their I-GENE
successful I-GENE
attentive O
processing O
in O
normal I-GENE
participants I-GENE
. O

We I-GENE
interpret I-GENE
these I-GENE
data I-GENE
as O
further I-GENE
evidence I-GENE
that I-GENE
interaction I-GENE
with I-GENE
a O
small I-GENE
GTPase O
is I-GENE
the O
main I-GENE
regulatory I-GENE
function I-GENE
of O
the O
C1 O
domain O
in O
yeast O
. O

This I-GENE
effect I-GENE
was I-GENE
observed I-GENE
in O
the O
absence I-GENE
of O
de I-GENE
novo I-GENE
protein I-GENE
synthesis O
and O
was I-GENE
independent I-GENE
of O
histone O
deacetylase O
activity I-GENE
. O

Mutation I-GENE
analyses I-GENE
identified I-GENE
the O
cobalt O
- O
responsive O
sequences O
as O
the O
stress O
- O
response O
elements O
( O
StREs O
). O

In I-GENE
order I-GENE
to O
quantify I-GENE
these I-GENE
effects I-GENE
, O
tests I-GENE
were I-GENE
conducted I-GENE
in O
the O
NASA O
MSFC O
Neutral O
Buoyancy O
Simulator O
, O
in O
the O
NASA I-GENE
KC I-GENE
- I-GENE
135 I-GENE
in O
parabolic O
flight O
, O
and O
in O
space I-GENE
with I-GENE
the O
EASE I-GENE
program I-GENE
during O
the O
Shuttle O
Atlantis O
mission O
61 O
- O
B O
. O

OBJECTIVE I-GENE
: O
To I-GENE
investigate I-GENE
the O
association I-GENE
between I-GENE
complete I-GENE
congenital I-GENE
heart O
block O
( O
CCHB O
) O
in O
the O
fetus I-GENE
and O
adult I-GENE
disease O
. O

The I-GENE
present I-GENE
chemotherapy I-GENE
of O
AE I-GENE
is I-GENE
based I-GENE
on I-GENE
the O
administration I-GENE
of O
benzimidazole O
carbamate O
derivatives O
, O
such I-GENE
as O
mebendazole O
and O
albendazole O
. O

The I-GENE
uptake I-GENE
of O
fluorine O
- O
18 O
fluorodeoxyglucose O
( O
F I-GENE
- I-GENE
18 I-GENE
FDG I-GENE
) I-GENE
by I-GENE
a O
malignant I-GENE
tumor I-GENE
depends I-GENE
on I-GENE
the O
blood O
glucose O
level I-GENE
. O

Deterministic O
effects I-GENE
. O

DESIGN I-GENE
: O
A I-GENE
retrospective I-GENE
chart I-GENE
review I-GENE
of O
9 O
, O
322 I-GENE
patients I-GENE
undergoing I-GENE
surgical I-GENE
procedures I-GENE
in O
the O
period I-GENE
January I-GENE
1993 I-GENE
to O
December I-GENE
1998 I-GENE
. O

Peripheral O
and O
preemptive O
opioid O
antinociception O
in O
a O
mouse I-GENE
visceral I-GENE
pain I-GENE
model I-GENE
. O

METHODS I-GENE
: O
We I-GENE
studied I-GENE
the O
clinical I-GENE
benefit I-GENE
of O
depth I-GENE
- I-GENE
dependent I-GENE
RR I-GENE
, O
nonuniform I-GENE
AC I-GENE
using I-GENE
a O
scanning I-GENE
line I-GENE
source I-GENE
, O
and O
scatter O
correction I-GENE
( I-GENE
photon I-GENE
energy I-GENE
recovery I-GENE
[ I-GENE
PER I-GENE
]) I-GENE
compared I-GENE
with I-GENE
filtered I-GENE
backprojection I-GENE
alone I-GENE
. O

Cloning I-GENE
and O
characterization I-GENE
of O
the O
murine I-GENE
beta I-GENE
( I-GENE
3 I-GENE
) I-GENE
integrin O
gene I-GENE
promoter I-GENE
: O
identification I-GENE
of O
an I-GENE
interleukin O
- I-GENE
4 I-GENE
responsive I-GENE
element I-GENE
and O
regulation O
by O
STAT O
- O
6 O
. O

DNA O
binding I-GENE
assays I-GENE
confirmed I-GENE
the O
interference I-GENE
of O
p30 I-GENE
( I-GENE
II I-GENE
) I-GENE
with I-GENE
the O
assembly I-GENE
of O
CREB O
- I-GENE
Tax I-GENE
- I-GENE
p300 O
/ O
CBP O
multiprotein O
complexes I-GENE
on I-GENE
21 I-GENE
- I-GENE
bp O
repeat I-GENE
oligonucleotides I-GENE
in O
vitro I-GENE
. O

Transient I-GENE
transfections I-GENE
showed I-GENE
that I-GENE
a O
single O
mutation O
( O
556M I-GENE
) I-GENE
decreased I-GENE
TBLV I-GENE
enhancer I-GENE
activity I-GENE
at O
least I-GENE
20 O
- O
fold O
in O
two I-GENE
different I-GENE
T I-GENE
- I-GENE
cell I-GENE
lines I-GENE
. O

In I-GENE
conclusion I-GENE
, O
tube I-GENE
size I-GENE
estimated I-GENE
by I-GENE
Cole I-GENE
' I-GENE
s I-GENE
formula I-GENE
tends I-GENE
to O
be I-GENE
smaller I-GENE
than I-GENE
practically I-GENE
appropriate I-GENE
tube I-GENE
size I-GENE
for O
pediatric I-GENE
cardiac I-GENE
anesthesia I-GENE
, O
and O
therefore I-GENE
we I-GENE
suggest I-GENE
new I-GENE
formula I-GENE
to O
estimate I-GENE
the O
tube I-GENE
size I-GENE
. O

Thus I-GENE
, O
in O
T47D I-GENE
breast I-GENE
carcinoma I-GENE
cells I-GENE
, O
IL I-GENE
- I-GENE
6 I-GENE
acts I-GENE
in O
synergy I-GENE
with I-GENE
EGF I-GENE
receptor I-GENE
autocrine I-GENE
activity I-GENE
to O
signal I-GENE
through I-GENE
the O
MAPK I-GENE
/ I-GENE
PI3K I-GENE
pathways I-GENE
. O

Nerve O
growth O
factor O
( O
NGF O
) O
and O
retinoic O
acid O
( O
RA O
) O
exert I-GENE
important I-GENE
actions I-GENE
on I-GENE
PC12 I-GENE
cells I-GENE
. O

HexA71 I-GENE
negatively I-GENE
affects I-GENE
RpoS I-GENE
, O
as O
the O
levels I-GENE
of O
this I-GENE
alternative O
sigma I-GENE
factor I-GENE
are I-GENE
higher O
in O
the O
HexA I-GENE
- I-GENE
mutant I-GENE
than I-GENE
in O
the O
HexA O
+ O
strain O
. O

Moreover I-GENE
, O
elderly I-GENE
men I-GENE
with I-GENE
bioavailable I-GENE
estradiol I-GENE
levels I-GENE
below I-GENE
the O
median I-GENE
[ I-GENE
40 I-GENE
pmol I-GENE
/ I-GENE
liter I-GENE
( I-GENE
11 I-GENE
pg I-GENE
/ I-GENE
ml I-GENE
)] I-GENE
had I-GENE
significantly I-GENE
higher O
rates I-GENE
of O
bone O
loss O
and O
levels I-GENE
of O
bone I-GENE
resorption I-GENE
markers I-GENE
than I-GENE
men I-GENE
with I-GENE
bioavailable I-GENE
estradiol I-GENE
levels I-GENE
above I-GENE
40 I-GENE
pmol I-GENE
/ I-GENE
liter I-GENE
. O

The I-GENE
histamine I-GENE
H1 I-GENE
receptor I-GENE
antagonists I-GENE
( I-GENE
antihistamines I-GENE
) I-GENE
are I-GENE
an I-GENE
important I-GENE
class I-GENE
of O
medications I-GENE
used I-GENE
for O
the O
relief O
of O
common I-GENE
symptoms I-GENE
associated I-GENE
with I-GENE
hyperhistaminic I-GENE
conditions I-GENE
occurring I-GENE
in O
children I-GENE
and O
adults I-GENE
. O

The I-GENE
production I-GENE
of O
ceramide O
is O
emerging O
as O
a O
fixture O
of O
programmed I-GENE
cell O
death O
. O

The I-GENE
flux I-GENE
rates I-GENE
of O
p O
- I-GENE
toluidine I-GENE
decreased I-GENE
as O
the O
pH I-GENE
value I-GENE
in O
the O
donor I-GENE
solution I-GENE
increased I-GENE
. O

Managing O
HIV O
. O

BACKGROUND I-GENE
: O
There I-GENE
is I-GENE
increasing I-GENE
interest I-GENE
on I-GENE
the O
part I-GENE
of O
investigators O
and O
the O
public O
at O
large O
in O
finding I-GENE
ways I-GENE
to O
study I-GENE
and O
improve I-GENE
treatments I-GENE
for O
the O
seriously O
mentally O
ill O
without I-GENE
exposing I-GENE
such I-GENE
individuals I-GENE
to O
unnecessary O
risks O
. O

Multidrug O
resistance O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
mainly I-GENE
results I-GENE
from O
the O
overexpression I-GENE
of O
genes O
coding O
for O
the O
membrane O
efflux O
pumps O
, O
the O
major O
facilitators O
and O
the O
ABC I-GENE
binding I-GENE
cassette I-GENE
transporters I-GENE
, O
under I-GENE
the O
control O
of O
key I-GENE
transcription I-GENE
regulators I-GENE
encoded I-GENE
by I-GENE
the O
PDR1 I-GENE
and O
PDR3 I-GENE
genes I-GENE
. O

Serum I-GENE
PTH I-GENE
tended I-GENE
to O
increase I-GENE
in O
the O
WL O
group O
but I-GENE
not I-GENE
in O
the O
WM O
group O
( O
P O
< I-GENE
0 O
. O
06 I-GENE
). O

Bandshift O
experiments I-GENE
demonstrate I-GENE
that I-GENE
BmHR3A I-GENE
binds I-GENE
specifically I-GENE
to O
RORE I-GENE
( I-GENE
Retinoic I-GENE
acid I-GENE
- I-GENE
related I-GENE
Orphan I-GENE
receptor I-GENE
Response I-GENE
Element I-GENE
)- I-GENE
like I-GENE
sequences O
in O
the O
promoters O
of O
both I-GENE
genes I-GENE
, O
thus I-GENE
suggesting I-GENE
a O
direct I-GENE
role I-GENE
for O
BmHR3A I-GENE
in O
regulating O
the O
expression O
of O
BmGATAbeta O
and O
ESP O
genes O
during O
vitellogenesis O
. O

Efficacy O
of O
first O
- I-GENE
generation I-GENE
Cavermap I-GENE
to O
verify I-GENE
location I-GENE
and O
function I-GENE
of O
cavernous I-GENE
nerves I-GENE
during O
radical I-GENE
prostatectomy O
: O
a O
multi O
- I-GENE
institutional I-GENE
evaluation I-GENE
by I-GENE
experienced I-GENE
surgeons I-GENE
. O

During I-GENE
most I-GENE
of O
the O
cell O
cycle O
, O
separase O
is I-GENE
kept I-GENE
inactive I-GENE
by I-GENE
binding I-GENE
to O
an I-GENE
inhibitory I-GENE
protein I-GENE
called I-GENE
securin I-GENE
. O

In I-GENE
conclusion I-GENE
, O
obesity I-GENE
, O
alcohol I-GENE
intake I-GENE
, O
and O
multimetabolic O
disorders I-GENE
were I-GENE
determined I-GENE
to O
be I-GENE
independent I-GENE
predictors I-GENE
for O
the O
development I-GENE
of O
hyperuricemia O
. O

This I-GENE
study I-GENE
examined I-GENE
the O
role I-GENE
of O
cholesteryl I-GENE
ester I-GENE
transfer I-GENE
( I-GENE
CET I-GENE
), O
cholesteryl I-GENE
ester I-GENE
transfer I-GENE
protein I-GENE
( I-GENE
CETP I-GENE
) I-GENE
activity I-GENE
, O
and O
phospholipid O
transfer O
protein O
( O
PLTP O
) O
activity O
in O
the O
increased I-GENE
prevalence I-GENE
of O
coronary I-GENE
artery I-GENE
calcification I-GENE
( I-GENE
CAC I-GENE
) I-GENE
in O
diabetic I-GENE
subjects I-GENE
compared I-GENE
with I-GENE
nondiabetic I-GENE
subjects I-GENE
and O
in O
the O
loss O
of O
the O
sex O
difference I-GENE
in O
CAC I-GENE
in O
diabetes I-GENE
. O

In I-GENE
the O
mouse I-GENE
, O
both I-GENE
genes I-GENE
reside I-GENE
in O
the O
syntenic O
region O
8E1 I-GENE
on I-GENE
chromosome O
8 O
. O

We I-GENE
observed I-GENE
NP I-GENE
/ I-GENE
NMP4 I-GENE
/ I-GENE
CIZ I-GENE
expression O
in O
osteocytes O
, O
osteoblasts O
, O
and O
chondrocytes O
in O
rat O
bone O
. O

Following I-GENE
baseline I-GENE
clinical I-GENE
examination I-GENE
and O
initial I-GENE
periodontal I-GENE
therapy I-GENE
, O
32 I-GENE
patients I-GENE
received I-GENE
mucogingival I-GENE
surgery I-GENE
with I-GENE
free I-GENE
gingival I-GENE
grafts I-GENE
for O
treatment I-GENE
of O
insufficient I-GENE
attached I-GENE
gingiva I-GENE
. O

In I-GENE
contrast I-GENE
, O
the O
failure I-GENE
of O
the O
QKTT O
motif O
and O
TGN46 O
cytoplasmic O
tail O
to O
induce I-GENE
steady I-GENE
- I-GENE
state I-GENE
ER I-GENE
localization I-GENE
of O
vesicular I-GENE
stomatitis I-GENE
virus I-GENE
glycoprotein I-GENE
( I-GENE
VSVG I-GENE
) I-GENE
chimeras I-GENE
in O
HeLa I-GENE
and O
NRK I-GENE
cells I-GENE
indicates I-GENE
that I-GENE
significant I-GENE
differences I-GENE
in O
early I-GENE
secretory I-GENE
trafficking I-GENE
also I-GENE
exist I-GENE
. O

We I-GENE
previously I-GENE
showed I-GENE
that I-GENE
this I-GENE
proteolysis I-GENE
1 I-GENE
) I-GENE
can I-GENE
be I-GENE
acutely I-GENE
promoted I-GENE
by I-GENE
the O
phorbol I-GENE
ester I-GENE
phorbol I-GENE
12 I-GENE
- I-GENE
myristate I-GENE
13 O
- I-GENE
acetate I-GENE
( I-GENE
PMA I-GENE
), O
2 I-GENE
) I-GENE
requires I-GENE
a O
metalloprotease I-GENE
activity I-GENE
, O
3 I-GENE
) I-GENE
generates I-GENE
both I-GENE
shed I-GENE
GHBP I-GENE
and O
a O
membrane O
- O
associated O
GHR O
transmembrane O
/ O
cytoplasmic O
domain O
remnant O
, O
and O
4 O
) O
results I-GENE
in O
down I-GENE
- I-GENE
regulation O
of O
GHR I-GENE
abundance I-GENE
and O
GH I-GENE
signaling O
. O

Our I-GENE
data I-GENE
indicate I-GENE
that I-GENE
SIP1 I-GENE
is I-GENE
required I-GENE
to O
confine O
XBra O
gene O
expression O
to O
the O
mesoderm I-GENE
. O

Changes I-GENE
of O
the O
DB I-GENE
sequence I-GENE
without I-GENE
affecting I-GENE
the O
postulated I-GENE
stem I-GENE
structure O
led I-GENE
to O
drastic O
losses O
of O
translation O
efficiency I-GENE
. O

This I-GENE
subfamily I-GENE
of O
genes I-GENE
all I-GENE
have I-GENE
a O
single O
ATP O
- O
binding O
domain O
at O
the O
N O
- O
terminus O
and O
a O
single O
C I-GENE
- I-GENE
terminal I-GENE
set I-GENE
of O
transmembrane O
segments O
. O

Subsequently O
, O
these I-GENE
coordinates I-GENE
must I-GENE
be I-GENE
interpreted I-GENE
to O
define I-GENE
particular I-GENE
tissues I-GENE
and O
organs I-GENE
. O

The I-GENE
cyclins I-GENE
bind I-GENE
to O
and O
activate I-GENE
the O
CDK O
, O
which I-GENE
leads I-GENE
to O
phosphorylation O
( O
and O
then I-GENE
inhibition I-GENE
) O
of O
the O
tumor O
suppressor O
protein O
, O
pRb O
. O
pRb O
controls I-GENE
commitment I-GENE
to O
progress I-GENE
from O
the O
G1 O
to O
S O
phase O
, O
at O
least I-GENE
in O
part I-GENE
by I-GENE
repressing I-GENE
the O
activity I-GENE
of O
the O
E2F O
transcription I-GENE
factors I-GENE
known I-GENE
to O
promote I-GENE
cell O
proliferation O
. O

The I-GENE
mean I-GENE
serum I-GENE
creatinine I-GENE
level I-GENE
did I-GENE
not I-GENE
change I-GENE
during O
the O
first O
6 I-GENE
months I-GENE
after I-GENE
withdrawal I-GENE
of O
MMF I-GENE
. O

The I-GENE
severity I-GENE
of O
pathologic I-GENE
changes I-GENE
increased I-GENE
with I-GENE
the O
magnitude I-GENE
of O
percussion O
. O

Patients I-GENE
with I-GENE
antibody I-GENE
peaks I-GENE
, O
defined I-GENE
as O
fivefold O
or O
higher O
increase I-GENE
in O
antibody I-GENE
titer I-GENE
compared I-GENE
to O
the O
lowest I-GENE
antibody I-GENE
titer I-GENE
over I-GENE
the O
course I-GENE
of O
GBS I-GENE
, O
had I-GENE
higher O
disability I-GENE
scores I-GENE
during O
the O
first O
two I-GENE
weeks I-GENE
of O
GBS O
and O
a O
worse O
clinical I-GENE
outcome I-GENE
( I-GENE
anti I-GENE
- I-GENE
GM1 I-GENE
IgG I-GENE
and O
anti I-GENE
- I-GENE
GD1a I-GENE
IgM I-GENE
antibody I-GENE
peaks I-GENE
) I-GENE
and O
axonal I-GENE
damage I-GENE
( I-GENE
anti I-GENE
- I-GENE
GD1a I-GENE
IgM I-GENE
antibody I-GENE
peaks I-GENE
), O
compared I-GENE
to O
patients I-GENE
without I-GENE
peak I-GENE
antibody I-GENE
titers I-GENE
. O

At I-GENE
20 I-GENE
days I-GENE
( O
D O
) O
and O
at O
3 I-GENE
months I-GENE
post I-GENE
- I-GENE
TBI I-GENE
, O
irradiated I-GENE
rats I-GENE
had I-GENE
a O
significantly I-GENE
lower I-GENE
percentage I-GENE
of O
avoidance I-GENE
than I-GENE
controls I-GENE
but I-GENE
no O
statistical I-GENE
difference I-GENE
was I-GENE
found I-GENE
at O
5 I-GENE
months I-GENE
post I-GENE
- I-GENE
TBI I-GENE
. O
b I-GENE
/ I-GENE
Two I-GENE
- I-GENE
way I-GENE
avoidance I-GENE
test I-GENE
: O
this I-GENE
test I-GENE
was I-GENE
performed I-GENE
only I-GENE
after I-GENE
TBI I-GENE
. O

TE I-GENE
- I-GENE
671 I-GENE
cells I-GENE
that I-GENE
were I-GENE
transfected I-GENE
with I-GENE
cAMP I-GENE
response I-GENE
element I-GENE
mutant I-GENE
constructs I-GENE
demonstrated I-GENE
a O
diminished I-GENE
basal I-GENE
activity I-GENE
of O
the O
GnRH O
- I-GENE
II I-GENE
promoter I-GENE
. O

The I-GENE
severity I-GENE
of O
clinical I-GENE
course I-GENE
was I-GENE
expressed O
by I-GENE
means I-GENE
of O
SOFA I-GENE
score I-GENE
( O
group O
A O
0 O
. O
3 I-GENE
- I-GENE
1 I-GENE
- I-GENE
1 I-GENE
. O
3 I-GENE
point I-GENE
, O
group I-GENE
B I-GENE
2 I-GENE
. O
2 I-GENE
- I-GENE
2 I-GENE
. O
9 I-GENE
- I-GENE
2 I-GENE
. O
6 I-GENE
point I-GENE
, O
group O
C O
7 O
. O
4 O
- O
8 O
. O
3 O
- O
7 O
. O
7 O
point I-GENE
) I-GENE
and O
APACHE I-GENE
II I-GENE
score I-GENE
( O
group O
A O
3 O
. O
7 O
- O
7 O
. O
6 O
- O
8 O
. O
1 I-GENE
point I-GENE
, O
group O
B O
8 O
. O
6 O
- O
11 O
. O
1 O
- O
10 O
. O
5 O
point I-GENE
, O
group O
C O
16 O
. O
3 O
- O
15 O
. O
2 O
- O
14 O
. O
3 I-GENE
point I-GENE
). O

A I-GENE
novel I-GENE
potential O
effector I-GENE
of O
M O
- O
Ras O
and O
p21 O
Ras O
negatively I-GENE
regulates I-GENE
p21 O
Ras O
- O
mediated O
gene I-GENE
induction I-GENE
and O
cell O
growth O
. O

Promoter I-GENE
transcriptional I-GENE
activity I-GENE
was I-GENE
determined I-GENE
for O
a O
wide I-GENE
5 I-GENE
' I-GENE
portion I-GENE
of O
the O
human I-GENE
annexin I-GENE
A5 I-GENE
gene I-GENE
, O
from O
bp O
- I-GENE
1275 I-GENE
to O
+ I-GENE
79 I-GENE
relative I-GENE
to O
the O
most I-GENE
5 I-GENE
' I-GENE
of O
several I-GENE
discrete I-GENE
transcription I-GENE
start I-GENE
points I-GENE
. O

Structure I-GENE
of O
the O
EMAPII O
domain O
of O
human I-GENE
aminoacyl I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
complex I-GENE
reveals I-GENE
evolutionary I-GENE
dimer I-GENE
mimicry I-GENE
. O

Adding O
10 O
mmol I-GENE
SDS I-GENE
/ I-GENE
l I-GENE
led I-GENE
to O
transient I-GENE
inhibition I-GENE
of O
acidification I-GENE
, O
metal I-GENE
solubilization I-GENE
and O
sulfur I-GENE
oxidation I-GENE
. O

Competition I-GENE
electrophoretic I-GENE
mobility I-GENE
shift I-GENE
and O
immunoshift I-GENE
assays I-GENE
confirmed I-GENE
that I-GENE
NF1 O
factors I-GENE
present I-GENE
in O
nuclear I-GENE
extracts I-GENE
of O
HeLa I-GENE
and O
CV I-GENE
- I-GENE
1 I-GENE
cells I-GENE
bind I-GENE
to O
the O
BKV I-GENE
- I-GENE
MLP I-GENE
. O

Northern I-GENE
and O
Western I-GENE
blot I-GENE
analyses I-GENE
demonstrated I-GENE
that I-GENE
Graf2 I-GENE
is I-GENE
expressed O
in O
several I-GENE
tissues I-GENE
, O
with I-GENE
the O
highest I-GENE
expression O
in O
skeletal O
muscle O
. O

A O
minimal O
ER3 O
sequence O
of O
DNA O
was I-GENE
further I-GENE
demonstrated I-GENE
to O
function I-GENE
as O
a O
FXR O
HRE O
and O
was O
bound O
in O
vitro I-GENE
by I-GENE
FXR I-GENE
- I-GENE
expressing I-GENE
yeast I-GENE
extracts I-GENE
. O

In I-GENE
Ka13 I-GENE
cells I-GENE
, O
CoCl O
( O
2 O
) O
stimulated O
expression O
of O
a O
luciferase O
reporter I-GENE
gene I-GENE
under I-GENE
the O
control O
of O
a O
15 O
- O
kilobase O
pair O
mouse I-GENE
ho I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
( I-GENE
pHO15luc I-GENE
). O

Nine O
strains I-GENE
were I-GENE
subtyped O
as O
Camp O
. O
jejuni O
subsp O
. O
jejuni O
biotype O
II O
and O
the O
remaining I-GENE
ones I-GENE
as O
biotype I-GENE
I I-GENE
. O

The O
Ig O
- O
related O
, O
typical I-GENE
metazoan I-GENE
, O
module I-GENE
is I-GENE
classified I-GENE
to O
the O
disulphide O
lacking O
Ig O
members O
and O
represents I-GENE
the O
phylogenetic I-GENE
earliest O
member O
of O
this O
group O
. O

In I-GENE
budding I-GENE
yeast I-GENE
, O
this I-GENE
latter I-GENE
checkpoint I-GENE
response I-GENE
involves I-GENE
the O
proteins I-GENE
Mad1 I-GENE
, O
2 O
, O
3 O
, O
Bub1 I-GENE
and O
Bub3 I-GENE
, O
whose I-GENE
vertebrate I-GENE
counterparts I-GENE
localize I-GENE
to O
unattached O
kinetochores O
. O

We I-GENE
investigated I-GENE
the O
production I-GENE
of O
hyaluronan I-GENE
( I-GENE
HA I-GENE
) I-GENE
and O
its I-GENE
effect I-GENE
on I-GENE
cell I-GENE
motility I-GENE
in O
cells I-GENE
expressing I-GENE
the O
v I-GENE
- I-GENE
src O
mutants I-GENE
. O

Oral O
supplementation I-GENE
of O
L I-GENE
- I-GENE
arginine I-GENE
significantly I-GENE
increased I-GENE
plasma I-GENE
L I-GENE
- I-GENE
citrulline I-GENE
, O
which I-GENE
indicated I-GENE
enhancement I-GENE
of O
NO I-GENE
production I-GENE
. O

We I-GENE
can I-GENE
classify I-GENE
antibiotics I-GENE
into I-GENE
two I-GENE
groups I-GENE
based I-GENE
on I-GENE
initial I-GENE
bactericidal I-GENE
activity I-GENE
against I-GENE
P I-GENE
. O
aeruginosa I-GENE
; O
one I-GENE
class I-GENE
is I-GENE
antibiotics I-GENE
having I-GENE
rapid I-GENE
initial I-GENE
killing I-GENE
such I-GENE
as O
AMK O
, O
IPM O
and O
PAPM O
, O
the O
other I-GENE
is I-GENE
CAZ I-GENE
, O
MEPM I-GENE
showing I-GENE
slow I-GENE
initial I-GENE
killing I-GENE
. O

The I-GENE
presence I-GENE
of O
truncated I-GENE
receptor I-GENE
isoforms I-GENE
in O
diverse I-GENE
species I-GENE
suggests I-GENE
that I-GENE
these I-GENE
proteins I-GENE
may I-GENE
have I-GENE
important I-GENE
functional I-GENE
roles I-GENE
in O
regulating O
EGFR O
activity I-GENE
. O

Of I-GENE
its I-GENE
gene I-GENE
products I-GENE
, O
E6 I-GENE
binds I-GENE
to O
and O
inactivates O
p53 O
tumor I-GENE
suppressor I-GENE
protein I-GENE
by I-GENE
ubiquitin O
/ I-GENE
proteasome I-GENE
- I-GENE
dependent I-GENE
degradation O
. O

Low I-GENE
affinity I-GENE
binding I-GENE
of O
Rab6A I-GENE
- I-GENE
GTP I-GENE
was I-GENE
also I-GENE
observed I-GENE
( I-GENE
K I-GENE
( I-GENE
d I-GENE
) I-GENE
= I-GENE
16 I-GENE
microm I-GENE
), O
whereas I-GENE
Rab1B I-GENE
, O
- O
5 O
, O
- O
7 O
, O
- O
8 O
, O
or O
- I-GENE
11A I-GENE
did I-GENE
not I-GENE
bind I-GENE
. O

( O
1997 I-GENE
) I-GENE
Nature I-GENE
387 I-GENE
, O
370 I-GENE
- I-GENE
376 I-GENE
)], I-GENE
we I-GENE
suggest I-GENE
that I-GENE
the O
metal I-GENE
fluoride I-GENE
ions I-GENE
replaced I-GENE
phosphate I-GENE
at O
the O
two I-GENE
ATP I-GENE
- I-GENE
binding I-GENE
sites I-GENE
of O
the O
iron I-GENE
protein I-GENE
, O
Kp2 I-GENE
. O

A O
1 O
- O
base O
pair O
mismatch O
within I-GENE
the O
corresponding I-GENE
region O
of O
the O
CYP3A4 I-GENE
gene I-GENE
was I-GENE
sufficient I-GENE
for O
a O
differential I-GENE
enhancer I-GENE
activity I-GENE
. O

AIMS O
: O
To I-GENE
establish I-GENE
a O
baseline I-GENE
and O
intraindividual I-GENE
fluctuations I-GENE
of O
the O
tumour O
markers I-GENE
CEA I-GENE
, O
CA I-GENE
50 I-GENE
and O
CA I-GENE
242 I-GENE
in O
patients I-GENE
cured O
from O
colorectal O
cancer O
, O
and O
to O
test I-GENE
the O
hypothesis I-GENE
that I-GENE
serum I-GENE
concentrations I-GENE
and O
intraindividual I-GENE
fluctuations I-GENE
do I-GENE
not I-GENE
differ I-GENE
from O
the O
concentrations I-GENE
in O
cancer O
- I-GENE
free I-GENE
individuals I-GENE
. O

Substitution I-GENE
of O
serine O
residues O
at O
the O
C I-GENE
- I-GENE
terminus I-GENE
indicated I-GENE
that I-GENE
loss O
of O
phosphorylation O
sites I-GENE
did I-GENE
not I-GENE
appear I-GENE
to O
have I-GENE
any I-GENE
effect I-GENE
on I-GENE
transcription I-GENE
and O
replication O
. O

Molecular I-GENE
analysis I-GENE
of O
the O
pRA2 O
partitioning O
region O
: O
ParB I-GENE
autoregulates I-GENE
parAB I-GENE
transcription I-GENE
and O
forms I-GENE
a O
nucleoprotein I-GENE
complex I-GENE
with I-GENE
the O
plasmid O
partition O
site O
, O
parS I-GENE
. O

Tumor I-GENE
cell I-GENE
lines I-GENE
transduced I-GENE
at O
an I-GENE
MOI I-GENE
of O
8 O
for O
3 I-GENE
days I-GENE
led I-GENE
to O
> I-GENE
90 O
% I-GENE
gene I-GENE
transfer I-GENE
efficiency I-GENE
. O

No I-GENE
ISREs I-GENE
could I-GENE
be I-GENE
identified I-GENE
in O
the O
mouse O
promoter O
. O

GABA O
( O
B I-GENE
) I-GENE
R1g I-GENE
was I-GENE
expressed O
in O
both I-GENE
brain I-GENE
and O
peripheral I-GENE
tissues I-GENE
. O

Granulocyte O
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( I-GENE
G I-GENE
- I-GENE
CSF I-GENE
) I-GENE
administration I-GENE
in O
vivo I-GENE
has I-GENE
been I-GENE
shown I-GENE
to O
improve I-GENE
the O
defence I-GENE
mechanisms I-GENE
against I-GENE
infection I-GENE
by I-GENE
different I-GENE
microbes I-GENE
. O

Use I-GENE
of O
a O
dual I-GENE
- I-GENE
pulse I-GENE
lithotripter I-GENE
to O
generate I-GENE
a O
localized I-GENE
and O
intensified I-GENE
cavitation I-GENE
field I-GENE
. O

The I-GENE
best I-GENE
regression I-GENE
model I-GENE
for O
predicting I-GENE
changes I-GENE
in O
the O
WCXR I-GENE
included I-GENE
time I-GENE
to O
first O
positive I-GENE
culture I-GENE
and O
antibody I-GENE
titer I-GENE
for O
Pa O
elastase O
. O

RESULTS I-GENE
: O
The I-GENE
parameters I-GENE
SF2 I-GENE
and O
plating I-GENE
efficiency I-GENE
were I-GENE
stable I-GENE
throughout I-GENE
the O
4 I-GENE
- I-GENE
year I-GENE
test I-GENE
period I-GENE
. O

The I-GENE
process I-GENE
has I-GENE
been I-GENE
applied I-GENE
to O
the O
river O
reclamation O
in O
Yangpu O
District O
of O
Shanghai O
City I-GENE
, O
China O
. O

Multiple I-GENE
regression I-GENE
analysis I-GENE
performed I-GENE
between I-GENE
these I-GENE
long I-GENE
- I-GENE
term I-GENE
abiotic I-GENE
factors I-GENE
and O
nymphal I-GENE
abundance I-GENE
in O
positive I-GENE
sites I-GENE
showed I-GENE
high I-GENE
relationship I-GENE
( I-GENE
R2 I-GENE
coefficients I-GENE
) I-GENE
for O
every I-GENE
habitat I-GENE
category I-GENE
and O
explained I-GENE
> I-GENE
50 I-GENE
% I-GENE
of O
the O
variation I-GENE
in O
tick I-GENE
abundance I-GENE
. O

The I-GENE
v I-GENE
- I-GENE
Src O
SH3 O
domain O
facilitates O
a O
cell O
adhesion I-GENE
- I-GENE
independent I-GENE
association I-GENE
with I-GENE
focal I-GENE
adhesion I-GENE
kinase I-GENE
. O

Of I-GENE
the O
six O
cases I-GENE
of O
malignant I-GENE
polyposis I-GENE
, O
none I-GENE
were I-GENE
identified I-GENE
using I-GENE
CT O
, O
and O
only I-GENE
two I-GENE
were I-GENE
diagnosed I-GENE
by I-GENE
small I-GENE
bowel I-GENE
follow I-GENE
- I-GENE
through I-GENE
. O

Right O
LHR O
( O
R O
- O
LHR O
) O
provided I-GENE
the O
best I-GENE
interobserver I-GENE
and O
intraobserver I-GENE
reproducibility I-GENE
. O

We I-GENE
also I-GENE
reported I-GENE
the O
identification I-GENE
of O
three I-GENE
corresponding I-GENE
alternative O
first O
exons I-GENE
and O
an I-GENE
intronic I-GENE
promoter I-GENE
in O
the O
human I-GENE
PDE5A I-GENE
gene I-GENE
. O

Of I-GENE
major I-GENE
concern I-GENE
to O
food I-GENE
processors I-GENE
is I-GENE
the O
inadvertent I-GENE
cross I-GENE
- I-GENE
contact I-GENE
of O
food I-GENE
products I-GENE
with I-GENE
allergenic I-GENE
residues I-GENE
, O
which I-GENE
could I-GENE
result I-GENE
in O
potentially I-GENE
life I-GENE
- I-GENE
threatening I-GENE
reactions I-GENE
in O
those I-GENE
with I-GENE
a O
food I-GENE
allergy I-GENE
. O

Diffuse O
myalgias O
were I-GENE
more I-GENE
frequent I-GENE
in O
patients I-GENE
with I-GENE
than I-GENE
without I-GENE
an I-GENE
MMF I-GENE
lesion I-GENE
at O
deltoid I-GENE
muscle I-GENE
biopsy I-GENE
( I-GENE
P I-GENE
< I-GENE
0 O
. O
0001 I-GENE
). O

Functional I-GENE
analysis I-GENE
of O
various I-GENE
PTP O
- I-GENE
deficient O
DT40 I-GENE
B I-GENE
cell I-GENE
lines I-GENE
stably I-GENE
expressing I-GENE
wild I-GENE
- I-GENE
type I-GENE
chimeric I-GENE
Fc O
gamma I-GENE
RIIB1 I-GENE
- I-GENE
PECAM I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
indicated I-GENE
that I-GENE
cytoplasmic I-GENE
Src O
homology I-GENE
2 I-GENE
- I-GENE
domain I-GENE
- I-GENE
containing I-GENE
phosphatases I-GENE
, O
SHP O
- O
1 O
and O
SHP O
- O
2 O
, O
were I-GENE
both I-GENE
necessary I-GENE
and O
sufficient I-GENE
to O
deliver O
inhibitory O
negative O
regulation O
upon I-GENE
coligation I-GENE
of O
BCR I-GENE
complex I-GENE
with I-GENE
inhibitory I-GENE
receptor I-GENE
. O

Subtraction O
hybridization I-GENE
identified I-GENE
melanoma I-GENE
differentiation I-GENE
associated I-GENE
gene I-GENE
- I-GENE
7 O
( O
mda O
- O
7 O
), O
as O
a O
gene O
induced O
during O
these I-GENE
physiological I-GENE
changes I-GENE
in O
human I-GENE
melanoma I-GENE
cells I-GENE
. O

A I-GENE
rare I-GENE
case I-GENE
of O
primary O
group O
A O
streptococcal O
peritonitis O
. O

Among I-GENE
individuals I-GENE
, O
however I-GENE
, O
changes I-GENE
were I-GENE
strongly I-GENE
correlated I-GENE
with I-GENE
ACR I-GENE
levels I-GENE
at O
baseline I-GENE
. O

RESULTS I-GENE
: O
The I-GENE
subjects I-GENE
in O
the O
augmented I-GENE
feedback I-GENE
group I-GENE
significantly I-GENE
reduced O
their I-GENE
peak I-GENE
vertical I-GENE
ground I-GENE
reaction I-GENE
force I-GENE
in O
both I-GENE
post I-GENE
- I-GENE
test I-GENE
conditions I-GENE
( I-GENE
2 I-GENE
- I-GENE
minute I-GENE
post I-GENE
- I-GENE
test I-GENE
reduction I-GENE
, O
0 O
. O
85 O
+/- O
0 O
. O
62 O
; O
1 I-GENE
- I-GENE
week I-GENE
post I-GENE
- I-GENE
test I-GENE
reduction I-GENE
, O
0 O
. O
74 O
+/- O
0 O
. O
58 I-GENE
) I-GENE
as O
compared I-GENE
to O
the O
sensory I-GENE
, O
control O
I O
, O
and O
control O
II I-GENE
feedback I-GENE
groups I-GENE
. O

The O
blood O
levels O
of O
lactate O
, O
pyruvate O
and O
amino O
acids O
were I-GENE
not I-GENE
elevated I-GENE
. O

Histological I-GENE
examination I-GENE
showed I-GENE
lichenoid I-GENE
changes I-GENE
, O
acantholytic I-GENE
blister I-GENE
formation I-GENE
and O
apoptotic I-GENE
keratinocytes I-GENE
. O

Enantiomer O
separation I-GENE
of O
venlafaxine O
and O
O O
- O
desmethylvenlafaxine O
in O
human O
plasma O
. O

Paul O
Monagle O
addresses O
the O
epidemiology O
of O
neonatal I-GENE
thrombosis I-GENE
outside I-GENE
of O
the O
central I-GENE
nervous I-GENE
system O
in O
both I-GENE
arterial I-GENE
and O
venous I-GENE
locations I-GENE
, O
and O
those I-GENE
that I-GENE
occur I-GENE
in O
utero O
. O

The I-GENE
MSL I-GENE
complex I-GENE
is I-GENE
specifically I-GENE
localized I-GENE
on I-GENE
the O
male I-GENE
X I-GENE
chromosome O
to O
increase I-GENE
its I-GENE
expression O
approximately O
2 O
- O
fold O
. O

Effects I-GENE
of O
a O
booster O
dose I-GENE
of O
tetanus I-GENE
toxoid I-GENE
after I-GENE
different I-GENE
primary O
courses I-GENE
of O
vaccination I-GENE
: O
implications I-GENE
on I-GENE
the O
use I-GENE
of O
immune O
globulin O
. O

Our I-GENE
results I-GENE
suggest I-GENE
that I-GENE
the O
C I-GENE
- I-GENE
terminal O
region O
of O
Crk O
contains I-GENE
negative I-GENE
regulatory I-GENE
elements I-GENE
important I-GENE
for O
both I-GENE
Abl O
and O
FAK O
dependent I-GENE
signal I-GENE
pathways I-GENE
, O
and O
offers I-GENE
a O
paradigm O
for O
an O
autoinhibitory O
region O
in O
the O
SH3 O
linker O
/ O
C O
- O
terminal O
SH3 O
domain O
. O

The I-GENE
distribution I-GENE
of O
red O
rice O
cultivation O
in O
Sri O
Lanka O
is O
coincident O
with O
the O
HIDD O
villages O
. O

Prophylactic O
lymph I-GENE
node I-GENE
dissection I-GENE
or O
radiation I-GENE
therapy I-GENE
to O
the O
nodal I-GENE
chain I-GENE
may I-GENE
decrease I-GENE
local I-GENE
recurrence I-GENE
but I-GENE
does I-GENE
not I-GENE
consistently I-GENE
affect I-GENE
overall I-GENE
survival I-GENE
. O

Secretion O
of O
interleukin O
- O
8 O
, O
RANTES O
, O
macrophage I-GENE
inflammatory I-GENE
protein I-GENE
1alpha O
, O
and O
10 O
- O
kappaDa O
IFN O
- I-GENE
gamma I-GENE
- I-GENE
inducible I-GENE
protein I-GENE
were I-GENE
increased I-GENE
in O
differentiating I-GENE
keratinocytes I-GENE
by I-GENE
E6 I-GENE
. O

CONCLUSIONS I-GENE
: O
ChromaFlo I-GENE
- I-GENE
enhanced O
IVUS I-GENE
demonstrates I-GENE
colorized I-GENE
blood O
flow I-GENE
inside I-GENE
the O
vessel I-GENE
lumen I-GENE
, O
which I-GENE
is I-GENE
helpful I-GENE
in O
distinguishing O
echolucent O
disease O
from O
luminal I-GENE
blood O
flow I-GENE
and O
can I-GENE
also I-GENE
be I-GENE
used I-GENE
to O
perform I-GENE
peripheral I-GENE
interventions I-GENE
in O
patients I-GENE
with I-GENE
renal O
failure I-GENE
or O
allergy I-GENE
, O
avoiding O
the O
use I-GENE
of O
contrast I-GENE
media I-GENE
. O

Additional O
factors I-GENE
such I-GENE
as O
advanced I-GENE
age I-GENE
, O
concomitant I-GENE
use I-GENE
of O
corticosteroids I-GENE
or O
anticoagulants O
, O
prior I-GENE
ulcer I-GENE
complications I-GENE
and O
co O
- I-GENE
morbid I-GENE
diseases I-GENE
may I-GENE
further I-GENE
increase I-GENE
the O
risk I-GENE
of O
bleeding I-GENE
. O

CONCLUSIONS I-GENE
: O
Using I-GENE
icodextrin I-GENE
- I-GENE
based I-GENE
instead I-GENE
of O
glucose I-GENE
- I-GENE
based I-GENE
PD I-GENE
fluids I-GENE
can I-GENE
largely I-GENE
reduce I-GENE
the O
formation I-GENE
of O
Amadori O
albumin O
and O
AGEs O
. O

A I-GENE
central I-GENE
finding I-GENE
is I-GENE
the O
identification I-GENE
of O
a O
GC O
- O
rich O
sequence O
in O
the O
- I-GENE
99 I-GENE
/- I-GENE
91 I-GENE
Cp O
region I-GENE
that I-GENE
is I-GENE
essential I-GENE
for O
oriPI I-GENE
- I-GENE
EBNA1 I-GENE
- I-GENE
independent I-GENE
as O
well O
as O
oriPI I-GENE
- I-GENE
EBNA1 I-GENE
- I-GENE
dependent I-GENE
activity I-GENE
of O
the O
promoter O
. O

Furthermore I-GENE
, O
SB203580 I-GENE
inhibited I-GENE
LPS I-GENE
- I-GENE
induced O
activation O
of O
Sp1 I-GENE
, O
as O
well O
as O
the O
promoter I-GENE
activity I-GENE
in O
cells I-GENE
transfected I-GENE
with I-GENE
a O
plasmid O
containing O
the O
Sp1 I-GENE
consensus I-GENE
sequence I-GENE
. O

A I-GENE
new I-GENE
echocardiographic I-GENE
technique I-GENE
is I-GENE
described I-GENE
with I-GENE
a O
conventional I-GENE
M I-GENE
mode I-GENE
, O
digitalised I-GENE
2D I-GENE
and O
tissular I-GENE
Doppler I-GENE
which I-GENE
has I-GENE
a O
comparable I-GENE
ability I-GENE
to O
identify I-GENE
the O
anomalous I-GENE
pathways I-GENE
of O
electric I-GENE
conduction I-GENE
using I-GENE
a O
non I-GENE
- I-GENE
invasive I-GENE
method I-GENE
. O

Is I-GENE
clopidogrel I-GENE
superior I-GENE
to O
aspirin I-GENE
in O
secondary I-GENE
prevention I-GENE
of O
vascular I-GENE
disease O
? I-GENE
The I-GENE
cornerstone I-GENE
in O
clinical I-GENE
evidence I-GENE
of O
the O
relative I-GENE
efficacy I-GENE
of O
thienopyridines O
( O
clopidogrel O
, O
ticlopidine O
) O
versus I-GENE
aspirin I-GENE
in O
the O
secondary I-GENE
prevention I-GENE
of O
vascular O
disease O
is O
the O
Clopidogrel O
versus I-GENE
Aspirin I-GENE
in O
Patients I-GENE
at O
Risk I-GENE
of O
Ischaemic I-GENE
Events I-GENE
trial I-GENE
. O

The I-GENE
role I-GENE
of O
the O
Vp1 I-GENE
DBD I-GENE
during O
infection I-GENE
was I-GENE
investigated I-GENE
by I-GENE
taking I-GENE
advantage I-GENE
of O
NLS I-GENE
phenotypic O
complementation O
( O
N O
. O

The O
probability O
of O
treatment I-GENE
with I-GENE
lamotrigine I-GENE
being I-GENE
maintained I-GENE
for O
six O
months I-GENE
was I-GENE
86 I-GENE
%, I-GENE
for O
twelve I-GENE
months I-GENE
61 I-GENE
% I-GENE
and O
for O
three I-GENE
years I-GENE
31 I-GENE
%. I-GENE

Recent I-GENE
advances I-GENE
have I-GENE
shown I-GENE
that I-GENE
volatile I-GENE
sulfur I-GENE
is I-GENE
a O
result I-GENE
of O
ecological I-GENE
interactions I-GENE
and O
transformation I-GENE
processes I-GENE
through I-GENE
planktonic I-GENE
food I-GENE
webs I-GENE
. O

OsBBPI I-GENE
was I-GENE
found I-GENE
to O
be I-GENE
rapidly I-GENE
induced O
in O
rice O
seedling O
leaf I-GENE
in O
response O
to O
cut O
, O
exogenous O
jasmonic O
acid O
( O
JA O
), O
and O
two I-GENE
potent I-GENE
protein I-GENE
phosphatase I-GENE
2A I-GENE
( O
PP2A O
) O
inhibitors O
, O
cantharidin O
( O
CN O
) O
and O
endothall O
( O
EN O
), O
in O
a O
light I-GENE
/ I-GENE
dark I-GENE
-, I-GENE
time I-GENE
- I-GENE
and O
dose I-GENE
- I-GENE
dependent I-GENE
manner I-GENE
; O
this I-GENE
induction I-GENE
was I-GENE
completely I-GENE
inhibited I-GENE
by I-GENE
cycloheximide I-GENE
( I-GENE
CHX I-GENE
), O
indicating I-GENE
a O
requirement I-GENE
for O
de I-GENE
novo I-GENE
protein I-GENE
synthesis O
in O
its I-GENE
induction I-GENE
. O

Analysis I-GENE
of O
ace2Delta I-GENE
cells I-GENE
reveals I-GENE
that I-GENE
Ace2p I-GENE
is I-GENE
required I-GENE
for O
cell I-GENE
separation I-GENE
but I-GENE
not I-GENE
for O
polarized I-GENE
growth I-GENE
. O

The I-GENE
purpose I-GENE
of O
this I-GENE
investigation I-GENE
was I-GENE
to O
study I-GENE
the O
morphological I-GENE
characteristics I-GENE
of O
the O
fibrous O
tissue O
capsule O
resulting I-GENE
from O
the O
implantation I-GENE
of O
aluminum I-GENE
calcium O
phosphate O
( O
ALCAP O
) O
and O
hydroxyapetite O
( O
HA O
) O
bioceramics O
. O

The I-GENE
event I-GENE
rate I-GENE
in O
patients I-GENE
with I-GENE
chronic I-GENE
Irr I-GENE
- I-GENE
rMFP I-GENE
or O
Un I-GENE
- I-GENE
nrMFP I-GENE
was I-GENE
markedly I-GENE
higher O
than I-GENE
it I-GENE
was I-GENE
in O
those I-GENE
with I-GENE
Rev I-GENE
- I-GENE
rMFP I-GENE
or O
Sta I-GENE
- I-GENE
nrMFP I-GENE
. O

In I-GENE
summary I-GENE
, O
we I-GENE
conclude I-GENE
that I-GENE
the O
adenoviral I-GENE
oncoprotein I-GENE
E1A O
activates I-GENE
transcription O
from O
the O
endogenous I-GENE
AP I-GENE
- I-GENE
2alpha O
gene I-GENE
, O
an I-GENE
effect I-GENE
that I-GENE
involves I-GENE
transcriptional I-GENE
derepression I-GENE
of O
the O
AP I-GENE
- I-GENE
2alpha O
promoter I-GENE
by I-GENE
interaction O
of O
E1A O
with O
the O
AP I-GENE
- I-GENE
2rep I-GENE
corepressor I-GENE
CtBP1 I-GENE
. O

Unusual O
two I-GENE
- I-GENE
domain I-GENE
arginine I-GENE
kinases I-GENE
( I-GENE
AKs I-GENE
) I-GENE
arose I-GENE
independently I-GENE
at O
least I-GENE
two I-GENE
times I-GENE
during O
molecular O
evolution I-GENE
of O
phosphagen I-GENE
kinases I-GENE
: O
AKs O
from O
the O
primitive O
sea O
anemone O
Anthopleurura O
japonicus O
and O
from O
the O
clam O
Pseudocardium O
sachalinensis O
. O

Mutagenesis O
of O
SNT1 O
( O
IRS O
) O
CX I-GENE
identified I-GENE
three I-GENE
classes I-GENE
of O
effector I-GENE
motifs I-GENE
within I-GENE
SNT I-GENE
critical I-GENE
for O
both I-GENE
sustained I-GENE
ERK O
activation O
and O
neuronal O
differentiation I-GENE
: O
1 I-GENE
) I-GENE
four I-GENE
phosphotyrosine I-GENE
motifs I-GENE
that I-GENE
mediate I-GENE
recruitment I-GENE
of O
Grb2 O
, O
2 O
) O
two I-GENE
phosphotyrosine I-GENE
motifs I-GENE
that I-GENE
mediate I-GENE
recruitment I-GENE
of O
Shp2 I-GENE
, O
and O
3 O
) O
a O
C I-GENE
- I-GENE
terminal I-GENE
motif I-GENE
that I-GENE
functions I-GENE
by I-GENE
helping I-GENE
to O
recruit I-GENE
Sos O
. O

CONCLUSIONS I-GENE
: O
Our I-GENE
meta I-GENE
- I-GENE
analysis I-GENE
of O
randomized I-GENE
controlled O
trials I-GENE
of O
HRT I-GENE
noted I-GENE
a O
statistically I-GENE
significant I-GENE
reduction I-GENE
in O
nonvertebral O
fractures O
. O

However I-GENE
, O
C4B I-GENE
proteins I-GENE
encoded I-GENE
by I-GENE
monomodular I-GENE
short I-GENE
genes I-GENE
may I-GENE
have I-GENE
relatively I-GENE
higher O
concentrations I-GENE
than I-GENE
those I-GENE
from O
long I-GENE
C4A I-GENE
genes I-GENE
. O

CSR I-GENE
is I-GENE
directed I-GENE
to O
specific I-GENE
heavy I-GENE
chain I-GENE
isotypes I-GENE
by I-GENE
cytokines I-GENE
and O
B I-GENE
cell I-GENE
activators I-GENE
that I-GENE
induce I-GENE
transcription I-GENE
from O
the O
unrearranged O
, O
or O
germline O
( O
GL O
), O
C O
( O
H O
) O
region O
genes O
. O

The I-GENE
patterns I-GENE
of O
early O
mRNA O
and O
protein O
expression O
in O
these I-GENE
seven O
mutants I-GENE
were I-GENE
examined I-GENE
, O
and O
it I-GENE
was I-GENE
found I-GENE
that I-GENE
mutation I-GENE
of O
the O
T I-GENE
'( I-GENE
135 I-GENE
) I-GENE
acceptor I-GENE
site I-GENE
resulted I-GENE
in O
the O
utilization I-GENE
of O
cryptic O
splice O
sites O
and O
the O
generation I-GENE
of O
new I-GENE
T I-GENE
' I-GENE
species I-GENE
. O

Mutational I-GENE
analysis I-GENE
showed I-GENE
that I-GENE
the O
U I-GENE
- I-GENE
box I-GENE
, O
like I-GENE
the O
RING I-GENE
finger I-GENE
in O
other I-GENE
proteins I-GENE
, O
forms I-GENE
the O
physical I-GENE
basis I-GENE
for O
the O
interaction O
with O
E2 O
enzymes O
. O

GafChromic O
( O
MD I-GENE
- I-GENE
55 I-GENE
- I-GENE
2 I-GENE
) I-GENE
radiochromic I-GENE
film I-GENE
has I-GENE
become I-GENE
increasingly I-GENE
popular I-GENE
for O
medical I-GENE
applications I-GENE
and O
has I-GENE
proven I-GENE
to O
be I-GENE
useful I-GENE
for O
brachytherapy O
dosimetry O
. O

The I-GENE
438 I-GENE
bp O
EcoRI O
fragment O
, O
which I-GENE
was I-GENE
detected I-GENE
by I-GENE
Southern I-GENE
hybridization I-GENE
, O
reveals I-GENE
an I-GENE
open I-GENE
reading I-GENE
frame I-GENE
which I-GENE
encodes I-GENE
a O
protein I-GENE
of O
103 I-GENE
amino O
acids O
. O

Furthermore I-GENE
, O
hormonal I-GENE
regulation O
of O
G I-GENE
( I-GENE
1 I-GENE
) I-GENE
gene I-GENE
transcription I-GENE
can I-GENE
occur I-GENE
even I-GENE
without I-GENE
additional I-GENE
activation O
of O
the O
Mek O
- I-GENE
Erk1 I-GENE
/ I-GENE
2 I-GENE
pathway O
by I-GENE
estrogen I-GENE
receptors I-GENE
. O

In I-GENE
mammalian I-GENE
tissue I-GENE
culture I-GENE
cells I-GENE
, O
overexpression I-GENE
of O
any I-GENE
of O
the O
four I-GENE
mouse I-GENE
deltex I-GENE
homologs I-GENE
suppressed I-GENE
the O
transcriptional O
activity O
of O
E47 O
, O
a O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
( I-GENE
bHLH I-GENE
) I-GENE
protein I-GENE
, O
in O
a O
manner I-GENE
similar I-GENE
to O
suppression I-GENE
by I-GENE
an I-GENE
activated I-GENE
form I-GENE
of O
human I-GENE
Notch1 I-GENE
or O
human I-GENE
DTX1 I-GENE
. O

The I-GENE
authors I-GENE
undertook I-GENE
a O
retrospective I-GENE
analysis I-GENE
of O
pathology I-GENE
with I-GENE
quantification O
of O
the O
percentage I-GENE
of O
papillary O
serous O
component O
(% O
PSC O
) O
and O
p53 O
expression O
. O

This I-GENE
function I-GENE
requires I-GENE
not I-GENE
only I-GENE
the O
kinase I-GENE
domain I-GENE
of O
Csk O
, O
but I-GENE
also I-GENE
its I-GENE
Src O
homology O
3 O
( O
SH3 O
) O
and O
SH2 I-GENE
regions I-GENE
. O

Nucleotide I-GENE
sequence I-GENE
, O
transcription I-GENE
map I-GENE
, O
and O
mutation O
analysis O
of O
the O
13q14 O
chromosomal O
region O
deleted O
in O
B I-GENE
- I-GENE
cell I-GENE
chronic I-GENE
lymphocytic I-GENE
leukemia I-GENE
. O

In I-GENE
conclusion I-GENE
, O
primary O
chemotherapy I-GENE
based I-GENE
on I-GENE
high I-GENE
dose I-GENE
MTX I-GENE
and O
ara I-GENE
- I-GENE
C I-GENE
is I-GENE
highly I-GENE
efficient I-GENE
in O
PCNSL I-GENE
. O

NGF O
, O
but I-GENE
not I-GENE
EGF I-GENE
, O
enhances I-GENE
the O
upper I-GENE
bands I-GENE
, O
corresponding I-GENE
to O
phosphorylated O
Fra O
- O
2 O
. O

METHODS I-GENE
AND I-GENE
RESULTS I-GENE
: O
Palmaz I-GENE
- I-GENE
Schatz I-GENE
stents I-GENE
were I-GENE
dip I-GENE
- I-GENE
coated I-GENE
with I-GENE
paclitaxel O
( O
0 O
, O
0 O
. O
2 O
, O
15 O
, O
or O
187 I-GENE
microgram I-GENE
/ I-GENE
stent I-GENE
) I-GENE
by I-GENE
immersion I-GENE
in O
ethanolic O
paclitaxel O
and O
evaporation O
of O
the O
solvent I-GENE
. O

Currently O
, O
the O
clinical I-GENE
use I-GENE
of O
5 O
- O
aminolaevulinic O
acid O
( O
ALA O
) O
induced O
protoporphyrin O
IX O
( O
PPIX O
) O
for O
photodynamic O
therapy I-GENE
( I-GENE
PDT I-GENE
) I-GENE
is I-GENE
limited I-GENE
by I-GENE
the O
maximum I-GENE
tolerated I-GENE
oral I-GENE
ALA I-GENE
dose I-GENE
( I-GENE
60 I-GENE
mg I-GENE
/ I-GENE
kg I-GENE
). O

A O
twelfth O
insertion O
disrupts O
two I-GENE
genes I-GENE
, O
Nrk O
, O
a O
" O
neurospecific O
" O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
, O
and O
Tpp O
, O
which I-GENE
encodes I-GENE
a O
neuropeptidase O
. O

These I-GENE
results I-GENE
indicate I-GENE
that I-GENE
ATF4 I-GENE
regulates I-GENE
basal O
and O
CdCl O
( O
2 O
)- O
induced O
expression O
of O
the O
ho O
- I-GENE
1 I-GENE
gene I-GENE
in O
a O
cell O
- I-GENE
specific I-GENE
manner I-GENE
and O
possibly I-GENE
in O
a O
complex I-GENE
with I-GENE
Nrf2 I-GENE
. O

Adjuvant O
and O
neoadjuvant O
treatment I-GENE
of O
breast I-GENE
cancer O
. O

The I-GENE
% I-GENE
SVend I-GENE
of O
HCM I-GENE
- I-GENE
I I-GENE
was I-GENE
significantly I-GENE
lower I-GENE
than I-GENE
the O
respective I-GENE
values I-GENE
of O
the O
HCM I-GENE
- I-GENE
II I-GENE
and O
Control I-GENE
groups I-GENE
. O

Inhibition I-GENE
of O
the O
Raf O
- O
1 O
target O
ERK O
kinase O
( O
MEK O
) O
either I-GENE
attenuated I-GENE
or O
abolished I-GENE
Rp I-GENE
- I-GENE
cAMPS I-GENE
- I-GENE
and O
PKI I-GENE
- I-GENE
induced O
ERK O
activation O
, O
caldesmon O
phosphorylation O
, O
and O
stress O
fiber I-GENE
formation I-GENE
. O

In I-GENE
the O
TVD I-GENE
- I-GENE
patients I-GENE
decreases I-GENE
in O
skin O
blood O
flow I-GENE
were I-GENE
similar I-GENE
compared I-GENE
with I-GENE
the O
healthy I-GENE
controls I-GENE
. O

Analysis I-GENE
of O
mCTR I-GENE
mRNAs I-GENE
has I-GENE
revealed I-GENE
that I-GENE
the O
three I-GENE
alternative O
promoters I-GENE
give I-GENE
rise I-GENE
to O
at O
least I-GENE
seven O
mCTR I-GENE
isoforms I-GENE
in O
the O
5 O
' O
region O
of O
the O
gene I-GENE
and O
generate I-GENE
5 O
'- O
untranslated O
regions O
of O
very I-GENE
different I-GENE
lengths I-GENE
. O

The O
regulation O
of O
PGHS I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
and O
protein I-GENE
was I-GENE
studied I-GENE
in O
primary O
cultures I-GENE
of O
bovine I-GENE
uterine I-GENE
stromal I-GENE
cells I-GENE
stimulated I-GENE
with I-GENE
phorbol I-GENE
12 I-GENE
- I-GENE
myristate I-GENE
13 O
- I-GENE
acetate I-GENE
( I-GENE
PMA I-GENE
; O
100 O
nM I-GENE
). O

There I-GENE
was I-GENE
no O
evidence I-GENE
of O
linkage I-GENE
disequilibrium I-GENE
between I-GENE
the O
polymorphic I-GENE
site I-GENE
in O
the O
B O
cell O
specific O
promoter O
and O
those I-GENE
in O
the O
3 O
' O
UTR O
. O

Several I-GENE
dozen I-GENE
HIF O
- I-GENE
1 I-GENE
targets I-GENE
are I-GENE
known I-GENE
, O
including I-GENE
the O
gene I-GENE
encoding I-GENE
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
( O
VEGF O
). O

In O
Klinefelter O
' O
s O
syndrome O
( O
47XXY I-GENE
), O
serum I-GENE
testosterone I-GENE
levels I-GENE
are I-GENE
at O
the O
lower I-GENE
end I-GENE
of O
the O
normal I-GENE
range I-GENE
and O
dihydrotestosterone I-GENE
levels I-GENE
are I-GENE
low O
. O

The I-GENE
protein I-GENE
is I-GENE
composed I-GENE
of O
two I-GENE
major I-GENE
domains I-GENE
separated I-GENE
by I-GENE
a O
hydrophobic I-GENE
linker I-GENE
region O
of O
20 O
amino O
acid O
residues O
. O

When I-GENE
mixed I-GENE
with I-GENE
aqueous I-GENE
solutions I-GENE
of O
TMT I-GENE
- I-GENE
55 I-GENE
, O
aqueous I-GENE
solutions I-GENE
of O
either I-GENE
reagent I-GENE
- I-GENE
grade I-GENE
zinc I-GENE
, O
cadmium I-GENE
, O
or O
lead I-GENE
salts I-GENE
precipitate I-GENE
crystalline I-GENE
" I-GENE
Zn I-GENE
- I-GENE
TMT I-GENE
", I-GENE
amorphous I-GENE
or O
crystalline I-GENE
" I-GENE
Cd I-GENE
- I-GENE
TMT I-GENE
" O
or O
amorphous O
" O
Pb O
- O
TMT O
" O
( O
M3 O
[ O
S3C3N3 O
] O
2 O
. O
nH2O I-GENE
, O
where I-GENE
M I-GENE
= I-GENE
Cd2 I-GENE
+, I-GENE
Pb2 I-GENE
+, I-GENE
and O
Zn2 I-GENE
+ I-GENE
and O
n I-GENE
> I-GENE
or O
= I-GENE
0 O
) I-GENE
that I-GENE
may I-GENE
eventually I-GENE
crystallize I-GENE
if I-GENE
stored I-GENE
in O
air I-GENE
. O

Online O
teaching O
: O
design I-GENE
and O
techniques I-GENE
. O

This I-GENE
interaction I-GENE
is I-GENE
reciprocal I-GENE
, O
since I-GENE
C I-GENE
/ O
EBP O
dimer O
binding O
to O
a O
strong I-GENE
C I-GENE
/ I-GENE
EBP O
site I-GENE
leads I-GENE
to O
enhanced O
CREB O
- I-GENE
1 I-GENE
recruitment I-GENE
to O
ATF O
/ O
CREB O
sites I-GENE
that I-GENE
are I-GENE
weakly I-GENE
bound O
by I-GENE
CREB O
. O

The I-GENE
absorbed I-GENE
dose I-GENE
was I-GENE
measured I-GENE
by I-GENE
combination I-GENE
of O
two I-GENE
integrating O
detectors O
: O
thermo O
- O
luminescent O
dosemeter O
of O
Mg2SiO4 O
: O
Tb O
( O
TDMS O
) O
and O
plastic O
nuclear I-GENE
track I-GENE
detector I-GENE
( I-GENE
PNTD I-GENE
). O

To I-GENE
determine I-GENE
the O
genomic I-GENE
complexity I-GENE
of O
the O
deleted O
region O
shared I-GENE
among I-GENE
tumors I-GENE
, O
we I-GENE
assembled I-GENE
a O
physical I-GENE
map I-GENE
of O
the O
I I-GENE
Mbp I-GENE
SRO I-GENE
consisting I-GENE
predominantly I-GENE
of O
bacteriophage I-GENE
P1 I-GENE
- I-GENE
derived I-GENE
artificial I-GENE
chromosome O
( O
PAC O
) O
clones O
. O

Thus I-GENE
, O
Xlim I-GENE
- I-GENE
1 I-GENE
not I-GENE
only I-GENE
contains I-GENE
a O
unique I-GENE
tyrosine I-GENE
- I-GENE
rich I-GENE
activation I-GENE
domain I-GENE
but I-GENE
also I-GENE
contains I-GENE
a O
negative I-GENE
regulatory I-GENE
domain I-GENE
in O
CT239 I-GENE
- I-GENE
403 I-GENE
, O
suggesting I-GENE
a O
complex I-GENE
regulatory I-GENE
mechanism I-GENE
underlying I-GENE
the O
transcriptional O
activity O
of O
Xlim O
- O
1 O
in O
the O
organizer O
. O

Low I-GENE
- I-GENE
selenium I-GENE
diet I-GENE
has I-GENE
a O
human I-GENE
unfavourable I-GENE
impact I-GENE
. O

In I-GENE
the O
next I-GENE
week I-GENE
, O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
antagonist I-GENE
atenolol I-GENE
was I-GENE
added I-GENE
at O
an I-GENE
initial I-GENE
dose I-GENE
of O
25 I-GENE
mg I-GENE
/ I-GENE
day I-GENE
and O
titrated O
to O
50 I-GENE
mg I-GENE
/ I-GENE
day I-GENE
within I-GENE
1 I-GENE
week I-GENE
. O

To I-GENE
assess I-GENE
more I-GENE
specific I-GENE
PKA O
- I-GENE
dependent I-GENE
mediation I-GENE
of O
LH I-GENE
' I-GENE
s I-GENE
contribution I-GENE
to O
combined I-GENE
hormonal I-GENE
drive I-GENE
, O
the O
LDL O
receptor O
(- O
1076 O
to O
+ O
11 O
bp O
) O
reporter O
plasmid O
was I-GENE
cotransfected I-GENE
with I-GENE
a O
full I-GENE
- I-GENE
sequence I-GENE
rabbit I-GENE
muscle I-GENE
protein I-GENE
kinase I-GENE
inhibitor I-GENE
( I-GENE
PKI I-GENE
) I-GENE
minigene I-GENE
driven I-GENE
constitutively I-GENE
by I-GENE
a O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
promoter I-GENE
. O

In I-GENE
SN I-GENE
- I-GENE
48 I-GENE
neuronal I-GENE
cells I-GENE
that I-GENE
express I-GENE
MR I-GENE
, O
GR O
, O
and O
5 O
- I-GENE
HT1A I-GENE
receptors I-GENE
, O
deletion O
or O
inactivation I-GENE
of O
the O
nGRE O
( O
negative O
GRE O
) O
eliminated O
negative O
regulation O
of O
the O
rat I-GENE
5 I-GENE
- I-GENE
HT1A I-GENE
or O
heterologous I-GENE
promoters I-GENE
by I-GENE
corticosteroids I-GENE
, O
whereas I-GENE
its I-GENE
inclusion I-GENE
conferred I-GENE
corticosteroid I-GENE
- I-GENE
induced O
inhibition I-GENE
to O
a O
heterologous I-GENE
promoter I-GENE
. O

Transition O
between I-GENE
P I-GENE
- I-GENE
and O
H I-GENE
- I-GENE
BPPV I-GENE
was I-GENE
found I-GENE
in O
6 I-GENE
cases I-GENE
. O

These I-GENE
included I-GENE
HNF O
- I-GENE
3 I-GENE
beta I-GENE
, O
HFH I-GENE
- I-GENE
1 I-GENE
, O
HFH I-GENE
- I-GENE
2 I-GENE
, O
HFH I-GENE
- I-GENE
3 I-GENE
, O
C O
/ O
EBP O
, O
and O
C O
/ O
EBP O
beta I-GENE
, O
all I-GENE
of O
which I-GENE
are I-GENE
consistent I-GENE
with I-GENE
the O
tissue I-GENE
- I-GENE
specific I-GENE
expression O
profiles I-GENE
of O
the O
gene O
. O

RESULTS I-GENE
: O
Of I-GENE
the O
24 O
patients I-GENE
, O
6 I-GENE
had I-GENE
Grade I-GENE
1 I-GENE
pneumonitis O
, O
and O
13 O
had I-GENE
Grade I-GENE
2 I-GENE
pneumonitis I-GENE
. O

METHODS I-GENE
: O
The I-GENE
passive I-GENE
and O
active O
transport O
of O
fluorescein O
through I-GENE
the O
BRB I-GENE
was I-GENE
quantitated I-GENE
by I-GENE
vitreous I-GENE
fluorometry I-GENE
. O

Sixteen O
out I-GENE
of O
52 I-GENE
seropositive I-GENE
MS I-GENE
patients I-GENE
( O
30 O
. O
8 O
%) I-GENE
showed I-GENE
intrathecal O
synthesis O
of O
C O
. O
pneumoniae I-GENE
- I-GENE
specific I-GENE
IgG I-GENE
but I-GENE
only I-GENE
one I-GENE
of O
43 I-GENE
seropositive I-GENE
controls I-GENE
( I-GENE
2 I-GENE
. O
3 I-GENE
%). I-GENE

Consistent I-GENE
with I-GENE
the O
specificity O
observed I-GENE
for O
the O
interaction O
of O
DmCKIIalpha O
with I-GENE
these I-GENE
bHLH I-GENE
proteins I-GENE
, O
sequence I-GENE
alignment I-GENE
suggests I-GENE
that I-GENE
only I-GENE
m5 I-GENE
, O
m7 I-GENE
, O
and O
m8 I-GENE
contain I-GENE
a O
consensus O
site O
for O
phosphorylation O
by I-GENE
CKII I-GENE
within I-GENE
a O
subdomain I-GENE
unique I-GENE
to O
these I-GENE
three I-GENE
proteins I-GENE
. O

Deletion I-GENE
of O
the O
potential O
initiator O
element I-GENE
does I-GENE
not I-GENE
affect I-GENE
repression I-GENE
of O
the O
p21 O
promoter I-GENE
by I-GENE
c I-GENE
- I-GENE
Myc I-GENE
. O

PATIENTS I-GENE
AND I-GENE
METHODS I-GENE
: O
Between I-GENE
June I-GENE
1991 I-GENE
and O
December I-GENE
1996 I-GENE
, O
we I-GENE
administered I-GENE
the O
nucleoside I-GENE
analog I-GENE
2 I-GENE
- I-GENE
chlorodeoxyadenosine I-GENE
( I-GENE
2 I-GENE
- I-GENE
CDA I-GENE
) O
to O
73 O
children I-GENE
with I-GENE
primary O
AML O
and O
20 O
children I-GENE
with I-GENE
secondary I-GENE
AML I-GENE
or O
myelodysplastic O
syndrome O
( O
MDS O
). O

Drosophila I-GENE
Menin1 I-GENE
gene I-GENE
transcripts I-GENE
use I-GENE
alternative O
polyadenylation I-GENE
sites I-GENE
resulting I-GENE
in O
4 O
. O
3 O
and O
5 O
- O
kb O
messages O
. O

Mice O
homozygous I-GENE
for O
the O
dlg O
mutation I-GENE
exhibit I-GENE
growth I-GENE
retardation I-GENE
in O
utero O
, O
have O
hypoplasia O
of O
the O
premaxilla O
and O
mandible O
, O
have I-GENE
a O
cleft I-GENE
secondary I-GENE
palate O
, O
and O
die O
perinatally O
. O

In I-GENE
contrast I-GENE
, O
we I-GENE
did I-GENE
not I-GENE
detect I-GENE
a O
significant I-GENE
correlation I-GENE
between I-GENE
plasma I-GENE
TNFalpha I-GENE
and O
radiation I-GENE
pneumonitis I-GENE
. O

Its I-GENE
transcription I-GENE
in O
vitro I-GENE
by I-GENE
pol O
III I-GENE
requires I-GENE
the O
same I-GENE
factors I-GENE
as O
the O
U6 O
gene I-GENE
with I-GENE
the O
major I-GENE
exception I-GENE
that I-GENE
the O
modified I-GENE
TATA I-GENE
- I-GENE
box I-GENE
of O
this I-GENE
construct I-GENE
only I-GENE
interacts I-GENE
with I-GENE
a O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
TBP O
) O
mutant O
( O
TBP O
- I-GENE
DR2 I-GENE
) I-GENE
but I-GENE
not I-GENE
with I-GENE
TBP O
wild I-GENE
- I-GENE
type I-GENE
( O
TBPwt O
). O

Expression I-GENE
of O
the O
src O
homology O
3 O
( O
SH3 O
)- O
encoding O
, O
expressed O
in O
tumorigenic I-GENE
astrocytes I-GENE
( I-GENE
SETA I-GENE
) I-GENE
gene I-GENE
is I-GENE
associated I-GENE
with I-GENE
astrocyte I-GENE
transformation I-GENE
in O
culture I-GENE
and O
tumors I-GENE
in O
the O
adult I-GENE
brain I-GENE
. O

In I-GENE
such I-GENE
conditions I-GENE
, O
the O
following I-GENE
kinetic I-GENE
reactions I-GENE
have I-GENE
been I-GENE
studied I-GENE
: O
N2 I-GENE
( I-GENE
A I-GENE
) I-GENE
+ I-GENE
N2 I-GENE
( I-GENE
A I-GENE
) I-GENE
--> I-GENE
N2 I-GENE
( I-GENE
C I-GENE
, O
B I-GENE
, O
V I-GENE
') I-GENE
+ I-GENE
N2 I-GENE
( I-GENE
X I-GENE
), O
N2 I-GENE
( I-GENE
A I-GENE
) I-GENE
+ I-GENE
N2 I-GENE
( I-GENE
X I-GENE
, O
V I-GENE
> I-GENE
5 I-GENE
) I-GENE
--> I-GENE
N2 I-GENE
( I-GENE
X I-GENE
) I-GENE
+ I-GENE
N2 I-GENE
( I-GENE
B I-GENE
, O
V I-GENE
') I-GENE
in O
pure I-GENE
N2 I-GENE
post I-GENE
- I-GENE
discharges I-GENE
and O
N2 I-GENE
( I-GENE
A I-GENE
) I-GENE
+ I-GENE
CH4 I-GENE
--> I-GENE
products I-GENE
, O
C I-GENE
+ I-GENE
N I-GENE
+ I-GENE
M2 I-GENE
--> I-GENE
CN I-GENE
( I-GENE
B I-GENE
, O
V I-GENE
') I-GENE
+ I-GENE
M2 I-GENE
, O
N2 I-GENE
( I-GENE
X I-GENE
, O
V I-GENE
> I-GENE
4 I-GENE
) I-GENE
+ I-GENE
CN I-GENE
--> I-GENE
N2 I-GENE
( O
X O
) O
+ O
CN O
( O
B O
, O
A O
, O
V O
'), O
in O
N2 I-GENE
- I-GENE
1 I-GENE
% I-GENE
CH4 I-GENE
post I-GENE
- I-GENE
discharges I-GENE
. O

BACKGROUND I-GENE
/ I-GENE
AIMS I-GENE
: O
Hepatitis O
C O
and O
nonalcoholic O
fatty O
liver O
disease O
( O
NAFL O
) O
are I-GENE
the O
two I-GENE
most I-GENE
common I-GENE
forms I-GENE
of O
liver O
disease O
in O
the O
United I-GENE
States I-GENE
. O

These I-GENE
results I-GENE
suggested I-GENE
a O
critical I-GENE
role I-GENE
for O
tyrosine O
residue O
1229 O
in O
the O
regulation O
of O
L1 O
endocytosis O
. O

The I-GENE
androgen I-GENE
receptor I-GENE
( I-GENE
AR I-GENE
) O
amino O
- O
terminus O
imposes O
androgen O
- O
specific O
regulation O
of O
AR I-GENE
gene I-GENE
expression O
via I-GENE
an I-GENE
exonic I-GENE
enhancer I-GENE
. O

Can O
survival I-GENE
be I-GENE
prolonged I-GENE
for O
patients I-GENE
with I-GENE
hormone I-GENE
- I-GENE
resistant I-GENE
prostate O
cancer O
? O

In I-GENE
conclusion I-GENE
, O
NF I-GENE
- I-GENE
Y I-GENE
and O
Sp1 I-GENE
binding I-GENE
sites I-GENE
play I-GENE
a O
decisive I-GENE
role I-GENE
in O
the O
basal O
expression O
of O
the O
rat I-GENE
mrp2 I-GENE
gene I-GENE
, O
while I-GENE
the O
human I-GENE
MRP2 I-GENE
gene I-GENE
is I-GENE
regulated I-GENE
differently I-GENE
. O

Intact O
Flag O
- O
tagged O
protein O
products O
from O
all I-GENE
six O
were I-GENE
produced I-GENE
from O
genomic O
expression O
vectors I-GENE
, O
although I-GENE
the O
ORF40 I-GENE
/ O
41 O
transcript O
encoding O
a O
primase O
- I-GENE
helicase I-GENE
component I-GENE
proved I-GENE
to O
be I-GENE
spliced O
with I-GENE
a O
127 I-GENE
- I-GENE
bp O
intron O
. O

Hypomorphic O
dSLBP I-GENE
alleles I-GENE
support I-GENE
zygotic I-GENE
development I-GENE
but I-GENE
cause I-GENE
female I-GENE
sterility I-GENE
. O

In I-GENE
hypertensive I-GENE
nephrosclerosis I-GENE
, O
therapy I-GENE
containing I-GENE
an I-GENE
ACEI I-GENE
alone I-GENE
or O
in O
combination I-GENE
significantly I-GENE
reduces I-GENE
the O
incidence I-GENE
of O
renal O
events I-GENE
. O

We I-GENE
confirmed I-GENE
the O
interaction I-GENE
between I-GENE
TLS I-GENE
and O
p65 I-GENE
by I-GENE
the O
pull I-GENE
- I-GENE
down I-GENE
assay I-GENE
in O
vitro I-GENE
and O
by I-GENE
a O
coimmunoprecipitation I-GENE
experiment I-GENE
followed I-GENE
by I-GENE
Western I-GENE
blot I-GENE
of O
the O
cultured I-GENE
cell I-GENE
in O
vivo I-GENE
. O

In I-GENE
addition I-GENE
, O
we I-GENE
did I-GENE
not I-GENE
detect I-GENE
significant I-GENE
differences I-GENE
in O
CDR3 I-GENE
sequences I-GENE
of O
endogenous I-GENE
Ig O
lambdaL I-GENE
and O
kappaL I-GENE
chain I-GENE
gene I-GENE
loci I-GENE
cloned O
from O
peripheral I-GENE
blood O
lymphocytes I-GENE
of O
an I-GENE
NBS I-GENE
patient I-GENE
and O
of O
healthy I-GENE
individuals I-GENE
. O

The I-GENE
diet I-GENE
of O
migrants I-GENE
showed I-GENE
both I-GENE
positive I-GENE
( O
macronutrients O
) O
and O
negative O
( O
micronutrients O
) O
differences I-GENE
with I-GENE
the O
general I-GENE
Dutch I-GENE
diet I-GENE
. O

Copyright I-GENE
2001 I-GENE
Academic I-GENE
Press I-GENE
. O

Experimental I-GENE
study I-GENE
of O
ta O
chengchi O
tang O
decoction O
for O
relieving O
lung O
injury I-GENE
during O
acute I-GENE
necrotizing I-GENE
pancreatitis I-GENE
] I-GENE
The I-GENE
objectives O
of O
the O
study I-GENE
were I-GENE
to O
investigate I-GENE
the O
changes I-GENE
of O
leukocyte I-GENE
adhesiveness I-GENE
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
( O
TNF O
) O
in O
the O
early O
stage O
of O
acute I-GENE
necrotizing I-GENE
pancreatitis I-GENE
( O
ANP O
), O
to O
go O
further I-GENE
into I-GENE
the O
relation I-GENE
of O
those I-GENE
changes I-GENE
to O
lung O
injury I-GENE
of O
ANP O
, O
and O
to O
evaluate I-GENE
the O
prohibitive I-GENE
effect I-GENE
of O
ta O
chengchi O
tang O
Decoction O
on O
leukocyte O
adhesion O
and O
TNF O
secretion O
. O

We I-GENE
suggest I-GENE
that I-GENE
ventriculopleural I-GENE
shunting I-GENE
should I-GENE
be I-GENE
considered I-GENE
as O
the O
preferred I-GENE
alternative O
to O
peritoneal I-GENE
drainage I-GENE
in O
children I-GENE
with I-GENE
intra I-GENE
- I-GENE
abdominal I-GENE
adhesions I-GENE
or O
with I-GENE
a O
history I-GENE
of O
recent I-GENE
peritoneal I-GENE
infection I-GENE
. O

Positive O
and O
significant I-GENE
correlations I-GENE
were I-GENE
found I-GENE
between I-GENE
the O
weeks I-GENE
of O
pregnancy O
and O
Se O
levels O
in O
kidney O
( O
r O
= I-GENE
0 O
. O
433 I-GENE
, O
P I-GENE
= I-GENE
0 O
. O
023 O
) O
and O
heart O
( O
r O
= I-GENE
0 O
. O
313 I-GENE
, O
P I-GENE
= I-GENE
0 O
. O
030 O
). O

Doxorubicin O
( O
DOX I-GENE
) I-GENE
is I-GENE
commonly I-GENE
used I-GENE
for O
the O
treatment I-GENE
of O
hematological O
and O
solid I-GENE
tumors I-GENE
. O

There I-GENE
was I-GENE
no O
significant I-GENE
difference I-GENE
in O
developmental I-GENE
scores I-GENE
at O
9 O
or O
18 O
months I-GENE
, O
although I-GENE
PDF I-GENE
infants I-GENE
had I-GENE
a O
2 O
. O
8 O
(- O
1 O
. O
3 O
- O
6 O
. O
8 O
) O
point I-GENE
advantage I-GENE
in O
Bayley I-GENE
motor I-GENE
score I-GENE
scales I-GENE
. O

Immunofixation O
experiments I-GENE
of O
C4A I-GENE
and O
C4B I-GENE
demonstrate I-GENE
> I-GENE
41 O
allotypes O
in O
the O
two I-GENE
classes I-GENE
of O
proteins I-GENE
. O

These I-GENE
effects I-GENE
were I-GENE
not I-GENE
seen I-GENE
with I-GENE
SHIP2 I-GENE
possessing O
a O
mutation O
in O
the O
SH2 I-GENE
domain I-GENE
( I-GENE
R47G I-GENE
). O

Myasthenia O
gravis O
is I-GENE
an I-GENE
autoimmune I-GENE
disease O
resulting I-GENE
from O
the O
production I-GENE
of O
antibodies I-GENE
against I-GENE
the O
ACh O
receptors O
of O
the O
neuromuscular I-GENE
synapse I-GENE
. O

Human I-GENE
homologue I-GENE
of O
yeast I-GENE
Rad23 I-GENE
protein I-GENE
A I-GENE
interacts I-GENE
with I-GENE
p300 O
/ I-GENE
cyclic I-GENE
AMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
( I-GENE
CREB O
)- I-GENE
binding I-GENE
protein I-GENE
to O
down I-GENE
- I-GENE
regulate I-GENE
transcriptional I-GENE
activity I-GENE
of O
p53 O
. O

METHODS I-GENE
: O
Sixteen I-GENE
pigs I-GENE
were I-GENE
assigned I-GENE
randomly I-GENE
to O
control O
and O
shock I-GENE
groups I-GENE
. O

RESULTS I-GENE
: O
There I-GENE
is I-GENE
a O
considerable I-GENE
amount I-GENE
of O
variation I-GENE
between I-GENE
the O
results I-GENE
of O
TRA1 I-GENE
and O
TRA2 I-GENE
and O
between I-GENE
the O
results I-GENE
of O
both I-GENE
TRA I-GENE
' O
s O
and O
the O
door O
- O
to O
- I-GENE
door I-GENE
survey I-GENE
. O

Thus I-GENE
, O
our I-GENE
studies I-GENE
define I-GENE
Rac O
/ O
Cdc42 O
/ O
Pak O
as O
a O
module O
upstream O
of O
Raf O
- I-GENE
1 I-GENE
during O
its I-GENE
activation I-GENE
by I-GENE
microtubule I-GENE
disruption I-GENE
. O

Zhu O
, O
V O
. O

However I-GENE
, O
plasmids I-GENE
carrying I-GENE
the O
yeast I-GENE
TyrRS I-GENE
gene I-GENE
could I-GENE
not I-GENE
be I-GENE
stably I-GENE
maintained I-GENE
in O
E O
. O
coli O
. O

This I-GENE
supports I-GENE
previous I-GENE
arguments O
for O
the O
improbability O
of O
biological I-GENE
effects I-GENE
at O
UHF I-GENE
frequencies I-GENE
unless I-GENE
a O
mechanism I-GENE
can I-GENE
be I-GENE
found I-GENE
for O
accumulating I-GENE
energy I-GENE
over I-GENE
time I-GENE
and O
space I-GENE
and O
focussing I-GENE
it I-GENE
. O

The I-GENE
students I-GENE
who I-GENE
had I-GENE
abnormal I-GENE
urine I-GENE
screening I-GENE
results I-GENE
at O
the O
first O
time I-GENE
received I-GENE
a O
second I-GENE
urine I-GENE
analysis I-GENE
10 O
to O
15 O
days I-GENE
later I-GENE
to O
confirm I-GENE
the O
abnormal I-GENE
urine I-GENE
analysis I-GENE
. O

Cells O
containing O
alpha I-GENE
subunits I-GENE
that I-GENE
lacked I-GENE
a O
distal I-GENE
domain I-GENE
( I-GENE
term I-GENE
- I-GENE
3 I-GENE
) I-GENE
or O
had I-GENE
the O
alternatively O
spliced O
alpha I-GENE
- I-GENE
2 I-GENE
distal I-GENE
domain I-GENE
showed I-GENE
markedly I-GENE
decreased I-GENE
ability I-GENE
to O
support I-GENE
tyrosine I-GENE
phosphorylation O
of O
Jak O
- O
2 O
and O
its O
substrates O
or O
to O
up O
- I-GENE
regulate I-GENE
CD86 I-GENE
. O

Despite I-GENE
abundant I-GENE
expression O
of O
NtmybAS I-GENE
transcripts I-GENE
in O
mature I-GENE
pollen I-GENE
, O
gPAL1 I-GENE
transcripts I-GENE
were I-GENE
not I-GENE
detectable I-GENE
in O
pollen I-GENE
. O

Finally I-GENE
, O
profiling O
of O
a O
gcn4Delta I-GENE
mutant I-GENE
uncovered I-GENE
an I-GENE
alternative O
induction I-GENE
pathway O
operating I-GENE
at O
many I-GENE
Gcn4p I-GENE
target I-GENE
genes I-GENE
in O
histidine I-GENE
- I-GENE
starved I-GENE
cells I-GENE
. O

The I-GENE
R2 I-GENE
between I-GENE
MFI I-GENE
of O
fresh I-GENE
and O
frozen O
muscle O
was O
0 O
. O
94 I-GENE
and O
0 O
. O
92 I-GENE
for O
lamb O
and O
pork O
longissimus O
, O
respectively I-GENE
. O

To I-GENE
this I-GENE
end I-GENE
, O
an I-GENE
expression O
cassette I-GENE
consisting I-GENE
of O
the O
gene O
for O
a O
green O
fluorescent O
protein I-GENE
( I-GENE
GFP I-GENE
) I-GENE
flanked I-GENE
at O
its I-GENE
3 I-GENE
' I-GENE
end I-GENE
by I-GENE
EAV I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
- I-GENE
regulating I-GENE
sequences I-GENE
was I-GENE
constructed I-GENE
. O

Significantly I-GENE
higher O
lung O
function I-GENE
parameters I-GENE
were I-GENE
obtained I-GENE
in O
extubated I-GENE
recipients I-GENE
of O
LPD I-GENE
preserved I-GENE
grafts I-GENE
2 I-GENE
weeks I-GENE
after I-GENE
TX I-GENE
. O

Lack O
of O
association I-GENE
between I-GENE
Kawasaki O
syndrome O
and O
infection I-GENE
with I-GENE
Rickettsia O
conorii O
, O
Rickettsia O
typhi O
, O
Coxiella O
burnetii O
or O
Ehrlichia O
phagocytophila O
group O
. O

These I-GENE
utilisation I-GENE
data I-GENE
imply I-GENE
annual I-GENE
drug I-GENE
costs I-GENE
in O
the O
range I-GENE
of O
$ I-GENE
US I-GENE
480 I-GENE
, O
000 O
to O
$ O
US I-GENE
3 I-GENE
, O
600 I-GENE
, O
000 O
for O
TNF O
antagonists I-GENE
for O
RA I-GENE
per I-GENE
1 I-GENE
million I-GENE
population I-GENE
. O

Alignment O
of O
different I-GENE
cDNAs I-GENE
of O
the O
NR5A2 I-GENE
( I-GENE
hB1F I-GENE
) I-GENE
gene I-GENE
with I-GENE
the O
genomic I-GENE
sequence I-GENE
facilitated I-GENE
the O
delineation O
of O
its I-GENE
structural I-GENE
organization I-GENE
, O
which I-GENE
spans I-GENE
over I-GENE
150 O
kb O
and O
consists I-GENE
of O
eight I-GENE
exons I-GENE
interrupted I-GENE
by I-GENE
seven O
introns O
. O

CONCLUSIONS I-GENE
: O
Ketamine I-GENE
- I-GENE
induced O
dissociative I-GENE
anesthesia I-GENE
produces I-GENE
persistently I-GENE
elevated I-GENE
BIS I-GENE
index I-GENE
which I-GENE
is I-GENE
different I-GENE
from O
thiamylal O
and O
those I-GENE
reported I-GENE
with I-GENE
other I-GENE
conventional I-GENE
anesthetic I-GENE
agents I-GENE
. O

In I-GENE
the O
remaining I-GENE
case I-GENE
, O
the O
aneurysm O
originated O
from O
the O
proximal O
end I-GENE
of O
the O
associated O
A1 I-GENE
fenestration I-GENE
. O

This I-GENE
domain I-GENE
without I-GENE
the O
canonical I-GENE
anticodon O
loop O
or O
the O
tyrosine I-GENE
anticodon I-GENE
acts I-GENE
as O
an I-GENE
anchor I-GENE
for O
TyrRS I-GENE
interaction O
leading I-GENE
to O
a O
better I-GENE
efficiency I-GENE
of O
tyrosylation O
. O

Temperature O
measurement I-GENE
in O
microfluidic O
systems O
using O
a O
temperature O
- O
dependent O
fluorescent O
dye O
. O

The O
first O
exon O
( O
exon O
1A I-GENE
) I-GENE
that I-GENE
corresponded I-GENE
to O
the O
5 O
'- O
untranslated O
region O
of O
the O
GHR I-GENE
1A I-GENE
mRNA I-GENE
was I-GENE
15 O
, O
250 O
bp O
upstream O
from O
exon O
2 O
in O
the O
GHR I-GENE
gene I-GENE
. O

The I-GENE
NAUSICAA I-GENE
system O
gives I-GENE
a O
good I-GENE
knowledge I-GENE
of O
LET I-GENE
spectra I-GENE
for O
the O
first O
time I-GENE
in O
space I-GENE
dosimetry I-GENE
. O

The I-GENE
MABP I-GENE
and O
MCBFV I-GENE
signals I-GENE
were I-GENE
bandpass O
filtered O
in O
the O
very I-GENE
low I-GENE
- I-GENE
frequency I-GENE
range I-GENE
( O
VLF O
, O
0 O
. O
015 O
- O
0 O
. O
07 I-GENE
Hz I-GENE
), O
low I-GENE
- I-GENE
frequency I-GENE
range I-GENE
( O
LF O
, O
0 O
. O
07 I-GENE
- I-GENE
0 O
. O
15 O
Hz I-GENE
) O
and O
high O
- I-GENE
frequency I-GENE
range I-GENE
( I-GENE
HF I-GENE
, O
0 O
. O
15 O
- O
0 O
. O
40 O
Hz I-GENE
) I-GENE
before I-GENE
applying I-GENE
CCF I-GENE
for O
the O
purpose I-GENE
of O
studying I-GENE
the O
effect I-GENE
of O
different I-GENE
bandwidths I-GENE
on I-GENE
the O
resulting I-GENE
mean I-GENE
CCFs I-GENE
. O

At I-GENE
cross I-GENE
purposes I-GENE
. O

For I-GENE
these I-GENE
patients I-GENE
the O
introduction I-GENE
of O
a O
separate I-GENE
category I-GENE
" I-GENE
extended I-GENE
oligoarthritis I-GENE
at O
onset I-GENE
" I-GENE
should I-GENE
be I-GENE
considered I-GENE
to O
establish I-GENE
comparable I-GENE
patient I-GENE
groups I-GENE
. O

The O
susceptibility O
of O
Aspergillus O
fumigatus O
to O
mulundocandin O
, O
an I-GENE
echinocandin I-GENE
- I-GENE
like I-GENE
compound I-GENE
, O
and O
other I-GENE
antifungal I-GENE
agents I-GENE
was I-GENE
assessed I-GENE
by I-GENE
the O
National I-GENE
Committee I-GENE
for O
Clinical I-GENE
Laboratory I-GENE
Standards I-GENE
( I-GENE
NCCLS I-GENE
) I-GENE
M38 I-GENE
- I-GENE
P I-GENE
method I-GENE
, O
a O
2 O
, O
3 O
- O
bis O
( O
2 I-GENE
- I-GENE
methoxy I-GENE
- I-GENE
4 I-GENE
- I-GENE
nitro I-GENE
- I-GENE
5 I-GENE
- I-GENE
sulfophenyl I-GENE
)- I-GENE
5 I-GENE
-[( I-GENE
phenyl I-GENE
- I-GENE
amino I-GENE
) I-GENE
carbonyl I-GENE
]- I-GENE
2H I-GENE
- I-GENE
tetrazolium I-GENE
hydroxide I-GENE
( I-GENE
XTT I-GENE
)- I-GENE
based I-GENE
colorimetric I-GENE
assay I-GENE
, O
and O
determination I-GENE
of O
morphologic I-GENE
alterations I-GENE
by I-GENE
microscopy I-GENE
. O

The I-GENE
most I-GENE
important I-GENE
risk I-GENE
factors I-GENE
are I-GENE
: O
1 I-GENE
) I-GENE
genetic I-GENE
; O
2 I-GENE
) I-GENE
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
( I-GENE
infectious I-GENE
mononucleosis I-GENE
); I-GENE
3 I-GENE
) I-GENE
congenital I-GENE
and O
acquired I-GENE
immunodeficiency I-GENE
; O
4 I-GENE
) I-GENE
occupational I-GENE
exposure I-GENE
( O
the O
wood O
industry O
). O

Members I-GENE
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
superfamily I-GENE
of O
basic I-GENE
- I-GENE
leucine I-GENE
zipper I-GENE
factors I-GENE
bind I-GENE
to O
the O
StRE I-GENE
. O

DNA O
recognition I-GENE
by I-GENE
F I-GENE
factor I-GENE
TraI36 I-GENE
: O
highly I-GENE
sequence I-GENE
- I-GENE
specific I-GENE
binding I-GENE
of O
single O
- O
stranded O
DNA O
. O

Overexpression I-GENE
of O
RORgamma I-GENE
has I-GENE
been I-GENE
shown I-GENE
to O
inhibit I-GENE
T I-GENE
cell I-GENE
receptor I-GENE
- I-GENE
mediated O
apoptosis I-GENE
in O
T O
cell O
hybridomas O
and O
to O
repress I-GENE
the O
induction I-GENE
of O
Fas O
- O
ligand O
and O
interleukin O
2 O
. O

Although I-GENE
metabolized I-GENE
by I-GENE
the O
cytochrome O
P O
- O
450 O
( O
CYP O
) O
system O
, O
venlafaxine O
inhibits I-GENE
CYP I-GENE
2D6 I-GENE
and O
3A4 I-GENE
to O
a O
far I-GENE
lesser I-GENE
extent I-GENE
than I-GENE
do I-GENE
the O
SSRIs O
. O

SAPK O
/ O
JNK O
activation O
was I-GENE
completely I-GENE
abolished I-GENE
in O
the O
absence I-GENE
of O
MKK7 I-GENE
, O
even I-GENE
though I-GENE
expression O
of O
MKK4 I-GENE
was I-GENE
strongly I-GENE
upregulated I-GENE
in O
mkk7 I-GENE
(-/-) I-GENE
mast I-GENE
cell I-GENE
lines I-GENE
, O
and O
phosphorylation O
of O
MKK4 I-GENE
occurred I-GENE
normally I-GENE
in O
response O
to O
multiple I-GENE
stress I-GENE
stimuli I-GENE
. O

However I-GENE
these I-GENE
search I-GENE
engines I-GENE
respond I-GENE
with I-GENE
such I-GENE
cumbersome I-GENE
results I-GENE
that I-GENE
domain I-GENE
specific I-GENE
experts I-GENE
can I-GENE
not I-GENE
tolerate I-GENE
. O

The I-GENE
titer I-GENE
of O
TSH I-GENE
binding I-GENE
inhibitor I-GENE
immunoglobulin O
( O
TBII O
), O
which I-GENE
had I-GENE
been I-GENE
8 I-GENE
. O
6 I-GENE
% I-GENE
at O
initial I-GENE
presentation I-GENE
, O
rose I-GENE
to O
14 O
. O
9 O
% I-GENE
in O
2 I-GENE
weeks I-GENE
. O

The I-GENE
extraordinary I-GENE
stability I-GENE
of O
peptide O
-- O
gp96 O
complexes O
and O
the O
plasticity O
of O
the O
peptide I-GENE
- I-GENE
binding I-GENE
pocket I-GENE
support I-GENE
the O
proposed I-GENE
relay I-GENE
of O
diverse I-GENE
peptides I-GENE
to O
MHC O
and O
/ O
or O
other I-GENE
molecules I-GENE
via I-GENE
molecular O
recognition O
. O

Elevated O
expression O
of O
full I-GENE
- I-GENE
length I-GENE
UhpB I-GENE
or O
of O
a O
soluble O
hybrid O
protein O
, O
GST O
- O
Bc O
, O
which I-GENE
is I-GENE
glutathione I-GENE
S I-GENE
- I-GENE
transferase O
( O
GST O
) O
fused I-GENE
to O
the O
cytoplasmic O
C I-GENE
- I-GENE
terminal I-GENE
portion I-GENE
of O
UhpB I-GENE
, O
results I-GENE
in O
complete O
blockage O
of O
uhpT O
expression O
in O
a O
uhp O
(+) O
strain O
. O

Physical O
principles O
in O
therapeutic I-GENE
apheresis I-GENE
. O

Evidence I-GENE
from O
a O
Northern I-GENE
hybridization I-GENE
indicated I-GENE
that I-GENE
jadM I-GENE
expression O
is I-GENE
correlated I-GENE
with I-GENE
jadomycin I-GENE
B I-GENE
synthesis O
. O

Multiple I-GENE
copies I-GENE
of O
rsmB I-GENE
+ I-GENE
DNA I-GENE
, O
on I-GENE
the O
other I-GENE
hand I-GENE
, O
stimulate I-GENE
exoenzyme I-GENE
production I-GENE
by I-GENE
relieving I-GENE
the O
negative I-GENE
effects I-GENE
of O
a O
chromosomal O
copy I-GENE
of O
hexA I-GENE
+. O

Systematic O
review I-GENE
of O
diagnostic I-GENE
tests I-GENE
for O
vaginal I-GENE
trichomoniasis I-GENE
. O

Anecdotal O
observations I-GENE
scattered I-GENE
throughout I-GENE
the O
literature I-GENE
have I-GENE
often I-GENE
provided I-GENE
clues I-GENE
to O
underlying I-GENE
variations I-GENE
in O
humans I-GENE
' I-GENE
ability I-GENE
to O
handle I-GENE
dietary I-GENE
chemicals I-GENE
. O

Here I-GENE
we I-GENE
show I-GENE
that I-GENE
phosphorylation O
- O
induced O
loss O
of O
the O
protein I-GENE
kinase I-GENE
activity I-GENE
of O
DNA I-GENE
- I-GENE
PK I-GENE
is I-GENE
restored I-GENE
by I-GENE
the O
addition I-GENE
of O
the O
purified O
catalytic O
subunit O
of O
either I-GENE
protein I-GENE
phosphatase I-GENE
1 I-GENE
or O
protein I-GENE
phosphatase I-GENE
2A I-GENE
( O
PP2A O
) O
and O
that I-GENE
this I-GENE
reactivation I-GENE
is I-GENE
blocked I-GENE
by I-GENE
the O
potent I-GENE
protein I-GENE
phosphatase I-GENE
inhibitor I-GENE
, O
microcystin O
. O

Herein O
PPARgamma O
, O
liganded O
by I-GENE
either I-GENE
natural I-GENE
( I-GENE
15d I-GENE
- I-GENE
PGJ I-GENE
( I-GENE
2 I-GENE
) I-GENE
and O
PGD I-GENE
( I-GENE
2 I-GENE
)) I-GENE
or O
synthetic I-GENE
ligands I-GENE
( I-GENE
BRL49653 I-GENE
and O
troglitazone O
), O
selectively I-GENE
inhibited I-GENE
expression O
of O
the O
cyclin I-GENE
D1 I-GENE
gene I-GENE
. O

An I-GENE
integrated I-GENE
RTC I-GENE
algorithm I-GENE
for O
the O
urban O
wastewater O
system O
is O
formulated O
, O
the O
parameters I-GENE
of O
which I-GENE
are I-GENE
optimized I-GENE
using I-GENE
various I-GENE
global I-GENE
optimization I-GENE
routines I-GENE
. O

Recently I-GENE
, O
we I-GENE
discovered I-GENE
that I-GENE
alanine I-GENE
substitutions I-GENE
of O
the O
active O
center O
cleft O
residues O
significantly I-GENE
impair O
the O
depurinating O
and O
ribosome O
inhibitory O
activity O
of O
PAP O
. O

This I-GENE
partial I-GENE
transection I-GENE
could I-GENE
permit I-GENE
vasopressin O
to O
be O
secreted O
in O
response O
to O
a O
larger I-GENE
rise I-GENE
in O
plasma I-GENE
sodium I-GENE
concentration I-GENE
. O

Reciprocally O
, O
HMGI I-GENE
- I-GENE
C I-GENE
expression O
also I-GENE
coordinately I-GENE
enhances I-GENE
PIAS3 I-GENE
- I-GENE
mediated O
repression I-GENE
of O
STAT3 O
- O
dependent O
transactivation O
. O

The O
genomic O
structure O
of O
the O
human I-GENE
SPEC1 I-GENE
gene I-GENE
reveals I-GENE
complex I-GENE
splicing I-GENE
and O
close I-GENE
promoter I-GENE
proximity O
to O
the O
AF1q I-GENE
translocation I-GENE
gene I-GENE
. O

Here I-GENE
, O
the O
PEX5 I-GENE
- I-GENE
TPR I-GENE
domains I-GENE
from O
human O
, O
tobacco O
, O
and O
nematode I-GENE
were I-GENE
inserted I-GENE
into I-GENE
a O
TPR I-GENE
- I-GENE
less I-GENE
yeast I-GENE
Pex5p I-GENE
construct I-GENE
to O
generate I-GENE
Pex5p I-GENE
chimaeras I-GENE
. O

This I-GENE
study I-GENE
demonstrates I-GENE
that I-GENE
inducible O
expression O
in O
response O
to O
either I-GENE
PMA I-GENE
or O
TPO I-GENE
is I-GENE
mediated O
through I-GENE
the O
Ets O
site O
in O
the O
proximal O
promoter O
of O
GPIX O
and O
is I-GENE
dependent I-GENE
upon I-GENE
the O
upstream O
activation O
of O
MAPK I-GENE
/ I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
. O

Molecular I-GENE
identification I-GENE
of O
smg I-GENE
- I-GENE
4 I-GENE
, O
required I-GENE
for O
mRNA O
surveillance O
in O
C O
. O
elegans O
. O

Cytosolic O
acetyl O
- O
CoA O
synthetase I-GENE
( I-GENE
AceCS1 I-GENE
) I-GENE
activates I-GENE
acetate I-GENE
to O
supply I-GENE
the O
cells I-GENE
with I-GENE
acetyl O
- O
CoA O
for O
lipid O
synthesis O
. O

There I-GENE
was I-GENE
an I-GENE
increase I-GENE
in O
protein I-GENE
binding I-GENE
onto I-GENE
this I-GENE
element I-GENE
only I-GENE
after I-GENE
peptide I-GENE
treatment I-GENE
. O

While I-GENE
these I-GENE
results I-GENE
are I-GENE
consistent I-GENE
with I-GENE
previously I-GENE
reported I-GENE
effects I-GENE
of O
the O
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
on I-GENE
nucleotide I-GENE
binding I-GENE
, O
they I-GENE
also I-GENE
demonstrate I-GENE
that I-GENE
interactions I-GENE
with I-GENE
the O
N I-GENE
- I-GENE
terminal I-GENE
domains I-GENE
are I-GENE
necessary I-GENE
to O
inhibit I-GENE
proton I-GENE
transport I-GENE
. O

These I-GENE
findings I-GENE
suggest I-GENE
that I-GENE
an I-GENE
intracellular O
WT I-GENE
- I-GENE
1 I-GENE
/ I-GENE
HSAL2 I-GENE
pathway O
may I-GENE
play I-GENE
a O
role I-GENE
in O
development I-GENE
and O
hematopoiesis O
. O

The I-GENE
radial I-GENE
forearm I-GENE
flap I-GENE
is I-GENE
used I-GENE
most I-GENE
commonly I-GENE
, O
however I-GENE
the O
lateral I-GENE
arm I-GENE
flap I-GENE
may I-GENE
be I-GENE
the O
flap I-GENE
of O
choice I-GENE
in O
certain I-GENE
situations I-GENE
. O

The I-GENE
procedure I-GENE
is I-GENE
less I-GENE
aggressive I-GENE
and O
painful I-GENE
than I-GENE
sternotomy I-GENE
. O

In I-GENE
addition I-GENE
, O
we I-GENE
have I-GENE
isolated I-GENE
a O
genomic O
fragment O
containing O
the O
most I-GENE
distal I-GENE
5 O
' O
sequences O
of O
the O
major O
GGT O
mRNA O
in O
HepG2 O
cells I-GENE
. O

Further I-GENE
, O
the O
osteo O
- I-GENE
retentive I-GENE
ability I-GENE
of O
the O
hydroxyapatite O
in O
the O
sockets O
was I-GENE
seen I-GENE
to O
be I-GENE
close I-GENE
to O
significance I-GENE
( I-GENE
after I-GENE
six O
months I-GENE
width I-GENE
differences I-GENE
, O
in O
the O
canine I-GENE
region I-GENE
: O
P I-GENE
= I-GENE
0 O
. O
059 O
, O
LHS O
, O
and O
P O
= I-GENE
0 O
. O
065 O
, O
RHS O
). O

These I-GENE
findings I-GENE
suggest I-GENE
a O
novel I-GENE
ankyrin I-GENE
- I-GENE
independent I-GENE
role I-GENE
for O
LAD I-GENE
- I-GENE
1 I-GENE
related I-GENE
to O
FGFR O
signaling O
. O

Managing O
vertigo O
and O
vertigo O
syndromes I-GENE
in O
the O
elderly O

A O
single O
base O
change I-GENE
( I-GENE
A8G I-GENE
) I-GENE
in O
either I-GENE
sequence I-GENE
reduces I-GENE
hnRNP I-GENE
A2 I-GENE
binding I-GENE
and O
, O
in O
the O
case I-GENE
of O
A2RE I-GENE
- I-GENE
2 I-GENE
, O
inhibits I-GENE
RNA I-GENE
transport I-GENE
. O

A I-GENE
method I-GENE
of O
three I-GENE
- I-GENE
station I-GENE
three I-GENE
- I-GENE
dimensional I-GENE
magnetic I-GENE
resonance I-GENE
( I-GENE
MR I-GENE
) I-GENE
angiography I-GENE
of O
the O
lower I-GENE
extremities I-GENE
with I-GENE
segmented I-GENE
volume I-GENE
acquisition I-GENE
is I-GENE
presented I-GENE
. O

Treatment I-GENE
of O
N18TG I-GENE
- I-GENE
2 I-GENE
cells I-GENE
with I-GENE
a O
demethylating I-GENE
agent I-GENE
, O
5 I-GENE
- I-GENE
aza I-GENE
- I-GENE
deoxycytidine I-GENE
, O
resulted I-GENE
in O
an I-GENE
expression O
of O
mlt O
1 O
, O
indicating I-GENE
that I-GENE
the O
repression I-GENE
of O
mlt I-GENE
1 I-GENE
is I-GENE
attributable I-GENE
to O
methylation I-GENE
Thus I-GENE
, O
mlt I-GENE
1 I-GENE
is I-GENE
a O
novel I-GENE
target I-GENE
gene I-GENE
that I-GENE
is I-GENE
silenced I-GENE
by I-GENE
methylation I-GENE
during O
liver I-GENE
tumorigenesis I-GENE
initiated I-GENE
by I-GENE
SV40 I-GENE
T I-GENE
antigen I-GENE
. O

We I-GENE
found I-GENE
in O
the O
control O
subjects I-GENE
rCBF I-GENE
increases I-GENE
in O
regions O
associated O
with O
the O
meso O
- O
striatal O
and O
meso O
- O
corticolimbic O
circuits O
in O
response O
to O
both O
monetary O
reward O
and O
nonmonetary O
reinforcement O
. O

Reverse O
transcriptase O
- I-GENE
polymerase I-GENE
chain I-GENE
reaction I-GENE
assays I-GENE
showed I-GENE
that I-GENE
PKRDeltaE7 I-GENE
is I-GENE
expressed O
in O
a O
broad I-GENE
range I-GENE
of O
human I-GENE
tissues I-GENE
at O
variable I-GENE
levels I-GENE
. O

For I-GENE
this I-GENE
purpose I-GENE
, O
the O
immediate O
and O
the O
final I-GENE
( I-GENE
after I-GENE
swelling I-GENE
) I-GENE
fixation I-GENE
strengths I-GENE
of O
two I-GENE
variations I-GENE
of O
the O
swellable O
bone O
anchor O
designs O
( O
a O
smooth O
anchor O
and O
a O
screw O
anchor O
) O
were I-GENE
measured I-GENE
in O
two I-GENE
different I-GENE
foams I-GENE
( I-GENE
used I-GENE
to O
simulate O
bone O
) O
with I-GENE
different I-GENE
densities I-GENE
. O

CYP2C19 I-GENE
genotype I-GENE
was I-GENE
determined I-GENE
by I-GENE
the O
polymerase I-GENE
chain I-GENE
reaction I-GENE
- I-GENE
restriction I-GENE
fragment I-GENE
length I-GENE
polymorphism I-GENE
method I-GENE
. O

It I-GENE
is I-GENE
useful I-GENE
as O
an I-GENE
adjunct O
to O
mammography O
in O
those I-GENE
patients I-GENE
with I-GENE
radiographically O
dense O
breasts O
for O
the O
characterization I-GENE
of O
palpable I-GENE
masses I-GENE
. O

Activation I-GENE
of O
transcription I-GENE
through I-GENE
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
in O
Jurkat I-GENE
cells I-GENE
by I-GENE
JunD I-GENE
and O
/ O
or O
Fra O
- I-GENE
2 I-GENE
was I-GENE
weak I-GENE
. O
c I-GENE
- I-GENE
Jun O
, O
JunB O
, O
and O
c I-GENE
- I-GENE
Fos O
activation I-GENE
was I-GENE
greater I-GENE
, O
although I-GENE
the O
level I-GENE
was I-GENE
still I-GENE
less I-GENE
than I-GENE
that I-GENE
with I-GENE
Tax I-GENE
. O

Thus I-GENE
, O
the O
screen I-GENE
for O
toxic I-GENE
p53 O
mutants I-GENE
in O
yeast I-GENE
can I-GENE
identify I-GENE
novel I-GENE
p53 I-GENE
variants I-GENE
that I-GENE
may I-GENE
be I-GENE
useful I-GENE
in O
dissecting O
p53 O
regulated O
cellular O
responses I-GENE
and O
in O
developing I-GENE
p53 O
- I-GENE
based I-GENE
cancer O
therapies O
. O

Local O
control O
rates I-GENE
were I-GENE
91 I-GENE
% I-GENE
for O
metastatic I-GENE
lung O
cancer O
, O
89 O
% O
for O
primary O
lung O
cancer O
and O
85 O
% O
for O
T1 O
, O
2N0M0 I-GENE
cases I-GENE
. O

The I-GENE
results I-GENE
show I-GENE
that I-GENE
cognitive I-GENE
stimulation O
enhanced O
performance I-GENE
on I-GENE
the O
Boston I-GENE
Naming I-GENE
Test I-GENE
and O
a O
Word O
List O
Recognition O
Task O
; O
physical I-GENE
intervention I-GENE
, O
however I-GENE
, O
did I-GENE
not I-GENE
reach I-GENE
statistical I-GENE
significance I-GENE
. O

Gimpl O
, O
F O
. O

The I-GENE
actA I-GENE
gene I-GENE
is I-GENE
present I-GENE
as O
a O
single O
copy I-GENE
in O
the O
genome I-GENE
of O
A O
. O
chrysogenum O
; O
and O
its I-GENE
expression O
level I-GENE
, O
opposite I-GENE
to O
pcbC I-GENE
and O
cefEF I-GENE
cephalosporin I-GENE
biosynthetic I-GENE
genes I-GENE
, O
was I-GENE
steady I-GENE
during O
cephalosporin O
fermentation O
, O
showing I-GENE
a O
single O
1 O
. O
4 O
- O
kb O
transcript O
. O

Maternal O
p O
, O
p O
' O
DDE O
and O
beta I-GENE
- I-GENE
HCH I-GENE
levels I-GENE
were I-GENE
also I-GENE
associated I-GENE
with I-GENE
newborn I-GENE
levels I-GENE
, O
but I-GENE
levels I-GENE
of O
PCBs I-GENE
were I-GENE
not I-GENE
. O

The I-GENE
patients I-GENE
and O
their I-GENE
families I-GENE
were I-GENE
closely I-GENE
questioned O
, O
and O
full I-GENE
clinical I-GENE
examination I-GENE
included I-GENE
a O
test I-GENE
for O
orthostasia O
. O

The O
expression O
of O
alpha I-GENE
- I-GENE
amylase O
can I-GENE
be I-GENE
transactivated I-GENE
by I-GENE
the O
transcription I-GENE
factor I-GENE
GAMyb I-GENE
, O
which I-GENE
is I-GENE
itself I-GENE
induced O
by I-GENE
GA I-GENE
. O

Cardiac I-GENE
output I-GENE
at O
anaerobic I-GENE
threshold I-GENE
( I-GENE
COAT I-GENE
) I-GENE
< I-GENE
or O
= I-GENE
7 I-GENE
. O
3 I-GENE
L I-GENE
/ I-GENE
min I-GENE
was I-GENE
the O
best I-GENE
cutoff I-GENE
value I-GENE
for O
identifying I-GENE
multivessel I-GENE
coronary I-GENE
artery I-GENE
disease O
( I-GENE
relative I-GENE
risk I-GENE
, O
3 O
. O
1 O
). O

Tolerance O
to O
ADAL I-GENE
- I-GENE
2 I-GENE
was I-GENE
similar I-GENE
to O
that O
of O
Vicryl O
suture O
and O
tolerance I-GENE
to O
ADAL I-GENE
- I-GENE
2 I-GENE
was I-GENE
superior I-GENE
to O
that O
to O
Tisuacryl O
. O

In O
the O
base O
- I-GENE
case I-GENE
analysis I-GENE
, O
total O
direct I-GENE
costs I-GENE
per I-GENE
patient I-GENE
were I-GENE
$ I-GENE
728 I-GENE
for O
zoledronic O
acid O
and O
$ O
776 O
for O
pamidronate O
. O

METHODS I-GENE
: O
We I-GENE
retrospectively O
selected O
13 O
TFCD I-GENE
patients I-GENE
who I-GENE
underwent I-GENE
surgery I-GENE
for O
intractable I-GENE
epilepsy I-GENE
with I-GENE
the O
aim I-GENE
of O
removing I-GENE
the O
magnetic I-GENE
resonance I-GENE
( I-GENE
MR I-GENE
)- I-GENE
detectable I-GENE
lesion I-GENE
and O
/ O
or O
the O
epileptogenic O
zone I-GENE
defined I-GENE
by I-GENE
stereoelectroencephalographic I-GENE
recordings I-GENE
. O

To I-GENE
gain I-GENE
an I-GENE
understanding I-GENE
of O
the O
mGSTM2 O
regulation O
, O
we I-GENE
have I-GENE
also I-GENE
cloned O
and O
analyzed I-GENE
its I-GENE
promoter I-GENE
region I-GENE
. O

Cyclins O
are I-GENE
one I-GENE
of O
the O
pivotal I-GENE
determinants O
regulating O
cell O
cycle O
progression I-GENE
. O

Architecture O
and O
anatomy O
of O
the O
genomic O
locus O
encoding O
the O
human I-GENE
leukemia I-GENE
- I-GENE
associated I-GENE
transcription I-GENE
factor I-GENE
RUNX1 I-GENE
/ I-GENE
AML1 I-GENE
. O

Three I-GENE
of O
the O
proteins I-GENE
involved I-GENE
in O
checkpoint O
signaling O
, O
Rad1 O
, O
Hus1 O
, O
and O
Rad9 I-GENE
, O
have I-GENE
been I-GENE
shown I-GENE
to O
interact I-GENE
by I-GENE
immunoprecipitation I-GENE
and O
yeast I-GENE
two I-GENE
- I-GENE
hybrid O
studies I-GENE
. O

Together I-GENE
these I-GENE
data I-GENE
imply I-GENE
that I-GENE
the O
HFV I-GENE
R I-GENE
region I-GENE
acts I-GENE
in O
the O
nucleus I-GENE
to O
modify I-GENE
the O
cytoplasmic I-GENE
fate I-GENE
of O
target I-GENE
HFV I-GENE
mRNA I-GENE
. O

However I-GENE
, O
patients I-GENE
with I-GENE
isolated I-GENE
office I-GENE
hypertension I-GENE
had I-GENE
fewer I-GENE
previous I-GENE
cardiovascular I-GENE
complications I-GENE
. O

Through O
deletion O
mutagenesis I-GENE
, O
we I-GENE
identify I-GENE
amino O
acids O
2003 O
to O
2212 O
of O
CBP O
, O
which I-GENE
we I-GENE
call I-GENE
carboxy I-GENE
- I-GENE
terminal I-GENE
region I-GENE
2 I-GENE
( I-GENE
CR2 I-GENE
), O
as O
the O
minimal O
region O
for O
Tax I-GENE
interaction O
. O

Fetal O
lung O
volume I-GENE
: O
estimation I-GENE
at O
MR I-GENE
imaging I-GENE
- I-GENE
initial I-GENE
results I-GENE
. O

Plane O
wave I-GENE
geometry I-GENE
is I-GENE
impractical I-GENE
for O
clinical I-GENE
use I-GENE
but I-GENE
the O
results I-GENE
of O
this I-GENE
work I-GENE
encouraged I-GENE
us I-GENE
to O
further I-GENE
develop I-GENE
the O
P3 O
approximation O
for O
a O
spherical O
geometry O
, O
described I-GENE
in O
this I-GENE
paper I-GENE
. O

For I-GENE
the O
sample I-GENE
of O
systematic I-GENE
reviews O
drawn O
from O
ACP O
Journal O
Club O
( O
n O
= I-GENE
103 I-GENE
), O
the O
PubMed O
strategy I-GENE
achieved I-GENE
a O
sensitivity I-GENE
of O
97 I-GENE
% I-GENE
( O
CI O
, O
91 I-GENE
% I-GENE
to O
99 O
%). O

In I-GENE
addition I-GENE
to O
that I-GENE
, O
she I-GENE
received I-GENE
hepatic I-GENE
intra I-GENE
- I-GENE
arterial I-GENE
infusion I-GENE
of O
levoforinate O
( O
l O
- I-GENE
LV I-GENE
) I-GENE
250 I-GENE
mg I-GENE
and O
5 I-GENE
- I-GENE
fluorouracil I-GENE
( I-GENE
5 I-GENE
- I-GENE
FU I-GENE
) I-GENE
500 I-GENE
mg I-GENE
for O
combined I-GENE
multiple I-GENE
hepatic I-GENE
metastases I-GENE
starting I-GENE
on I-GENE
postoperative I-GENE
day I-GENE
14 O
, O
and O
these I-GENE
medications I-GENE
were I-GENE
administered I-GENE
over I-GENE
48 I-GENE
hours I-GENE
once I-GENE
weekly I-GENE
by I-GENE
infuser I-GENE
pump I-GENE
. O

Because I-GENE
of O
differences I-GENE
in O
patient I-GENE
characteristics I-GENE
, O
control I-GENE
measurements I-GENE
were I-GENE
obtained I-GENE
from O
normal I-GENE
muscle I-GENE
in O
all I-GENE
patients I-GENE
. O

Two I-GENE
families I-GENE
with I-GENE
concordant I-GENE
inheritance I-GENE
of O
DNAH9 I-GENE
alleles I-GENE
in O
affected I-GENE
individuals I-GENE
were I-GENE
observed I-GENE
. O

NIRS I-GENE
was I-GENE
used I-GENE
for O
the O
quantitative I-GENE
measurement I-GENE
of O
muscle I-GENE
O I-GENE
( I-GENE
2 I-GENE
) I-GENE
consumption I-GENE
( I-GENE
mV I-GENE
. O
O I-GENE
( I-GENE
2 I-GENE
)) I-GENE
and O
forearm O
blood O
flow I-GENE
( O
FBF O
) O
in O
78 O
healthy I-GENE
subjects I-GENE
. O

Many I-GENE
factors I-GENE
do I-GENE
influence I-GENE
the O
educational I-GENE
outcome I-GENE
in O
students I-GENE
and O
large I-GENE
statistical I-GENE
power I-GENE
( I-GENE
such I-GENE
as O
meta I-GENE
analysis I-GENE
) I-GENE
should I-GENE
be I-GENE
helpful I-GENE
to O
eliminate I-GENE
many I-GENE
sources I-GENE
of O
error I-GENE
. O

B I-GENE
- I-GENE
myb O
is I-GENE
essential I-GENE
for O
G1 I-GENE
/ I-GENE
S I-GENE
transition I-GENE
and O
has I-GENE
been I-GENE
shown I-GENE
to O
be I-GENE
phosphorylated O
by I-GENE
the O
cyclin I-GENE
A2 I-GENE
/ O
cdk2 O
complex O
. O

Like I-GENE
the O
consensus I-GENE
mammalian I-GENE
LHbeta I-GENE
gene I-GENE
, O
the O
5 O
'- O
flanking O
region O
of O
the O
gpLH I-GENE
/ I-GENE
CGbeta I-GENE
gene I-GENE
contains I-GENE
a O
single I-GENE
TATA I-GENE
sequence I-GENE
37 I-GENE
bp O
upstream O
of O
the O
translation O
start O
codon O
. O

HTLV I-GENE
- I-GENE
1 I-GENE
decreases I-GENE
Th2 I-GENE
type I-GENE
of O
immune O
response O
in O
patients I-GENE
with I-GENE
strongyloidiasis I-GENE
. O

Indeed I-GENE
, O
mutation I-GENE
of O
two I-GENE
of O
these I-GENE
motifs I-GENE
, O
known I-GENE
to O
be I-GENE
important I-GENE
to O
regulation O
of O
sid1 I-GENE
, O
altered I-GENE
the O
differential I-GENE
regulation O
of O
sid2 I-GENE
by I-GENE
iron I-GENE
. O

Nutritional O
status I-GENE
in O
adults I-GENE
on I-GENE
an I-GENE
alternative O
or O
traditional O
diet I-GENE
] I-GENE
BACKGROUND I-GENE
: O
Plant I-GENE
food I-GENE
lacks I-GENE
vitamin I-GENE
B12 I-GENE
, O
vitamin O
D O
and O
higher O
n O
- O
3 O
polyunsaturated O
fatty O
acids O
. O

On I-GENE
the O
other I-GENE
hand I-GENE
, O
forced I-GENE
overexpression I-GENE
of O
the O
wild O
type O
, O
but I-GENE
not I-GENE
the O
kinase I-GENE
- I-GENE
inactivated I-GENE
mutant I-GENE
of O
nm23H1 I-GENE
, O
converted I-GENE
the O
GDP I-GENE
- I-GENE
bound O
forms I-GENE
of O
Rac1 O
, O
Cdc42 O
, O
and O
RhoA O
to O
their I-GENE
GTP I-GENE
- I-GENE
bound O
forms I-GENE
in O
vitro I-GENE
by I-GENE
its I-GENE
nucleoside I-GENE
diphosphate I-GENE
kinase I-GENE
activity I-GENE
, O
but I-GENE
nm23H1 I-GENE
alone I-GENE
apparently I-GENE
did I-GENE
not I-GENE
produce I-GENE
the O
GTP I-GENE
- I-GENE
bound O
form I-GENE
of O
these I-GENE
GTPases O
in O
vivo I-GENE
. O

Novel O
intronic O
promoter O
in O
the O
rat I-GENE
ER I-GENE
alpha I-GENE
gene I-GENE
responsible I-GENE
for O
the O
transient I-GENE
transcription O
of O
a O
variant I-GENE
receptor I-GENE
. O

RESULTS I-GENE
: O
Coronary I-GENE
mortality I-GENE
during O
the O
median I-GENE
follow I-GENE
- I-GENE
up O
time I-GENE
of O
17 I-GENE
months I-GENE
was I-GENE
6 I-GENE
- I-GENE
fold O
higher O
in O
the O
highest I-GENE
tertile O
for O
CRP O
and O
IL I-GENE
- I-GENE
6 I-GENE
and O
3 O
. O
5 O
- O
fold O
higher O
in O
the O
highest I-GENE
tertile O
for O
fibrinogen O
and O
TNF O
- I-GENE
alpha I-GENE
than I-GENE
in O
the O
respective I-GENE
combined I-GENE
lower I-GENE
tertiles I-GENE
. O

HIV I-GENE
- I-GENE
1 I-GENE
and O
hepatitis I-GENE
B I-GENE
virus I-GENE
infections I-GENE
in O
adolescents O
lodged O
in O
security O
institutes O
of O
Buenos O
Aires O
. O

However I-GENE
, O
the O
promoter I-GENE
region I-GENE
contains I-GENE
several I-GENE
potential O
cis I-GENE
- I-GENE
regulatory I-GENE
elements I-GENE
such I-GENE
as O
Sp1 I-GENE
, O
early I-GENE
growth I-GENE
response I-GENE
- I-GENE
1 I-GENE
, O
activator I-GENE
protein I-GENE
- I-GENE
2 I-GENE
, O
MyoD O
, O
p300 O
, O
nuclear I-GENE
factor I-GENE
- I-GENE
kappaB I-GENE
, O
myeloid I-GENE
zinc I-GENE
finger I-GENE
protein I-GENE
- I-GENE
1 I-GENE
, O
caudal I-GENE
- I-GENE
related I-GENE
homeobox I-GENE
( O
Cdx O
) O
gene O
A O
, O
and O
Cdx O
protein I-GENE
- I-GENE
2 I-GENE
binding I-GENE
sites I-GENE
. O

RPM I-GENE
/ I-GENE
RGL3 I-GENE
resembled I-GENE
AF I-GENE
- I-GENE
6 I-GENE
and O
Nore1 I-GENE
in O
interacting I-GENE
strongly I-GENE
with I-GENE
constitutively I-GENE
active I-GENE
M I-GENE
- I-GENE
Ras O
and O
p21 O
Ras O
. O

METHODS I-GENE
: O
93 I-GENE
female I-GENE
and O
43 I-GENE
male I-GENE
patients I-GENE
undergoing I-GENE
thyroid I-GENE
surgery I-GENE
were I-GENE
stratified I-GENE
according I-GENE
to O
gender I-GENE
and O
then I-GENE
randomised I-GENE
to O
receive I-GENE
double I-GENE
- I-GENE
blind I-GENE
one I-GENE
of O
four I-GENE
antiemetic I-GENE
regimes I-GENE
: O
50 I-GENE
mg I-GENE
dolasetron I-GENE
given I-GENE
orally I-GENE
45 O
minutes I-GENE
prior I-GENE
to O
induction I-GENE
of O
anaesthesia I-GENE
( O
group O
I O
), O
12 O
. O
5 O
mg I-GENE
dolasetron I-GENE
given I-GENE
intravenously I-GENE
during O
induction I-GENE
of O
anaesthesia I-GENE
( O
group O
II O
), O
1 O
. O
25 O
mg I-GENE
DHB I-GENE
given I-GENE
intravenously I-GENE
during O
induction I-GENE
of O
anaesthesia I-GENE
( O
group O
III O
) O
or O
placebo I-GENE
( O
group O
IV O
). O

Transcriptional I-GENE
regulation O
of O
the O
estrogen I-GENE
- I-GENE
inducible I-GENE
pS2 I-GENE
breast I-GENE
cancer O
marker I-GENE
gene I-GENE
by I-GENE
the O
ERR I-GENE
family I-GENE
of O
orphan I-GENE
nuclear I-GENE
receptors I-GENE
. O

